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ABSTRACT 
Objective: The purpose of this study was to investigate the effects of two different prophylactic 
behavioral swallowing exercise regimens performed by head and neck cancer/s (HNC) patients 
during radiation therapy with/without chemotherapy (RT/C) on swallowing physiology, function, 
quality-of-life (QOL) and weight outcomes at the completion of RT/C. Feeding tube (PEG) 
status  at 3 months post-treatment was also compared. 
Methods: This study was conducted via a prospective design. 50 patients diagnosed with HNC 
who were to undergo RT/C were recruited at pre-treatment based on the inclusion criteria: 
functional swallowing abilities; without prophylactic PEG tubes; ability to comprehend and 
perform therapy tasks and signed informed consent. Patients were assigned to the exercise group 
(EX: n=26) or repetitive swallow group (SW: n=24), by alternate assignment as well as matching 
for age, tumor site and stage. A no treatment group (NTx) of patients (n=23) was recruited 
retrospectively from co-facilities during identical timelines as the prospective cohort. The EX 
and SW treatment groups attended therapy sessions once a week and completed two different 
intensive exercise regimens throughout RT with maintenance of a daily home program.  
Outcome measures: All patients in the EX and SW treatment groups, underwent pre and post-
treatment MBS studies. The following outcomes were reported: physiological (aspiration and 
Penetration Aspiration Scale scores); functional (PEG tube dependence and Functional Oral 
Intake Scale scores); QOL (MD Anderson Dysphagia Inventory Scale scores) and weight loss. At 
3 months post-treatment, PEG tube dependence was assessed and compared. PEG tube 
dependence and weight loss in patients in the treatment and no treatment groups were compared 
at post-treatment and 3 months post-treatment.  
Results: The EX and SW groups did not statistically significantly differ on any outcomes at post-
treatment. The NTx group also did not differ from the EX and SW groups in terms of PEG tube 
   xv 
dependence and weight loss at post-treatment. However, the EX group exhibited a significantly 
higher rate of PEG tube elimination than the SW group at 3 months post-treatment (i.e. 16% vs. 
50%). Among patients who received both radiation and chemotherapy, patients in the EX group 
exhibited significantly lower PEG tube dependence rates at post-treatment and 3 months post-
treatment, compared to the SW and NTx groups. The EX group‟s post-treatment aspiration (i.e. 
18%) and PEG tube dependence (16%) rates at 3 months post-treatment were among the lowest 
reported in the literature.  
Conclusions: Performing swallowing exercises prophylactically, resulted in significantly 
improved rates of PEG tube elimination and oral intake abilities. Findings indicated substantial 
benefits of the EX group‟s exercise regimen, encouraging its utility in the clinical setting. 
Although statistically non-significant, the SW group exhibited better outcomes than no therapy, 
warranting future investigations to explore the benefits of the SW exercise regimen. 
   1 
CHAPTER 1: INTRODUCTION 
1.1. Statement of the Problem 
The last two decades have led to a dramatic alteration in the treatment of head and neck 
cancers (HNC). Landmark studies such as the VA study (i.e. Veteran‟s Administration) 1, 2 and 
the RTOG-9111 (i.e. Radiation Therapy Oncology Group) 
3
 among many others have altered 
head and neck oncologists‟ opinions of the management of HNC. Chemotherapy (ChT) and 
radiation therapy (RT) as concomitant therapies, have become the standard of care for even the 
most advanced stage tumors in the head and neck. While these changes have demonstrated 
significant advantages in patient survival and organ-preservation, their impact on function and 
quality-of-life (QOL) measures were initially not sufficiently monitored. Recognition of 
significantly detrimental functional impairments on voice and particularly swallowing, have not 
gone unnoticed 
4-12
 and a subsequent interest in QOL assessment both from voice and 
swallowing function standpoints has emerged in the field.   
Literature findings suggest that dysphagia may develop as a primary complication of 
head and neck tumors itself 
13-18
 or as a result of surgical and non-surgical interventions. 
14, 19-26
 
Serious complications resulting from dysphagia include aspiration pneumonia, malnutrition and 
impaired QOL. 
27, 28
 Dysphagia rates at one year following radiation therapy with/without 
chemotherapy (RT/C)
a
 have been recognized to range from 15% 
29
 to 100% 
9
 with frequent 
reports of significant long-term silent aspiration 
8, 30-33
 up to 44%. 
8
 Wide ranges in these reports 
are indicative of methodological differences between studies. 
14
 Studies have reported the need 
for alternative modalities of feeding during and after the completion of cancer treatments, to 
support maintenance of nutrition and hydration statuses. 
34
 Rieger, Zalmanowitz and Wolfaardt 
                                                             
a Throughout this document, the abbreviation RT/C will indicate radiation therapy with/without chemotherapy, as 
this is common practice. Wherever a differentiation is required, RT will indicate radiation therapy and ChT will 
indicate chemotherapy. 
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(2006) 
35
 conducted a review of the literature and reported evidence of feeding tube dependence 
(percutaneous endoscopic gastrostomy/ PEG tube) of 61% during RT/C; 
36
 86% at four  months 
post-treatment; 
37
 50% at five months; 
38
 20% 
39, 40
 to 60% 
41
 at one year and 8% to 18% long-
term dependence in surviving patients. 
36, 37, 40, 42-44
 In a recent review of the literature, Locher et 
al., (2011) 
45
 have reported PEG tube dependence rates of 4% to 18.7% before the initiation of 
RT/C, 29.6% to 40.8% during treatment, 18% at one month, 40% to 45% at three months, 9% to 
36% at six months and 8% to 60% at 12 months post-RT/C.  
32, 40, 41, 44, 46-51
 QOL impairments 
related to PEG tube placements have been described in the literature previously.
52-63
 In addition, 
diet restrictions and social dining difficulties have also been reported as negatively impacting 
patients‟ QOL post-cancer treatments. 20, 38-40, 42, 46, 64-70 At least 10% weight loss post-RT/C is 
typically reported in the literature, 
44
 increasing patients‟ risk of dehydration and malnutrition.  
Biomechanical and functional swallowing impairments resulting from RT are known to 
be related to short-term toxicities including but not limited to significant inflammation, edema, 
erythema and long-term tissue fibrosis, which is characterized by scar-tissue formation within 
irradiated structures. 
24
 Although, it has been reported that induction ChT alone, may not affect 
swallowing physiology or function in patients with HNC, 
71
 its pathophysiological impacts on 
impairing salivary function, resulting in the development of painful oral mucositis is well known. 
72
 Since HNC are almost never treated using ChT alone, except for palliative treatment, most all 
studies describe the effects of combined RT/C on swallowing changes. 
71
  
Speech-language pathologist/s (SLP) perform the critical role of assessing and managing 
cancer treatment-induced dysphagia. 
24, 28
 The primary goals of dysphagia treatment and 
management are to maintain efficient and safe swallowing function and to prevent aspiration. 
14
 
Several postural strategies, 
73, 74
 bolus volume and consistency modifications 
75
 and rehabilitation 
exercises 
76-82
 are employed by SLPs to alter patients‟ physiology of swallowing to reduce or 
   3 
eliminate the risk of aspiration and maintain safe swallow function. 
14
 Pauloski (2008) has 
reviewed currently employed behavioral swallowing therapy procedures including postural 
strategies, swallow maneuvers, bolus size and consistency modifications and exercises in 
managing dysphagia following treatment of HNC, along with their impact on patients‟ 
swallowing outcomes. 
83
 Medical treatments mainly for the management of proximal esophageal 
strictures, 
84
 have also been successfully employed more commonly to reduce or eliminate 
oropharyngeal and/or pharyngoesophageal swallowing impairments in this patient population. 
Additionally, advances in radiation-oncology treatment techniques, such as the introduction of 
intensity-modulated radiotherapy (IMRT) have offered the potential to spare anatomical 
structures involved in swallowing, while continuing to treat tumors effectively. 
85
 Currently, 
most clinicians and centers typically treat dysphagia at the completion of RT/C (i.e. reactively), 
if and when patients present with swallowing difficulties.
24
 While the positive impacts of such 
swallowing therapy on patients‟ swallowing physiology, function and QOL are evident clinically 
and supported by SLPs and Oncologists,
 
there is much paucity of objective data in the literature 
to support these benefits. 
14
 Hence, standardized behavioral dysphagia care protocols to be 
generalized to clinical practice, are currently not available. Emerging literature continues to 
focus on fully delineating standardized treatments in terms of establishing the most optimal 
exercises, their frequency and intensity and the timing of onset of therapy, to optimize the return 
of function in this challenging patient population. 
14, 83
  
Recent advances in the understanding of radiation fibrosis and the application of exercise 
physiology to the reintegration of radiated tissue have further resulted in the conceptualization of 
a highly aggressive approach to swallowing rehabilitation in patients with HNC. Proactive or 
prophylactic swallowing therapy, which is essentially introduced with an intention of potentially 
preventing or minimizing the known post-treatment swallowing impairments, has been one of 
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the most vital changes introduced to patients‟ therapeutic regimens. Few studies have 
demonstrated significant benefits of prophylactic swallowing therapy in swallowing physiology, 
function, QOL and weight outcomes. 
86-92
 Although evident, literature elaborating on these 
benefits is sparse and hence a standardized exercise program with a recommended intensity and 
frequency schedule of the most optimal exercises, is not available at this time. Systematic 
observations of the effects of swallow maneuvers on healthy and disordered swallowing, have 
laid the impetus for many of the swallowing strategies and exercises that are currently employed 
routinely in the management of dysphagia, post-RT/C. Advances in the understanding of the 
roles of neural plasticity and exercise physiology in the establishment of evidence-based, 
effective treatment protocols, have led researchers to further evaluate the adherence of 
swallowing strategies and maneuvers to the principles of neural plasticity and exercise 
physiology. 
93
 Complex dysphagia exercises have been introduced with the assumption of their 
superiority over the target activity of swallowing behavior itself, in impacting muscle structure 
and function. It is clinically known that patients undergoing RT/C for HNC often suffer 
treatment toxicities, negatively impacting oral intake and causing a sharp reduction in the use of 
swallowing muscles. Prolonged lack of swallowing may potentially cause atrophy in the muscles 
of swallowing. 
85, 94-97
 Although the importance of continuing to swallowing through RT/C has 
been acknowledged in the literature, no study has systematically evaluated the relative 
advantages of performing intensive, complex swallowing exercises over encouraging patients to 
perform simple, yet intensive repetitive swallows as the therapeutic task itself, on swallowing 
outcomes. The strenuous nature of behavioral swallowing exercises may be considered 
challenging to the swallowing muscles undergoing RT/C, beyond the already occurring side 
effects of cancer treatment, evidently reducing patient-compliance with exercises. Given, the 
simplicity and saliency of „repetitive swallowing‟ over performing relatively complicated  
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exercises in achieving the desired goal of safe swallowing, this area deserves much research. 
Therefore, based on the current understanding of the available literature on prophylactic 
behavioral swallowing rehabilitation in the HNC patient population, this study aims to 
investigate: 
Primary Research Questions 
 If performing intensive evidence-based „behavioral swallowing exercises‟ during radiation 
therapy with or without chemotherapy (RT/C) will result in better post-treatment swallowing 
physiology, function, quality-of-life (QOL) and weight outcomes than performing an intensive 
number of „swallows‟ as the therapeutic task. 
 If behavioral dysphagia therapy when initiated during RT/C, will reduce the number of reactive 
PEG tube placements in the HNC patient population, compared to that in patients who received 
no behavioral dysphagia therapy (NTx) 
 If physiological swallowing alterations will directly influence alterations in swallowing function, 
quality-of-life (QOL) and weight, post-RT/C. 
 If patient demographics, tumor characteristics or cancer-treatment related characteristics affect 
aspiration and PEG tube dependence outcomes in the treatment group of patients. 
Secondary Research Questions 
 How the severity of radiation toxicities including xerostomia, mucositis, pain, odynophagia, 
nausea/vomiting, dysgeusia, trismus and reduced appetite progress through RT/C 
 How the severity of dysphagia symptoms including choking with solids and liquids, nasal/ oral 
regurgitation, reflux, difficulty initiating a swallow, globus sensation, foods sticking in the 
throat, gagging, NPO status, hoarseness and wet/gurgly voice quality progress through RT/C 
 Patient-compliance with the exercise regimens. 
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1.2. Research Hypotheses 
The research hypotheses of this study, based on previous literature findings are: 
1. The „behavioral swallowing exercise (EX)‟ treatment group will exhibit significantly better 
swallowing outcomes post-RT/C than the „repetitive swallowing (SW)‟ treatment group in 
terms of, 
a) Physiological outcomes determined by aspiration and Penetration Aspiration Scale 
(PAS) scores 
b) Functional outcomes determined by PEG tube dependence and Functional Oral Intake 
Scale (FOIS) scores 
c) Quality-of-life (QOL) outcomes determined by the MD Anderson Dysphagia Inventory 
(MDADI) scores 
d) Weight outcomes determined by weight loss post-RT/C 
2. Swallowing intervention during RT/C will result in a significant reduction in PEG tube 
dependence when compared to a No Treatment (NTx) group. 
3. Severity of physiological outcomes (aspiration and PAS scores) will correlate with severity 
of functional outcomes (FOIS scores and PEG dependence), QOL outcomes (MDADI 
scores) and weight outcomes (weight loss) post- RT/C. 
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CHAPTER 2: LITERATURE REVIEW 
Advances in the understanding of the pathophysiological changes occurring in tissue-
structure post-RT/C, have led to a new prophylactic perspective to swallowing rehabilitation in 
patients with HNC. The foundation of this new perspective continues to be guided by evidence 
on the known impacts of several behavioral interventions on healthy and disordered swallowing 
outcomes. The principles of neural plasticity and exercise physiology have gained increased 
importance in current research undertaking the establishment of a therapeutic standard of care in 
patients with HNC. This chapter elaborates the available literature in each of these areas, vital to 
the current investigation. 
2.1. Pathophysiological Impacts of Radiation Therapy with/without Chemotherapy (RT/C) 
on Structures of the Swallowing Mechanism 
Radiation affects body cells through a small number of events, sometimes only one 
event.
98
 Cells that are mainly affected are those that replicate or reproduce. It has been 
established that the DNA (DeoxyriboNucleic Acid) is the radiosensitive component within cells, 
as it has the ability to replicate cell function. When exposed to ionizing radiations, DNA 
molecules physically break into two and its bases on both complementary strands are destroyed. 
This breakage or base-loss interferes with the continuity of the existence of DNA. 
98
 DNA 
damage occurs in both diseased as well as healthy tissues with subsequent apoptosis or mitotic 
cell death. 
99
 Along with damaging DNA, radiation promotes several mechanisms in the body 
including inflammation, epithelial regeneration, activation of the coagulation system and re-
modeling of tissues, which is caused by the interaction of cytokines, chemokines and growth 
factors. 
99
 Thus, the mechanisms of radiation-induced tissue injury begins with apoptosis of the 
cells in the endothelium, which in turn increases endothelium permeability and results in the 
attraction of adhesion molecules and chemokines. This causes reduced fibrinolysis, increased 
tissue factor and con Willebrand factor, reduced prostacyclin and thrombomodulin and 
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eventually reduced thrombi-resistance of blood vessels. 
99
 Subsequently increased vascular 
permeability causes an increase in tissue factor and thrombin formation intravascularly and also 
in the extracellular matrix and perivascular areas. Thrombin accumulation in the intravascular 
and perivascular areas is what causes continued increase in fibrotic sclerosis of tissues and is 
termed as radiation fibrosis. 
99
 Radiation fibrosis can occur in all tissues including skin, muscle, 
ligament, tendon, nerve, viscera and bone. 
100
 Radiation fibrosis induced in the swallowing 
musculature after exposure during the treatment of HNCs, is a known clinical complication. It 
may occur from early on during treatment to several years after treatment and is described as an 
irreversible phenomenon. 
101
 As blood vessels in tissues are exposed to radiation, fibrosis 
continues; it changes muscle fibers to connective tissue and this process may continue to occur 
for years. 
82
 A more serious form of long-term radiation fibrosis is osteoradionecrosis, which is 
essentially permanent damage to bone and vessels from exposure to radiation. 
102
 Progressive 
osteoradionecrosis can lead to severe pain or even fractures, requiring jaw resection. 
102
  From 
the swallowing perspective, radiation fibrosis interferes with the smooth transit of food and 
liquid boluses, causing clinically life-threatening aspiration of foods and liquids before, during 
and/or after swallowing, often silent in nature. 
24, 103
 
Chemotherapy (ChT), which is typically used in combination with radiation therapy 
(RT), is associated with additional reduction in salivary gland function. Induction-ChT alone has 
been found to not cause any impairment in oropharyngeal swallowing efficiency or speech 
intelligibility. 
71
 However, its impact on altered salivary function may have significant negative 
bearings on patients‟ abilities to swallow. Chemotherapeutic agents adversely affect cells with 
high turnover rates, such as the epithelium within the oral cavity. 
102
 Oral mucositis, along with 
saliva underproduction and taste dysfunction induced by ChT is reportedly much more 
aggressive than that resulting from RT. 
102, 104
 Oral ulcerations may occur due to direct cellular 
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cytotoxicity from chemotherapeutic agents as injured tissues are more susceptible to infections 
due to neutropenia, trauma or a combination of factors. 
102
 These significantly impact eating and 
speech functions in patients. 
102
 Significant nausea and vomiting are also highly specific 
reactions of chemotherapeutic agents, further reducing oral intake. 
105
 Recently, Sullivan (2005) 
explained the effects of RT/C on salivary glands including the processes of: acinar cell loss along 
with salivary duct metaplasia, ductal proliferation, increased fibrosis, chronic inflammation, 
nuclear atypia and cytoplasmic vacuolization. 
106
 Since HNC are almost never treated using ChT 
alone, except for palliative treatment, most all studies describe the effects of combined RT 
with/without ChT on swallowing changes. 
71
 
24
 
Thus, along with desirable eradication of cancer cells, RT/C causes significant 
undesirable changes in normal tissue, resulting in dysphagia. Permanent tissue changes make the 
process of rehabilitation of swallowing function quite challenging. This renders greater 
importance to a need for techniques to prophylactically prevent and/or maintain a safe and 
efficient swallow function in these patients. The following section presents a review of the 
RT/C-induced toxicities in patients. 
2.1.1. Toxicities Associated with Radiation Therapy with/without Chemotherapy (RT/C) 
and Their Management in Head and Neck Cancers (HNC) 
 
Patients undergoing RT/C exhibit several physical toxicities during and after the 
completion of treatment due to treatment-induced pathophysiological alterations described in the 
previous section. Short-term toxicities including edema (i.e. swelling), xerostomia (i.e. dry 
mouth), mucositis (i.e. sores in the mouth and throat), nausea, odynophagia (i.e. pain on 
swallowing), reduced appetite, fatigue and dysgeusia (i.e. loss of taste), and long-term radiation 
fibrosis (i.e. tissue scarring) are the most commonly presented side-effects of RT/C. 
67, 103, 107-109
 
Clinically, these toxicities are known to directly result in swallowing difficulties during 
treatment, including choking, difficulty initiating a swallow, foods sticking in the throat, loss of 
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appetite and subsequently diminished oral intake, particularly of solid foods. 
103
 Patients may 
even begin to spit their own secretions due to the pain associated with swallowing. This may 
cause a significant reduction in the use of swallowing muscles. Prolonged muscle inactivity is 
associated with a serious risk of atrophy. 
85, 97
 Despite intact swallowing physiology, associated 
toxicities impacting oral intake, may result in severe weight loss. 
109
 Rademaker et al., (2003) 
reported that at pre-treatment, oral intake for 7% patients was ≤ 50%.48 Immediately post-
treatment, 39% consumed ≤ 50% of their nutrition and hydration orally. Thin liquids were best 
tolerated by patients at any timeline, and crunchy foods the hardest.
48
 Weight loss can result in 
malnutrition and has also been associated with a sharp increase in morbidity and mortality. 
110
 A 
PEG tube may have to be considered to meet the patient‟s nutrition and hydration needs during 
treatment. 
24
 It is not uncommon for some patients to exhibit reduced tolerance of PEG tube 
feedings, necessitating total parenteral nutrition (TPN) dependence, which in turn is not 
complication-free either. Alternative modalities of nutrition and hydration further reduce the use 
of swallowing muscles, prolonging the duration of avoidance of swallowing. This may have 
significant bearings on return of swallowing function. 
97
  
Several medical interventions have been employed to manage radiation-induced 
toxicities. Eilers and Million (2011) have evaluated the literature to present the evidence for 
various interventions for oral mucositis in patients undergoing RT/C. Cryotherapy, keratinocyte 
growth factor (palifermin®) and sucralfate have been shown to benefit in the reduction of oral 
mucositis. 
111
 Rodriguez-Caballero, et al., (2011) have presented a summary of intensive oral 
care protocols, antimicrobial agents, anti-inflammatory agents, cytoprotective agents, nutritional 
supplements, bio-stimulants, low-energy laser therapy and natural and homoeopathic agents that 
have been employed to treat and manage RT/C-induced oral mucositis. 
104
 Shenoy, Shenoy, 
Rodrigues and Shetty (2007) have reviewed the management of oral health in patients who 
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underwent RT for HNC, including: timely dental evaluations and treatments both during and 
following the completion of RT; use of oral prophylaxis, fluoride treatments and patient 
education to maintain oral hygiene; topical and systemic antifungals to prevent and treat 
infections of the oral cavity; use of saliva substitutes, moisturizers, sugarless gums and candies to 
manage xerostomia; employment of coating agents, topical analgesics and anesthetics to treat the 
pain associated with mucositis and daily mouth opening exercises to manage trismus (i.e. 
reduced jaw opening) occurring as a result of fibrosis. 
112
 Delanian and Lefaix (2007) have 
described the use of various medical treatments in managing radiation-induced fibrosis 
including: anti-inflammatory treatments, vascular therapies and anti-oxidant treatments. 
113
 
O‟Sullivan and Levin, (2003) have discussed the use of pharmacological therapies, hyperbaric 
oxygen treatments and microcurrent therapies in the management of post-radiation fibrosis. 
114
 
Clinical trials assessing the impacts of various pharmacological therapies continue in the field, to 
reduce treatment-related toxicities. 
Oral, pharyngeal and/or esophageal phase dysphagia in varying degrees, frequently occur 
during and after the completion of RT/C. 
103
 The resultant oropharyngeal dysphagia is 
characterized by reduced tongue range-of-motion (ROM) and strength, inadequate bolus 
formation and anterior-posterior transit, prolonged oral transit time, increased oral cavity residue, 
reduced tongue-base retraction to make contact with the posterior pharyngeal wall, 
velopharyngeal sphincteric closure abnormalities, delayed pharyngeal swallow response trigger, 
reduced pharyngeal contraction and peristalsis, reduced hyolaryngeal excursion and reduced 
laryngeal closure. Additionally, reduced opening of the upper esophageal segment (UES) may 
result in inadequate bolus clearance from the pharynx, leaving residue at the tongue-base, 
valleculae, pyriform sinuses or throughout the pharynx. This residue can result in aspiration, 
typically after the swallow, often silent in nature. 
10, 82, 103, 115, 116
 Cricopharyngeal (CP) strictures 
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are not uncommon, and usually occur later after the completion of RT/C. 
85, 117
 Management of 
CP strictures may require medical interventions, such as dilating the area 
84
 to allow smoother 
transit of foods and liquids into the esophagus.  
Standard radiation for most head and neck primary tumors is delivered at a dose of 1.8 to 
2 Gy, once daily, 5 days a week. 
118
 Two modifications to this schedule exist: hyperfractionation 
and accelerated fractionation”. Hyperfractionation involves the delivery of two treatments in a 
day, ≥ 6 hours apart, each treatment‟s dosage being slightly lower than the standard dosage, yet 
allowing delivery of a slightly higher total dosage per day. 
118
 Accelerated fractionation on the 
other hand, allows the delivery of treatments more than 5 days a week, including the weekends 
and/or delivering two or more fractions on some days of the week. 
118
 Swallowing impairments 
arising from acute radiation toxicities may sometimes last only temporarily when relatively 
smaller radiation doses are employed in the treatment of smaller tumors. However, larger doses 
of RT employed to treat more advanced cancers may cause significant oropharyngeal and 
pharyngoesophageal dysphagia, not uncommonly permanent in nature. 
85
  Tables 2.1 and 2.2 
present literature reviews of the rates of aspiration and PEG tube dependence within 3 months 
post-completion of RT/C. None of these studies report the employment of any behavioral 
swallowing interventions. 
Carnaby-Mann, Crary, Schmalfuss and Amdur (2012) recently conducted the only 
existing study to investigate the impact of performing behavioral swallowing exercises during 
RT/C, on muscle size and composition, assessed by T2-weighted Magnetic Resonance Imaging 
(MRI) at 6 months post-treatment. 
91
 The study indicated that although all patients who 
underwent RT/C exhibited significant deterioration of muscle composition through treatment, 
patients who performed swallowing exercises exhibited greater preservation of three prime 
swallowing muscles: genioglossus, mylohyoid and hyoglossus. Current dysphagia clinical 
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Table 2.1: Literature reports of aspiration rates (%) within 3 months of completion of radiation therapy with/without chemotherapy 
(RT/C) for head and neck cancers (HNC) 
 
Authors & RT/C protocol N 
 
Age (years) Sex T site (%) 
 
 
T stage (%) Aspiration@ < 3 
mos. 
Agarwal et al (2011) 
66-70 Gy RT + CC 
 
 
47 Median: 51 
Range: 40-65 
40M 
7F 
53% OPhx     34% HPhx 
13% Lx 
76% III/IV 23% 
 
Nguyen et al (2009)
 
(TL patients excluded)
 
59.4-66 Gy RT post-surgery 
37 Median: 58 
Range: 45-78 
37M 19% OC      19% OPhx 
22% Lx       40% O 
3% I        8% II 
35% III    51% IV   
3% R 
24%  
 
Nguyen et al (2006) 
66-70.2 Gy RT + CC 
 
 
63 
 
Median: 64 
Range: 49-86 
 
62M 
1F 
 
2% OC         56% OPhx 
3% NPhx     12% HPhx 
27% Lx 
 
 
3% II     32% III 
62% IV     3% R 
 
49%  
(21% trace,  
28% severe) 
 
Logemann et al (2006) 
67 to 72.75 Gy + CC 
53 Median: 56 
Range 38-78 
41M 
12F 
41% OPhx    6% NPhx 
26% Lx         8% HPhx 
19% O 
 
66% III/IV 23% 
Eisbruch et al (2002, 2004) 
70 Gy RT + CC 
26 ≥ 18 NR 8% OC          54% OPhx 
15% NPhx     8% Lx 
4% HPhx       11% O 
 
100% III/IV 65% 
Kotz et al (2004) 
69.3- 72.3 Gy + CC 
12 Mean: 50 
Range: 31-72 
 
9M 
3F 
8% OC          59% OPhx 
25% Lx         8% O 
100% III/IV 33% 
Newman et al (2002) 
2 protocols of RT + CC  
30 
(I=14 
II=16) 
Mean: 61 64 & 56% M 
34 & 44% F 
       21 & 6%   Oral 
64 & 81%   Phx 
14 & 13%    Lx 
  0 & 6%II 
14 & 13%III 
86 & 81%IV 
 
At least 40% 
RT/C= radiation therapy with or without chemotherapy; N= number of patients; T= tumor; mos: months; @= at; RT= radiation therapy; CC= concomitant 
chemotherapy; M= male; F= female; OC= oral cavity; OPhx= oropharynx; NPhx= nasopharynx; Lx= larynx; HPhx= hypopharynx; O= other; R: recurrence; 
NR= not reported 
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Table 2.2: Literature reports of PEG tube dependence (%) within 3 months of completion of radiation therapy with/without chemotherapy 
(RT/C) for head and neck cancers (HNC) 
Authors & RT/C protocol N 
 
Age (years) Sex T site (%) 
 
T stage (%) PEG @ <3 months 
 
 
Ackerstaff et al (2009) 
70 Gy RT + CC 
207 Mean: 55 73%M 
27%F 
19% OC 
62% OPhx 
18% HPhx 
100% III/IV 86% 
at post-treatment 
some PEGs were placed before treatment  
 
Murphy et al (2009) 
Several RT ± CC ± surgery 
protocols employed 
 
 
 
1877 Mean: 59 
Range: 19-97 
76%M 
24%F 
41% OPhx 
20% Lx 
16% OC 
4% NPhx 
4% HPhx 
15% O 
 
9% I 
10% II  
19% III 
63% IV 
8% missing 
40% academic centers 
30% community centers 
during treatment 
additional PEGs were placed before treatment 
Nguyen et al  (2009) 
(TL patients excluded)
 
59.4-66 Gy RT post-surgery 
37 Median: 58 
Range: 45-78 
37M 19% OC 
19% OPhx 
22% Lx 
40% O 
3% I 
8% II 
35% III 
51% IV 
3% R 
 
10%  
at post-treatment 
Hutcheson et al (2008) 
66 to 77 Gy RT ± CC 
 
40 Mean: 59 
SD: 11 
75%M 
25%F 
97.5% Lx 
2.5% O 
75% ≥T3 78% 
at some point  during treatment 
some patients underwent TL, not evaluated 
exclusively 
 
 
Salama et al (2008) 
8 Primary surgery 
72-75 Gy RT + CC 
95 Median: 58 
Range: 35-77 
NR 8% OC 
52% OPhx 
4% NPhx 
5% HPhx 
23% Lx 
7% O 
 
57% ≥ T3 
86% ≥ N1 
38%  
during treatment 
Lazarus, et al (2007) 
58.5 to 75.78 Gy RT ± CC 
 
46 Mean: 59 
Range: 29 to 78 
76%M 
24%F 
85% OPhx 
15% OC 
6% II 
11% III 
83% IV 
22% 
at 1 month post-treatment 
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(Table 2.2 continued) 
 
      
Authors & RT/C protocol N 
 
Age (years) Sex T site (%) 
 
T stage (%) PEG @ <3 months 
 
 
Oates et al (2007) 
60 to 70 Gy RT + CC 
 
14 Range: 27 to 71 NR 100% NPhx 86% III/IV 93% 
at post-treatment 
Goguen et al (2006) 
70-74 Gy RT + CC 
59 Mean: 54 
Range: 38-75 
73%M 
27%F 
5% OC 
71% OPhx 
19% Lx 
5% HPhx 
 
14% III 
86% IV 
73% 
at 3 months post-treatment 
Logemann et al (2006) 
67 to 72.75 Gy RT  ± CC 
53 Median: 56 
Range: 38 to 78 
77%M 
23%F 
6% NPhx 
41% OPhx 
26% Lx 
8% HPhx 
19% O 
66% ≥T3 
 
40%  
at post-treatment 
small number of PEG tubes were placed prior 
to treatment 
 
Shiley, Hargunani, Skoner, 
Holland & Wax (2006) 
71 Gy RT (mean) + CC 
27 Mean: 57 
Range: 45-80 
96%M 
4%F 
96% OPhx 
4% HPhx 
7% III 
93% IV 
81% 
prior to or during treatment 
 
45% 
at 3 months post-treatment 
Ahmed, Samant & Vieira (2005) 
68-74 Gy RT + CC 
 
 
 
477 Range: 18-86 220M 
257F 
16% OC 
41% OPhx 
19% Lx 
10% HPhx 
8% NPhx 
6% O 
 
100% III/IV 46% 
at post-treatment 
small number of PEGs were placed before 
treatment 
Rademaker et al (2003) 
 
70 Gy (median) (30-75.5 Gy) RT 
± CC 
 
255 Mean: 59 
Range: 24-80 
77%M 
23%F 
46% OPhx 
23% Lx 
10% OC 
9% HPhx 
5% NPhx 
7% unknown 
 
 
6% II 
19% III 
73% IV 
48% 
at 1 month post-treatment 
 
36%  
at 3 months 
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(Table 2.2 continued) 
 
      
Authors & RT/C protocol 
 
 
N 
 
Age (years) Sex T site (%) 
 
T stage (%) PEG @ <3 months 
Kies et al (2001) 
 
73.5 Gy RT (median) + CC 
64 Median: 57 
Range: 33-78 
 
84%M 
16%F 
27% OC 
2% NPhx 
33% OPhx 
9% HPhx 
14% Lx 
16% O 
 
98% IV 
 
78% 
at post-treatment 
Newman, et al (1998) 
 
63-70 Gy RT + CC 
47 Mean: 56.5 
Range: 38-83 
34M 
13F 
13% HPhx 
30% Lx 
9% OC 
49% OPhx 
 
91% ≥T3 
60% ≥N1 
26% 
at post-treatment 
small number of PEGs were placed before 
treatment 
 
RT/C= radiation therapy with or without chemotherapy; N = number of patients; T= tumor; @= at; RT= radiation therapy; CC= concomitant chemotherapy; M= 
male; F= female; OC= oral cavity; OPhx= oropharynx; NPhx= nasopharynx; Lx= larynx; HPhx= hypopharynx; O= other; NR= not reported 
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practice in the HNC population employs various ROM exercises and behavioral swallowing 
maneuvers, which reportedly alter and/or improve the functional ability of impaired structures. 
83
 
The support for this practice comes from a limited number of studies, described in the following 
sections of the document. Additionally, literature investigating the specific role of exercises in 
minimizing radiation fibrosis and its effects on swallowing function is emerging, and requires 
further investigations. Physiotherapy as a behavioral management modality is frequently 
employed in reducing post-RT fibrosis. Only a few reports currently exist to support the use of 
physical therapy in the rehabilitation of irradiated tissues. 
114
 Benefits of physical exercise in 
reducing risks of impaired shoulder movements following surgical and RT for breast cancer have 
been reported in the literature. 
119-121
 In particular, the irreversibility of radiation fibrosis assessed 
by relative maintenance of range-of-motion (ROM) at least partially in breast cancer patients has 
been demonstrated medically by Delanian and Lefaix, (2007). 
113
 However, there appears a need 
for confirmatory studies to evaluate the efficacies of such medical interventions specific to HNC. 
113, 114
 Such encouraging reports of the positive impacts of behavioral therapy in preserving 
and/or reducing muscle fibrosis, encourage the future potential of swallowing therapy in 
efficiently minimizing the occurrence of dysphagia associated with irradiated tissue.  
In summary, the effects of RT/C and its toxicities on swallowing physiology may result 
in inefficient and unsafe swallowing, frequently evidenced on post-treatment Modified Barium 
Swallow (MBS) studies.
24
 Radiation fibrosis frequently may cause aspiration, increased risk of 
aspiration as well as inadequate oral intake to meet the nutritional and hydration needs of the 
HNC patient-population. Reduced pharyngeal peristalsis which impairs the transit of foods and 
liquids into the esophagus, has direct impacts on oral intake and nutritional adequacy. Due to the 
permanent nature of RT-induced tissue fibrosis, a prophylactic approach targeting tissue while it 
is still healthy has emerged. 
91
 The rationale of this approach is to minimize reductions in the 
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range-of-motion of these tissues and muscles, prior to and during exposure to RT/C, rather than 
attempting the same, once RT damage has already been induced. Future studies expanding on 
this significant finding are highly warranted. The following section reviews current clinical 
practice in dysphagia rehabilitation in patients diagnosed with and treated for HNC.  
2.2. Review of Current Clinical Practice in Dysphagia Rehabilitation of the Head and Neck 
Cancer (HNC) Patient Population- Reactive Behavioral Swallowing Therapy 
 
 Current clinical practice utilizes a wide variety of postural strategies, 
73, 74, 122
 bolus 
volume and consistency modifications 
75
 and rehabilitation exercises 
76-82
 to manage swallowing 
impairments following RT/C. The following is a summary of the behavioral swallowing 
exercises routinely employed, along with the evidence supporting their benefits in post-RT/C 
swallowing impairments. 
Range-of-Motion (ROM) Exercises 
ROM of the lips, jaw, tongue and larynx are often disrupted following HNC treatments, 
typically from RT/C-induced fibrosis. ROM exercises involve stretching target structures in the 
desired direction, holding the position for a few seconds followed by relaxation. 
82
 ROM 
exercises can be used for the lips, jaw, oral tongue, tongue-base, larynx and the hyolaryngeal 
musculature. 
83
 A standardized treatment schedule for these exercises has not yet been 
determined. However, most commonly 5-10 repetitions of each exercise 5-10 times per day have 
been recommended in several studies. 
21, 82, 123
 
 Jaw Exercises 
HNC treatments have been reported to cause trismus (reduced jaw opening) due to RT-
induced fibrosis in 5% to 38% patients. 
124
 ROM exercises for the jaw are employed in patients 
with a restricted mouth opening, which may result from surgical removal of pertinent muscles of 
RT/C-induced fibrosis. Unassisted practice of ROM of the jaw, finger-assisted stretching,
stacked tongue depressors and mechanical assistance with devices such as the Therabite® (Atos  
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Medical AB, Horby, Sweden), which is a hand held device assisting in improving jaw opening 
for increased flexibility, motility and function, are currently utilized in treating reduced ROM of 
the jaw. 
83
 All of these techniques have proved effective in relieving some of the trismus and 
increasing jaw opening in HNC patients treated with surgery or RT/C. 
125-127
 Unassisted jaw 
opening exercises have recently been reported to result in a significant increase in suprahyoid 
muscle strength in healthy elderly subjects. 
128
  
Patients are instructed to open their mouths as widely as possible without causing pain, 
holding this open position for two seconds with or without assisted/ mechanical devices, then 
moving the jaw to the left side as much as possible, holding this position for two seconds and 
then relaxing. 
83
 The exercise is then repeated for the right side. Finally, the patient is encouraged 
to move the jaw in a circular pattern and relax after every full circle. 
 Tongue Exercises 
ROM exercises of the tongue are applicable in oral tongue and tongue-base movement 
impairments. 
82
 ROM exercises for tongue function in bolus manipulation include tongue-
cupping, side-to-side tongue movements and posterior tongue movements. These exercises 
intend to facilitate chewing, bolus formation and bolus transport functions of the tongue. 
82
 
Tongue-extension involves protrusion of the tongue as far past the lips as possible 
without pain, sustaining the stretch for two seconds followed by relaxation. 
82
 Tongue-
lateralization involves moving the tongue to either the left or right corner of the mouth, tightly 
sustaining the stretch for 2 seconds followed by relaxation. The exercise is repeated on the other 
corner of the mouth. Oral tongue-elevation requires that the tongue be lifted in the mouth with 
the tip of the tongue touching the alveolar ridge, sustaining the stretch for two seconds followed 
by relaxation. Tongue-base elevation can be performed by raising the back of the tongue to 
produce a /k/ or /g/ sound, holding the position for two seconds followed by relaxation. Tongue-
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retraction involves pulling the tongue back in the mouth as far as possible, holding the stretch for 
two seconds followed by relaxation. Tongue-cupping involves holding a piece of gauze soaked 
in water or a licorice stick or a lollipop on the middle of the tongue such that the sides of the 
tongue are cupped against the palate and the tip of the tongue rests on the alveolar ridge. The 
position is sustained for five seconds followed by relaxation. A soaked gauze piece may be 
employed to perform oral bolus retrieval, bolus manipulation, anterior-posterior bolus transit and 
swallowing tasks. Once the patient exhibits improved ability to handle a soaked gauze piece, 
harder textures such as hard candy may be introduced. Tongue-retraction and pretending to yawn 
and gargle have been shown to improve tongue-base retraction. 
82
 However, gargling as a 
tongue-base retraction exercise was found to be more effective in approximating the base of the 
tongue closest to the posterior pharyngeal wall than yawn exercises in a study of 20 patients with 
various diagnoses including some treated HNC patients. 
81
  
Tongue Resistance and Strengthening Exercises 
White, Cotton, Hind, Robbins and Perry (2009) reported significant differences in oro-
lingual swallowing pressures recorded in HNC patients vs. healthy adults. 
129
 Tongue 
strengthening exercises involve pushing the tongue against resistance and sustaining the resisted 
push for a few seconds followed by relaxation. 
82
 Tongue protrusion, lateralization at the corners 
of the mouth or inside the cheek may be employed against resistance applied by a wooden 
tongue depressor or the back of a spoon. Isometric tongue pressure increases have been reported 
in healthy subjects with lingual resistance exercise programs. Resistance training exercises have 
also shown to improve isometric tongue-strength in healthy older adults as well as those with 
stroke-related dysphagia. 
130, 131
 Van Nuffelen, Vanderwegen, Van den Steen and De Bodt (2012) 
recently reports benefits of a tongue strengthening exercise protocol in improving tongue 
strength in patients with dysphagia post-RT/C. 
132
 The IOWA Oral Pressure Instrument (IOPI) 
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helps to monitor pressure during tongue strengthening exercises; 
133
 however, no significant 
differences in physiological outcomes using a tongue depressor or the IOPI have been reported in 
normal subjects. 
134
 Whether improvements in strength with tongue-resistance exercises translate 
into functional improvements in swallowing are yet to be investigated. 
135, 136
  
Weakening of the tongue muscles in older adults has been demonstrated in the 
literature.
137-139
 Bond, Dietrich and Murphy (2011) have reported that advanced age may 
therefore further increase the burden of toxic symptoms to patients undergoing RT/C. 
140
 Given 
the increasing percentage of older adults, which may potentially increase the prevalence of HNC, 
establishment of a standard of care to keep treatment-related dysphagia to the minimum possible, 
is warranted in this high-risk age group of patients. Employment of objectively assessed tongue 
strength and ROM exercises in the HNC patient population (young and especially older adults) is 
therefore suggested.  
 Laryngeal Range-of-Motion (ROM) Exercises 
ROM exercises for the larynx are employed to improve laryngeal elevation in patients 
who exhibit reduced laryngeal movement typically following RT for HNCs. 
83
  
 The Falsetto Voice or Pharyngeal Squeeze Maneuver 
The falsetto voice is a simple maneuver produced by gliding up the pitch scale as high as 
possible until a high-pitched squeaky voice is reached and sustaining phonation at this pitch for 
as long as able. Manual assistance may be provided initially but should be eliminated gradually. 
Rodrigues, Roth, Rees and Belafsky (2007) conducted an investigation to assess the reliability of 
the pharyngeal squeeze maneuver on 40 individuals undergoing the Fiberoptic Endoscopic 
Evaluation of Swallowing (FEES) procedure for various reasons. 
141
 The investigation revealed 
reliable differentiation of a normal vs. abnormal pharyngeal squeeze; but not between a 
diminished vs. absent pharyngeal squeeze. Fuller, Leonard, Aminpour and Belafsky (2009) 
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conducted an investigation to validate the pharyngeal squeeze maneuver by conducting 
simultaneous Videofluoroscopic Swallowing Study (VFSS) and endoscopic evaluation of 
swallowing procedures on patients with dysphagia. 
142
 Their findings suggested that the 
pharyngeal squeeze maneuver is a valid measure of pharyngeal strength and “motor integrity”. 
Patients with dysphagia affecting hyolaryngeal excursion, often exhibit reduced pharyngeal 
strength and diminished or absent ability to perform the maneuver. 
82
 Setzen et al., (2003) have 
shown that impairments in laryngopharyngeal sensation and pharyngeal motor function associate 
with high risk of aspiration. 
143
 Aviv et al., (2009) have also reported in their study consisting of 
patients with dysphagia from varied causes including some HNC that, patients who have a 
diminished or impaired pharyngeal squeeze are at greater risk for penetration and aspiration. 
144
 
Emerging evidence supports the pharyngeal squeeze technique in the swallowing rehabilitation 
of structural dysphagia, such as that post-RT/C, where in tissue fibrosis can cause a reduction in 
hyolaryngeal ROM. The current study therefore includes the pharyngeal squeeze maneuver as 
one of the exercises targeting the pharyngeal phase of swallowing aimed to potentially minimize 
post-RT swallowing impairments. 
 The Shaker Exercise 
The Shaker exercise consists of three one-minute sustained neck -lifts in a supine position 
with a one-minute rest period between each lift. Following this, the patient is required to lift the 
neck 30 times in the same position without sustaining each lift and without any rest period 
between the lifts. 
145
 The Shaker exercise is considered as an isometric/isokinetic exercise and 
has been reported to improve the strength of the suprahyoid musculature resulting in both 
improved hyolaryngeal movement and UES opening in healthy adults and some patients post-RT 
for HNCs. 
145-147
 Logemann, et al., (2009) found that the Shaker exercise resulted in significantly 
reduced post-swallow aspiration compared to traditional eclectic swallowing therapy in a small 
   23 
group of patients with varied diagnoses including post-RT/C for HNC. 
148
 Thus, although 
limited, the evidence is encouraging in applying the Shaker exercise to swallowing rehabilitation 
of the irradiated swallowing mechanism, which commonly involves impairments in UES 
opening. 
83
 The current study employs the Shaker exercise prophylactically based on two vital 
reasons: 1) it is one of the few evidence-based exercises shown to improve UES opening post-
RT/C 
83
 and 2) it has been shown to improve UES opening in the tissues of healthy older adults 
as well as previously treated HNC. 
145-147
 Given the known UES opening impairments commonly 
occurring post-RT/C, these explanations justify employment of the Shaker exercise in the 
prophylactic rehabilitation of swallowing in HNC patients. 
Swallowing Maneuvers 
 The Mendelsohn’s Maneuver 
The Mendelsohn maneuver was designed to prolong the extent and duration of 
hyolaryngeal elevation and cricopharyngeal opening. 
76
 Therefore it may be employed in patients 
with dysphagia who exhibit reduced laryngeal movement, delayed or reduced CP opening and/or 
a less coordinated swallow.
83
 Three HNC patients treated with organ preservations therapies with 
or without surgery exhibited significantly improved mean pressure amplitude at the tongue base- 
posterior pharyngeal wall contact, longer duration of contact and reduced pharyngeal residue 
using the Mendelsohn maneuver. 
149
 In fact, the Mendelsohn maneuver resulted in the longest 
duration of tongue base to posterior pharyngeal wall contact when compared to other maneuvers. 
In a patient who underwent right composite resection for cancer of the right retromolar trigone, 
the Mendelsohn maneuver improved tongue base retraction to the posterior wall in relation to 
both laryngeal closure and CP opening, improved the coordination and timing of events of the 
pharyngeal phase of swallowing and eliminated aspiration. 
77
  
The Mendelsohn maneuver requires that the patient initiates a swallow normally, then  
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grabs the voice box using the throat muscles as it is felt elevating, holding the position for a 
count of three and then completing the swallow. 
76
 Typically training of this maneuver begins 
without food and gradually as the patient is able to demonstrate the maneuver accurately, food 
may be introduced.
83
 Difficulty to comprehend and inability to monitor accuracy of its 
performance without the use of an external monitoring tool, have been two primary concerns 
with the employment of this maneuver in swallowing therapy. These may influence patient 
compliance and negatively impact the clinician‟s ability to provide accurate feedback.  
 Masako Maneuver 
The Masako or tongue-hold maneuver involves protruding the tongue and holding the 
anterior tongue between the central incisor teeth while swallowing. 
150
 The Masako technique is 
shown to improve contact between the tongue base and the posterior pharyngeal wall, 
150
 which 
is thought to be essential for bolus transit by inducing necessary pressure on the bolus.  In a 
study by Lazarus et al., (2002) three HNC patients treated with organ-preservation therapies with 
or without surgery exhibited improved pressure at tongue base- posterior pharyngeal wall and 
improved duration of contact. 
149
 The improvement remained limited to the structure‟s ROM 
without functional changes in the overall swallowing of patients. However, if appropriate 
swallowing exercises, which have been shown to address deficiencies in specific physiologic 
events during the swallow, are combined, the outcome of the therapy could lead to an overall 
improvement of swallowing function. This holds especially true for HNC patients, who exhibit 
dysphagia at multiple levels of the structural pathway. 
 The Supraglottic and Super-supraglottic Swallow Maneuvers 
The aim of the super-supraglottic swallow is to forcefully close the vocal folds both 
before and during the swallow thus preventing aspiration. 
79, 82
 Prolonged airway closure in 
normal and treated HNC patients has been demonstrated with the use of both, supraglottic and 
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super-supraglottic maneuvers on MBS studies and Fiberoptic Endoscopic Evaluation of 
Swallowing (FEES) procedures. 
77, 151
 The super-supraglottic swallow has been shown to result 
in earlier CP opening, prolonged pharyngeal swallow, initiation of laryngeal closure to an extent, 
prior to the swallow and altered extent of hyolaryngeal elevation prior to the swallow, than the 
supraglottic swallow. 
151
 The super-supraglottic maneuver provides additional airway protection 
as compared to the supraglottic swallow in that it involves anterior arytenoid tilting to contact the 
base of the epiglottis or base of tongue in case the epiglottis is resected. 
79
 In patients with HNC 
treated with RT/C, the super-supraglottic maneuver results in early laryngeal closure, 
149
 
improved tongue-base retraction, 
149
 improved hyolaryngeal elevation at the time of UES 
opening and improved maximum hyolaryngeal displacement. 
21
 
The super-supraglottic swallow involves taking a deep breath and holding it tightly, 
bearing down and swallowing while continuing to hold the breath and coughing when finished.
83
 
Although the supraglottic and super-supraglottic maneuvers have been shown to improve 
hyolaryngeal elevation and laryngeal closure, these maneuvers are designed for patients who 
mainly aspirate before or during the swallow and/or who have undergone a surgical procedure 
such as a partial laryngectomy or supraglottic laryngectomy, to help compensate for some loss of 
structure. In addition these swallow maneuvers are considered as compensatory techniques rather 
than behavioral exercises and they need to be performed prior to each swallow of a bolus.  
 Effortful Swallow 
By forcing the bolus through the pharynx and the UES, the effortful swallow helps to 
reduce the amount of residue in the pharynx after the swallow. 
82
 The effortful swallow may be 
employed in patients treated for HNC who exhibit diminished tongue strength, reduced 
pharyngeal contraction, reduced hyolaryngeal elevation, reduced laryngeal closure and 
dysmotility of the CP sphincter. 
83
 In healthy normal subjects, an effortful swallow results in 
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significantly increased oral pressure, reduced oral residue, prolonged laryngeal closure, increased 
hyoid excursion and elevation, 
152
 prolonged pharyngeal pressure duration, prolonged UES 
relaxation duration 
153
 and increased peristaltic amplitude in the distal esophagus. 
154
 Three HNC 
patients treated with organ preservations therapies with or without surgery exhibited highest 
mean pressure amplitudes at the tongue base- posterior pharyngeal wall contact, with the use of 
an effortful swallow. 
149
 Also, a longer duration of tongue base contact with the posterior 
pharyngeal wall was evident with the use of an effortful swallow versus no maneuver in all three 
patients. The effortful swallow maneuver requires that patients swallow by squeezing hard with 
all their throat muscles thus increasing tongue base retraction, pharyngeal pressure and bolus 
transit from the vallecular spaces. 
82
 On the downside, particularly in HNC patients, it has been 
reported that the effortful swallow may result in fatigue causing a reduction in the accuracy of its 
performance. 
14
 The McNeil Dysphagia Therapy Program (MDTP) 
155
 employs the hard swallow 
maneuver intensively (1 hour daily for 3 weeks in therapy), in conjunction with bolus 
consistency and volume modifications and gradual increases in eating rate and amount of oral  
intake. The program has been shown to result in the following physiological and functional 
improvements in patients with persistent dysphagia (>12 months) post- HNC treatments and/or 
neurological injury: improvements in scores on the Mann Assessment of Swallowing Ability 
(MASA), improved FOIS scores,  improves scores on the Visual Analog Scale (VAS)- a measure 
of patient perception of swallowing ability, reduction in PEG tube dependence (from 78% to 
33%), biomechanical swallowing improvements with at least one consistency (hyolaryngeal 
elevation, lingual-palatal pressure, pharyngeal manometric measures, sEMG mean 
amplitude).
155, 156
 Most gains were statistically significant; most gains were maintained at the 3-
month follow-up.  
Table 2.3 provides a summary of the studies investigating the impacts of behavioral  
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swallowing exercises that have been employed in swallowing rehabilitation of HNC patients, 
post-RT/C. Research continues to be warranted to address specific benefits of exercises to 
irradiated tissue. Limitations of the available literature in concluding the impact of reactive 
swallowing therapy include but are not limited to: 1) small sample sizes, limiting generalization 
of findings, 2) employment of different combinations of exercises between studies, 3) mixed 
subject pool with various diagnoses, 4) lack of reports of correlation of physiological outcomes 
to function and QOL, 5) failure to include control groups, 6) failure to include comparison 
groups, 7) use of non-standardized assessment tools and outcome measures, 8) sham treatment 
groups or crossover of treatment groups to identify placebo effects, 9) majority non-experimental 
or quasi-experimental designs raising questions regarding reported outcomes, 10) lack of 
collection of baseline data to address natural variability among individuals‟ performance, 11) 
lack of control of confounding factors, and 12) employment of convenience samples rather than 
randomization and lack of assessor blinding. 
157
 Methodological inadequacies and differences 
within and between studies; make objective conclusions regarding the effectiveness of 
swallowing therapy in patients quite difficult. 
14
 This results in much reliance on the clinician‟s 
knowledge, judgment and clinical experience in the management of structurally induced 
dysphagia. Therefore research addressing these gaps in dysphagia treatment for the HNC 
population is warranted to achieve an evidence-based standard of care. Amidst continued 
investigations of the effects of behavioral swallowing techniques on swallowing outcomes post-
RT/C, an aggressive, prophylactic approach to swallowing therapy is underway, and currently 
appears to already be influencing the assessment and management approaches employed by 
clinicians to rehabilitate this group of patients. 
 
   28 
Table 2.3: Summary of studies investigating the impacts of behavioral swallowing exercises in 
improving swallowing biomechanics and function following radiation therapy with/without 
chemotherapy (RT/C) for head and neck cancers (HNC) 
Target Exercise Findings 
 
Jaw ROM Unassisted ROM Improved jaw opening 
126, 127
 
 
 Stacked tongue 
depressors 
 
Improved jaw opening 
127
 
 Therabite® Improved jaw opening 
125, 127
 
 
Tongue ROM Unassisted ROM Improved tongue-base retraction 
81
 
 
 Masako Improved pressure at the tongue base- posterior pharyngeal wall 
contact 
77, 149
 
Longer duration of contact 
149
 
 
Tongue strength Tongue-depressor/spoon N/A 
 
 IOPI N/A 
 
Laryngeal 
ROM 
Pharyngeal squeeze  
 
N/A 
 Mendelsohn Improved pressure at the tongue base- posterior pharyngeal wall 
contact 
77, 149
 
Longer duration of contact 
149
 
Reduced pharyngeal residue 
149
 
Improved coordination & timing of pharyngeal phase events of 
swallowing 
77
 
Eliminated aspiration 
77
 
 
 Shaker exercise Improved UES opening 
145
 
Improved anterior laryngeal excursion 
145
 
Eliminated aspiration after the swallow 
145, 148
 
Resumed oral feeding 
145
 
 
Maneuvers Supraglottic swallow Prolonged airway closure 
77, 151
 
 
 Super-supraglottic 
swallow 
Prolonged airway closure 
77, 151
 
Anterior arytenoid tilting to contact the base of the epiglottis or base 
of tongue in case the epiglottis is resected 
79
  
Early laryngeal closure 
149
 
Improved tongue-base retraction 
149
  
Improved hyolaryngeal elevation at the time of UES opening 
21
 
Improved maximum hyolaryngeal displacement 
21
 
 
 Effortful swallow Highest mean pressure amplitudes at the tongue base- posterior 
pharyngeal wall contact 
149
  
Longer duration of tongue base contact with the posterior pharyngeal 
wall 
149
 
 
*ROM: range-of-motion; N/A: not available 
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2.3 Review of Current Clinical Practice in Dysphagia Rehabilitation of the Head and Neck 
Cancer (HNC) Patient Population- Prophylactic Behavioral Swallowing Therapy 
Recent advances in neural plasticity and exercise physiology sciences, and the 
applications of their principles to reintegration of fibrotic tissue post-RT/C, have resulted in the 
emergence of proactive or prophylactic swallowing therapy, which is essentially introduced with 
an intention of potentially preventing or minimizing the known post-RT/C swallowing 
impairments. This has been one of the most vital changes in patients‟ therapeutic regimens in the 
last decade. Experts in the field have promoted the concept of prophylactic swallowing exercises 
for HNC patients, for several years. 
80, 82, 96, 103, 158
 However, it wasn‟t until recently that this 
approach to swallowing rehabilitation attracted the focus of several experts in the field. Only five 
studies have been conducted to evaluate the impacts of introducing swallowing exercises prior to 
or during RT/C on post-RT/C swallowing outcomes. 
86, 88-91
 Their research protocols and 
findings are summarized in Table 2.4.  
In summary, the five investigations that have been conducted so far have addressed the 
impacts of prophylactic swallowing exercises on swallowing biomechanics, 
86, 89, 91
 muscle 
preservation, 
91
 PEG tube dependence, 
86, 89, 91
 eating ability, 
89-91
 salivary, taste and smell 
functions, 
91
 weight loss, 
89, 90
 QOL, 
88, 90
 and compliance with swallowing exercises.
89, 91
 
Additionally, Retel et al., (2011) have demonstrated the cost-effectiveness of prophylactic 
swallowing therapy (Netherlands‟ healthcare costs and currency) over usual patient care in 
terms of tube dependency at 12 months and number of days of hospital admission upto 1 year 
post-RT/C. 
159
 Unfortunately, all studies report the employment of highly varied exercise 
protocols, making clinical generalization difficult. Nonetheless, this is necessary in obtaining the 
most beneficial exercise protocol (i.e. type of task, frequency and intensity). Not all interventions 
employed by the above studies yielded significantly better outcomes than control or sham 
groups; hence continued research to investigate the most optimal exercise schedule is warranted. 
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Table 2.4: Summary of the available literature investigating the impacts of prophylactic swallowing therapy on swallowing 
outcomes post- radiation therapy with/without chemotherapy (RT/C) 
STUDY & PROTOCOL SUBJECTS & METHODS 
 
 
OUTCOMES FINDINGS LIMITATIONS 
 
 
Kulbersh et al., 2006 
 
Mailed survey to patients 
1) h/o RT + ChT 
2) h/o University of Alabama 
(UAB) dysphagia therapy 
protocol  
 
Exercise Protocol: Mendelsohn, 
tongue-hold & tongue resistance 
(5 sets of 10 rep); Shaker (5 
sets); Falsetto phonation (few 
patients) 
 
 
Experimental (2)  Control  
 
Experimental Group 1: n=25 
Mean age: 55.1 years          
Gender (%): 76M: 24F 
Tumor size: T1-2 = 29.2%; T3-4 = 70.8% 
T site: OPhx = 92%; Lx = 8% 
Therapy 2 wks before RT; f/u at 2 & 6 wks 
 
Experimental Group 2: n=12 
Mean age: 60.3 years          
Gender (%): 75M: 25F 
T size: T1-2 = 50%; T3-4 = 50% 
T site: OPhx = 58.3%; Lx = 25%;  
           NPhx = 8.3%; Neck = 8.3% 
Therapy 1
st
 wk of RT; f/u at 2 & 6 wks 
 
 
 
QOL 
-MDADI score  
 
Group 1 f/u:  
6-12 mos  
(median= 9 mos) 
 
Group 2 f/u:  
6-20 mos 
(median=14 mos)  
 
 
 
MDADI scores: 
 
Group 1 sig > than Group 2 
-overall, global, emotional & 
physical scores 
 
No sig diff in: 
-Functional score 
 
Concurrent chemotherapy: 
No impact on scores  
 
 
-Not randomized 
 
-Varied accrual 
times of Groups 
 
-MDADI completed 
at different f/u times 
 
-Did not report raw 
scores 
 
-Not assessed: 
Physiological 
Functional  
Weight 
Compliance 
 
Carroll et al., 2008 
 
Retrospective case-control 
design 
1) III/IV cancers 
2) h/o RT/C  
3) Dose ≥ 70 Gy  
 
Exercise Protocol: 
Mendelsohn, tongue-hold, 
tongue resistance & effortful 
swallow (5 sets of 10 rep); 
Shaker (1 set) 
 
 
Experimental  Control  
 
Experimental Group (EG): n=9 
Mean age: 57.5 years         
Gender (%): 78M: 22F 
T site: OPhx= 78%; Lx= 22% 
Therapy ~ 2 wks prior to RT/C 
 
Control Group (CG): n=9 
Mean age: 60.7 years          
Gender (%): 56M: 44F 
T site: OPhx= 78%; Lx= 11%;  
           HPhx= 11% 
Therapy post-treatment as is typical 
 
Physiological 
-MBS study @ 3 mos 
post-RT/C 
 
Functional 
- Rate of PEG tube 
d/c @ 12 mos 
 
 
 
All patients had PEG tubes 
placed prophylactically 
 
EG- sig > than CG: 
-Tongue base position  
-Epiglottis inversion 
 
No significant difference: 
-Hyoid elevation 
-Tongue base movement 
-CP opening 
-Aspiration score 
-PEG tube elimination 
 
-Small sample size 
 
-Not randomized 
 
-Not assessed: 
QOL 
Weight 
Compliance 
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(Table 2.4 continued) 
 
van der Molen et al., 2011 
 
Prospective randomized trial  
1) III/IV cancers 
2) RT +ChT 
3) Dose 70 Gy 
 
EG Exercise protocol: 
TheraBite® (Atos Medical AB, 
Horby, Sweden) (Stretch 
exercises 3 times & strength 
exercises 10 times daily) 
 
SG Exercise protocol: 
Logopedic strengthening 
exercises including jaw ROM (3 
sets daily) & effortful swallow, 
Masako maneuver & supraglottic 
swallow (5 sets daily) 
 
Experimental (2)  Control  
 
Experimental Group (EG): n=24 
Mean age: 56 years               
Gender(%): 96M: 4F 
T site: OC= 6%; OPhx= 43%; HPhx= 35%     
           Lx= 2%; NPhx= 14% 
Therapy ~ 2 wks prior to RT/C 
 
Standard Group (SG): n=25 
Mean age: 57                      
Gender(%): 64M: 36F 
T site: OC= 12%; OPhx= 36%;  
           HPhx= 32%; Lx= 4%; NPhx= 16% 
Therapy ~ 2 wks prior to RT/C 
 
Baseline & 10 wks 
post-RT/C 
 
Physiological 
-MBS studies 
-mouth opening 
-Pain scale 
 
Functional 
-FOIS scores 
-PEG tube 
 
Weight & Body Mass 
Index 
 
Compliance 
- Familiarity 
- # Practice days 
- Reason for quitting 
Post-RT/C physiology: 
- 18% aspiration 
- decreased residue  
- decreased mouth opening  
- weight loss (6.1 kg) 
- no decrease in BMI 
- decrease FOIS scores  
(35% scores 1, 2 or 3) 
- SG < residue than EG 
 
Post-RT/C Function: 
PEG post-RT/C: 38/49 (78%)  
PEG at 10 weeks: 17/49 (35%)  
 
Compliance: 
-57% “very familiar with the 
exercises” (as a group) 
- SG complied > EG 
- Females complied > Males 
-Lack of a control 
group 
 
-Not assessed 
QOL  
 
Ahlberg et al., (2011) 
 
Prospective non-randomized trial 
1) Mean RT EG= 65 Gy 
2) Mean RT CG= 63 Gy 
3) ± surgery pre/post 
4) ± ChT 
 
EG Exercise protocol: 
Mendelsohn‟s maneuver (10 rep 
x 2 daily); tongue ROM 
exercises (5 rep each x 2 daily) 
Received PT & nutrition 
counseling prior to RT 
 
 
Experimental  Control  
 
Experimental Group (EG): n=84 
Mean age: 63.6                    
Gender(%): 67M:33F 
T stage: I= 11%; II= 19%; III= 14%;  
             IV= 45%; Missing= 11% 
T site: OC= 36%; OPhx= 33%; HPhx= 7%   
           Lx= 10%; O= 14% 
Therapy prior to the initiation of RT. 
 
Control group (CG): n=121 
Mean age= 64.1                        
Gender: 68M: 32F 
T stage: I= 14%; II= 16%; III=19%;  
             IV= 37%; Missing= 14% 
T site: OC= 30%; OPhx= 31% 
No SLP or PT 
Pre-treatment and 3 
mos post-treatment 
 
Physiological 
-Bedside swallow 
 
-Weight loss 
 
QOL  
-EORTC-QOLO-C30 
-EORTC-H&N35 
-HADS 
-Project specific  
EG = CG: 
-physiology 
-weight loss  
(5.9 kg EG vs. 6.2 kg CG) 
-QOL assessment 
 
All consistencies po: 
- EG: 35% vs. CG: 58% 
 
- CG returned to work at a 
higher rate than the EG 
- 61% dysphagia 
- 92% xerostomia 
 
At 6mos 
- 61% chewing problems  
- 51% less mouth opening  
- 70% stiffness in neck  
-EG & CG were 
recruited at different 
centers 
 
-No instrumental 
evaluations were 
used to report 
physiology of 
dysphagia  
 
-Patients were seen 
by SLP only once 
prior to RT. 
 
-Not assessed 
Functional  
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(Table 2.4 continued) 
 
Carnaby-Mann et al., (2011) 
 
Randomized, controlled trial 
1) OPhx cancers 
2) RT (38) ± CC (22) ± neck 
dissection  
3) no h/o PEG for cancer 
 
CG Exercise regimen: 
Supervision for feeding & safe 
swallow precautions if at all. 
Weekly phone calls to monitor 
 
SG Exercise regimen: 
Buccal extension maneuver (10 
reps in 4 sets, each 10 mins) + 
diet modifications, twice daily in 
a 45 min session 
 
Pharyngocise Exercise regimen: 
falsetto, tongue press, hard 
swallow, Therabite (10 reps in 4 
sets, each 10 mins) + diet 
modifications, twice daily in a 45 
min session 
 
Experimental Control Sham 

Exercise Group (Pharyngocise): n= 20 
Mean age= 59                       
Gender(%): 90M:10F 
T stage median (range):  2 (1 to 4) 
T site: Base of tongue, Tonsil 
Mean RT dosage: 72.5 Gy 
 
Control group (CG): n= 20 
Mean age: 54 
Gender (%): 75M: 25F 
T stage median (range): 2 (0-4) 
Tumor site: Base of tongue, Tonsil 
Mean RT dosage: 67.5 Gy 
 
Sham group (SG): n=18 
Mean age: 60 
Gender (%): 61M:39F 
T stage median (range): 2 (1-4) 
Tumor site: Base of tongue, Tonsil 
Mean RT dosage: 69.2 Gy 
 
 
  
Baseline & post-
RT/C  
 
Physiology 
- T2-weighted MRI 
(change in muscle 
size & composition) 
- MBS study 
- Mouth opening 
- Saliva production 
 
Function 
- FOIS scores 
- PEG 
- Mann assessment of 
swallowing ability 
(MASA) 
- Smell & taste 
- Nutrition exam 
- Weight loss 
 
- QOL questionnaires 
 
 
Overall 
- 14% aspiration 
- 21% PEG (4/6 in CG) 
- 23% maintained normal diet 
- 31% reduced MASA scores 
- 6.69 kg weight loss 
- 65% mucositis 
- 14% oral yeast infection 
  
Pharyngocise exhibited: 
- more genioglossus, 
mylohyoid & hyoglossus 
muscle preservation vs. CG & 
SG 
- less decline in mouth 
opening than SG & CG 
- more preservation of saliva 
- better maintenance of PO 
intake (i.e. 42% vs. 14% CG) 
- Median FOIS (5 post-RT/C) 
(not sig vs. CG & SG) 
- less PEG (25%) 
- less deterioration in MASA 
scores vs. CG & SG 
- more preservation of taste 
- more preservation of smell 
- weight loss  
 
Compliance 
- overall 68% 
- SG > Pharyngocise 
 
 
Only 31/58 patients 
had a 6 month f/u 
hence no data on f/u 
after post-treatment 
 
 
OC: oral cavity; NPhx: nasopharynx; OPhx: oropharynx; HPhx: hypopharynx; Lx: larynx; O: other; M: male; F: female; T: tumor; mos: months; 
SLP: speech language pathology; PT: physical therapy; QOL: quality-of-life; EG: experimental group; CG: control group; SG: Sham group or 
Standard group; RT: radiation therapy; ChT: Chemotherapy; RT/C: radiation therapy with/ without chemotherapy; f/u: follow-up; wks: weeks; 
MDADI: MD Anderson Dysphagia Inventory; MBS: Modified Barium Swallow; d/c discharged; rep: repetitions; MRI: Magnetic Resonance 
Imaging; mins: minutes 
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The current study therefore hypothesizes that a clinically feasible, evidence-based prophylactic 
exercise protocol will result in better swallowing outcomes in its patient group, compared with a 
no treatment group and with literature at post-treatment and at 3 months-post treatment.  
2.4. Application of the Principles of Exercise Physiology and Neural Plasticity to 
Swallowing Rehabilitation Post-Radiation Therapy with/without Chemotherapy (RT/C) for 
Head and Neck Cancers (HNC) 
Recent advances in the study of neural plasticity and exercise physiology have provided a 
new scientific direction to research in the rehabilitation of dysphagia. This is especially true of 
structurally-induced dysphagia from irradiation, which is particularly challenging to restore. 
RT/C is known to cause significant muscle change leading to edema and fibrosis as elaborated 
earlier. Further, the reduction in the use of swallowing muscles by patients going through 
treatment is postulated to result in muscle weakness and sometimes atrophy. Skeletal muscle 
exhibits notable plasticity in response to functional demands. 
160
 Swallowing exercises are 
performed prior to/ during/ after RT/C to facilitate muscle function and maintain or restore 
swallowing function. The evidence of the employment of behavioral exercises for these purposes 
is largely derived from the sciences of neural plasticity and exercise physiology.  
Kent (2004) described speech as one of the fastest discrete-rate human motor behaviors 
and “speech muscles have distinctive lifespan patterns, functional properties and molecular 
phenotypes.” 161 Kent‟s (2004) and Kent and Robbins‟ (2011) review of the literature has 
indicated that oropharyngeal musculature significantly varies in structure and function from all
other muscles of the human body. 
161, 162
 Oropharyngeal muscles are capable of not only causing 
a constriction in the aerodigestive tract to allow smooth downward passage of the bolus; but 
these muscles also dilate the same tract during inhalation. 
93, 161
 Animal studies have indicated 
that the tongue in rats has motor units that are fatigue-resistant. 
163
 Even after prolonged 
speaking, speech muscles are not easily fatigued. 
161
 According to Stal and Lindman (2000), 
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palatal muscles including the levator veli palatini and the tensor veli palatini have high aerobic  
capacity and a rich supply of capillaries making these muscles highly fatigue-resistant. 
164
 
Fatigue in speech muscles is evident typically in cases of pathologies such as Myasthenia Gravis, 
impairing the continuous muscular demands of speaking.  
The structural and functional differences between speech muscles and the remaining 
muscles of the body have also been shown to translate into differences in treatment options. For 
example, many medical interventions that are employed for non-speech muscle groups, such as 
the limbs either do not affect speech motor control desirably or result in worse outcomes. 
161
 
Even within neurological disorders, interventions highly vary and one intervention cannot be 
employed for every neurological condition, due to the differential manners in which muscles are 
affected. 
161
 Therefore, McComas (1998) has highlighted the importance of avoiding 
generalization of research findings from one group of muscles to the other. 
161
 The principles of 
exercise physiology, which have been established primarily from experiments involving large 
muscles such as limb muscles, should not be extrapolated for speech and swallowing muscle 
groups without conducting thorough investigations and experiments with these highly unique 
groups of muscles. Further, the unique nature of irradiated tissue is sufficient to question the 
applicability of rehabilitation adapted from the principles of exercise physiology employed 
mainly in other muscle groups or similar muscle groups with varied nature of impairments. 
However, these principles should serve as the foundation in initiating specific research in 
dysphagia.  
In reviewing the science of exercises, Burkhead (2009) has indicated that any muscle 
disease, injury, disuse or even normal aging causes reduced use of the particular muscle and 
resultant deconditioning. 
93
 Under deconditioning, muscles atrophy, become less efficient and 
easily fatigued. Such structural adaptations are accompanied by changes in nervous system 
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activation as well. When exercise training of muscles is initiated, typically neural changes begin 
to occur and precede structural changes. 
93
 Gradually, the role of neural adaptation decreases as 
the muscle fibers begin to enlarge and exhibit improved endurance. 
165
 Again, these processes of 
deconditioning and adaption have been explored only in larger muscles of the body, and not in 
the muscles specific to the swallowing mechanism . Therefore, when applying these principles to 
the muscles of swallowing, it is vital to first identify the treatment objective of strength training 
in dysphagia. 
93
 The clinician must determine whether the goal of therapy is to increase strength, 
improve coordination and/or improve speed of movement. Establishment of treatment goals are 
generally achieved following assessment via an instrumental evaluation of the individual‟s 
swallowing with various volumes of liquid and food consistencies. Based on the impairments 
identified, therapeutic tasks should be selected to build a therapeutic regimen for each individual 
patient. This concept is especially important in dysphagia treatment following treatments for 
HNC. Irradiated tissue is likely to exhibit reductions in muscle strength, coordination as well as 
speed of movement, and subsequent muscle atrophy. 
Neural plasticity has been defined as the ability of the brain to make alterations. 
166, 167
 
There is emerging evidence to show that following injury to the brain, neural plasticity is 
responsible for re-modeling of target functions. 
166
 The ten principles of neural plasticity
168
 as 
applied to dysphagia therapy
166
 include:  use it or lose it; use it and improve it; plasticity is 
experience-specific; intensity matters; repetition matters; time matters; salience matters; age 
matters; transference and interference. In selecting therapeutic tasks, the principles of saliency 
and intensity of exercises are vital. 
93
 The principle of specificity/ saliency suggests that the 
training task should resemble the target activity as much as possible to make maximum gains. 
Thus, general strengthening exercises alone may not improve activity or muscle function. 
According to the principle of intensity of exercises, any activity that does not result in working a 
 36 
muscle beyond its capacity (i.e. increased activity) may not result in neuromuscular adaptation.169 
Burkhead (2009) has recommended that it may be best to work a muscle until fatigue is reached 
rather than performing each exercise for a specific number of repetitions in a specific number of 
sets. 
93
 The intensity of the activity must then be increased both within a session and over a 
period of time to cause adaptations. In exercise sciences, this practice is referred to as 
progressive resistance. 
93
 Sapienza, Wheeler-Hegland, Stewart, and Nocera (2008) have 
proposed that no less than 2 weeks of direct treatment delivered 3-5 times per week may be 
recommended to expect improvements specific to dysphagia. 
170
  However again, these 
recommendations are not specific to cancer treatment-induced dysphagia and hence are not part 
of the standard of care in the field. Emerging studies 
86, 88-90
 particularly the one by Carnaby-
Mann et al., (2012) 
91
 has demonstrated the positive effects of exercises on muscle size and 
composition. These effects potentially reflect at least partially the adequacy of the type of 
therapeutic task, its intensity and frequency employed by the researchers. However, no research 
has established optimal treatment dosage at this time. Future investigations are recommended to 
derive optimal clinical decisions as well as provide insights into the much needed evidence to 
guide optimal standard of care for irradiated tissue.  
In dysphagia exercise literature, several strengthening exercises and swallowing 
maneuvers have been employed in multiple repetitions and sets, demonstrating the application of 
the principle of intensity in clinical practice. One of the high intensity exercises employed in the 
treatment of dysphagia is the Shaker exercise. 
93
 Shaker exercises employed in dysphagia include 
a frequency and intensity adapted from exercise physiology literature. 
170
 The Shaker exercise 
when performed over six weeks has been shown to result in improvements in the UES opening in 
the anterior-posterior direction, anterior laryngeal excursion, bolus clearance and safety and 
efficiency of oral intake. 
145
 Another high intensity and high effort exercise regimen, the Lee 
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Silverman Voice Therapy (LSVT) when employed for four weeks by patients with Parkinson‟s 
disease, has been shown to improve oral, pharyngeal and laryngeal swallowing measures. 
171
 
Healthy progressive lingual muscle strength training for eight weeks has been shown to improve 
the force generating capacity of the tongue, oral pressure generation and airway protection in 
patients with dysphagia post-stroke. 
131
 Muscle hypertrophy i.e. increased lingual volume was 
also evident in two patients in this study. Expiratory Muscle Strength Training (EMST) 
employed for four weeks has been shown to improve expiratory pressure generations and airway 
protection in patients with Parkinson‟s disease. 172 Authors have reported that the use of the 
EMST to exhale against 75% load of respective patients‟ maximal expiratory pressure, elicits 
notable neuromuscular activity in the suprahyoid muscles responsible for hyolaryngeal excursion 
and airway protection. Progressive resistive lingual strength training and EMST reportedly force 
adaptations in one or more muscle groups, which carry over to the function of swallowing. 
93
 25 
to 30 repetitions of lingual exercises per day and 3 sustained and 30 repetitive Shaker exercises 
per day, 3-5 days a week for 4-8 weeks have been recommended. Set frequency and intensity 
schedules are not available for other exercises and a clinically based intensity is often used. 
170
  
Similarly, although without direct reference, therapeutic tasks employed in dysphagia 
practice closely abide by the principles of saliency and specificity. It is noteworthy however, that 
most strength training exercises in dysphagia have been employed in patients with neurological 
impairments. Rehabilitation of the unique irradiated tissue which results in impairments in 
muscle strength, coordination and speed of movement, requires more specific exercise 
investigations focused towards resolving muscle fibrosis. For instance, the effortful swallow 
although helpful in some oropharyngeal dysphagia may require increased muscle effort, which in 
turn may cause fatigue to irradiated fibrotic tissue as well as fatigue to the person and affect its 
execution over time. 
14
 Yet, other studies have demonstrated the benefits of a hard swallow 
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incorporated into an exercise program, on swallowing outcome. 
155, 156
 This appears to warrant 
the evaluation/ redefinition of principles which may be specific to irradiated tissue structure and 
function. Robbins (2012) has reported that strength training alone may not be sufficient in 
improving swallowing function, sensorimotor stimulation involving a stimulus-response pattern 
may be essential. 
173
 Emerging literature focuses towards establishing an optimal prophylactic 
swallowing therapy protocol for HNC patients. Future studies are needed to determine which 
swallowing exercises are most appropriate at what intensities and frequencies to potentially 
minimize or resolve the effects of RT/C on irradiated muscle physiology and function. 
The current investigation aims at determining how prophylactic exercises based on the 
principles of exercise physiology and neural plasticity, (in particular, use it or lose it; intensity 
matters; repetition matters; and salience matters) 
166
 influence swallowing physiology and 
function outcomes following HNC treatments. This investigation is hypothesized to improve the  
understanding of the differential impacts of a combination of currently employed behavioral 
exercises vs. a swallow-specific intense therapeutic task, on swallowing outcomes. The „exercise 
group‟ of this study performed the Masako maneuver, the pharyngeal squeeze exercise and the 
Shaker exercises. The „repetitive swallow group‟ performed an intense number of repetitive 
swallows of saliva with sips of water as needed. The rationale for employing these therapeutic 
tasks is presented in the Procedures section of Chapter 3- Design and Methods, which follows.  
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CHAPTER 3: DESIGN AND METHODS 
To evaluate the proposed hypotheses, a prospective study was conducted at the Mary 
Bird Perkins Cancer Center (MBPCC) in Baton Rouge, Louisiana. Institutional Review Board 
(IRB) approvals to conduct the study at the MBPCC, were obtained from the Louisiana State 
University (LSU) in Baton Rouge, Louisiana State University Health Sciences Center 
(LSUHSC) in New Orleans, Earl K Long (EKL) Medical Center in Baton Rouge and Our Lady 
of the Lake (OLOL) Regional Medical Center (RMC) in Baton Rouge. 
3.1. Recruitment of Patients in the Experimental Groups 
All newly diagnosed HNC patients who were to undergo radiation therapy with/without 
chemotherapy (RT/C) between December 1, 2010 and January 30, 2012, at the MBPCC, were 
referred to the OLOL-Voice Center (VC) in Baton Rouge, for a routine, baseline MBS study, and 
were subsequently recruited upon eligibility. The MBS study protocol employed at the OLOL-
VC is described in Appendix A. Following the MBS study, patients were screened for 
qualification in the current study. The inclusion and exclusion criteria for patient recruitment in 
the experimental groups of the study are presented in Table 3.1. If patients met these inclusion 
criteria, a short recruitment session was conducted with the patient with/without their family 
members. During the session, the study coordinator briefly explained the objectives and 
procedures of the current study, fully outlined in the Informed Consent (Appendix B). If the 
patient expressed interest in participating in the study, he/she along with the family members 
were encouraged to read the Informed Consent. On obtaining patient-agreement to participate in 
the study, he/she was requested to sign the LSU-approved Informed Consent, the LSUHSC-
approved Informed Consent and the LSUHSC-approved Health Insurance Portability and 
Accountability Act (HIPAA) Statement.  
Neo-adjuvant (prior to RT) or concurrent (alongwith RT) chemotherapy (ChT) is typically 
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Table 3.1: Inclusion criteria and exclusion criteria for patient-recruitment to the experimental 
groups of this study 
Inclusion criteria Exclusion criteria 
i) Diagnosis of cancers of the oral cavity, 
oropharynx, nasopharynx, hypopharynx, 
larynx and/or nodal disease 
i) Evidently or reportedly with diminished 
ability to comprehend and perform therapy 
tasks, due to any reasons 
ii) Evidence of functional swallowing abilities 
assessed using a baseline MBS study, prior to 
the initiation of RT/C 
ii) Dysphagia warranting PEG tube placement 
prior to the initiation of RT/C 
iii) Without prophylactic PEG tube placement  
iv) Signed Informed Consent  
PEG: feeding tube; MBS: Modified Barium Swallow; RT/C: radiation therapy with/without chemotherapy 
employed in the treatment plan of advanced head and neck tumors vs. smaller tumors. 
102
 Not all 
patients received ChT in this study. As described in detail earlier, ChT by itself minimally affects 
patients‟ swallowing abilities; its toxicities co-exist with those of RT when used in combination. 
71, 24
 Therefore irrespective of whether patients received ChT prior to or during RT or not, as 
long as they continued with functional swallowing abilities without any indication for the need of 
a PEG tube prior to initiating RT, they qualified for recruitment in this study. Similarly, some 
patients in this study underwent pre-RT surgeries when considered appropriate. As long as these 
patients did not exhibit any swallowing impairments on their post-surgery MBS evaluation, they 
qualified for recruitment in the study. 
A total of 50 consecutively referred patients who met the inclusion criteria of the study 
were prospectively recruited in two groups: i) the exercise group i.e., EX and ii) the swallow 
group i.e. SW. The first 25 patients were recruited in the two groups by alternate-assignment; 
however the next 25 patients were recruited in the respective groups with the intention of 
matching the groups for age, tumor size (T size) and tumor site (T site), as possible. Twenty-six 
patients constituted the EX group and 24 patients constituted the SW group.  
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3.2. Recruitment of Patients in the ‘No Treatment’ Group 
Only patients who underwent RT/C at the Baton Rouge site of the MBPCC were 
recruited in the study‟s experimental groups. Therefore patients who underwent RT/C at the 
other sites of the MBPCC i.e. Gonzalez, Hammond, Houma and Covington, did not receive any 
swallowing intervention prior to or during RT/C, and constituted the study‟s no treatment (NTx) 
group, upon qualification. The inclusion and exclusion criteria for patient recruitment are 
presented in Table 3.2. All patients in the NTx group underwent RT/C within the same timeline 
as the patients in the experimental groups of this study, i.e. December 1, 2010 to September 30, 
2011.  
Patients in the NTx group were recruited in a retrospective manner. Since these non-
Baton Rouge MBPCC treating sites do not have an onsite SLP or a nearby SLP with expertise in 
the HNC patient-population, these patients were not referred for SLP services. Recruiting 
patients prospectively after being referred from their doctors at the Baton Rouge site would pose 
ethical issues, given the emerging literarture on benefits of prophylactic therapy; hence this 
retrospective method appeared to allow recruitment of the most representative no treatment 
(NTx) group in this study.  
Table 3.2: Inclusion criteria and exclusion criteria for patient-recruitment to the no treatment 
(NTx) group of this study 
Inclusion criteria Exclusion criteria 
i) Diagnosis of cancers of the oral cavity, 
oropharynx, hypopharynx, larynx and/or nodal 
disease 
i) Any doctor‟s reports of diminished patient-
ability to follow commands or comprehend 
information due to any reasons 
ii) Indication of no dysphagia in doctor‟s 
consult notes, prior to the initiation of RT/C 
ii) Dysphagia warrantying PEG tube placement 
prior to the initiation of RT/C 
iii) Without prophylactic PEG tube placement  
RT/C: radiation therapy with/without chemotherapy; PEG: feeding tube 
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3.3. Pre-treatment Assessment of Group Differences in Demographic, Cancer-Related, 
Swallowing-Related and Cancer Treatment-Related Characteristics 
 
Chapter 2 of this document explained the influence of advanced age, tumor sites and 
tumor stage on swallowing outcomes. Since the methods of recruitment in the study could not 
ensure matched treatment and non-treatment groups, it was considered necessary to utilize 
statistical analyses to determine if at pre-treatment, the three study groups were similar in these 
characteristics, and prevent an influence of potential confounding factors on the outcome-
measures proposed in this study. Table 3.3. lists the pre-treatment variables compared between 
the EX, SW, EX+SW and/or the NTx groups.  
Table 3.3: List of pre-treatment variables compared between the exercise (EX), swallow (SW) 
and/or no treatment (NTx) groups 
 
 Pre-treatment Variables  
(level of measurement) 
 
Test Statistic 
Patient demographic 
 
Age (continuous) Mann-Whitney U test 
 
 
Gender (nominal, 2 levels) Fisher‟s exact test 
Tumor-related  
 
Tumor site (nominal, 5 levels) Pearson chi square 
 
 
Tumor stage (nominal, 4 levels) Mann-Whitney U test 
Swallowing physiology 
 
Aspiration (nominal, 2 levels) Fisher‟s exact test 
 PAS scores (ordinal, 1 to 8) 
 
Mann-Whitney U test 
Swallowing function FOIS scores (ordinal, 1 to 8) 
 
Mann-Whitney U test 
Swallowing-related QOL MDADI scores (continuous) 
Overall (1 to 100) 
Global (1 to 5) 
Emotional (1 to 30) 
Functional (1 to 25) 
Physical (1 to 40) 
 
Mann-Whitney U test 
Cancer treatment-related Pre-treatment surgeries (nominal, 2 levels) 
 
Pearson chi square 
PAS: Penetration Aspiration Scale; FOIS: Functional Oral Intake Scale; QOL: quality-of-life; MDADI: MD 
Anderson Dysphagia Inventory 
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Non-parametric test statistics were employed to assess pre-treatment between-group 
differences for dichotomous and ordinal level variables appropriately. Additionally, due to 
normality issues, non-parametric tests were also employed to compare groups on the basis of 
continuous level variables. To compare nominal level variables between groups, the Pearson chi 
square test was employed. If a cell count has less than the expected count of 5, the Fisher‟s exact 
test was used. To compare ordinal level variables between groups, the Mann-Whitney U test was 
utilized. Due to evidence of non-normal distributions, the Mann-Whitney U test was also 
employed to assess group differences on continuous variables. The type I error rate was set at α = 
.05.  
Patient Demographics (Age and Gender) 
Table 3.4 summarizes the demographic characteristics, including age (years) and gender 
of patients in the EX (exercise) and SW (swallow) treatment groups and of patients in the NTx 
(no treatment) group. At the time of recruitment to the treatment groups, patients were alternately 
assigned to the EX and SW groups, matching for age as possible. The Mann-Whitney U test and 
Fisher‟s exact test analyses revealed no statistically significant differences between the treatment 
groups in age (p=.217) and gender distribution (p=.294), respectively. Also, the NTx group did  
Table 3.4: Demographics of patients, including age and gender, in the exercise (EX) and swallow 
(SW) treatment groups and no treatment group (NTx) 
 
Demographics 
 
 
 
EX  
(N=26) 
 
SW 
(N=24) 
 
NTx 
(N=23) 
 
p value 
 
Age (years) 
 
Mean  
(range) 
Median 
Mode 
 
 
64  
(24 to 90) 
61 
60 
 
60  
(43 to 85) 
56.5 
53 
 
62  
(39 to 79) 
60 
60 
 
Mann-Whitney U 
EX vs SW, p=.217 
EX+SW vs. NTx, p=.849 
Gender # (%) 
 
Males 
Females 
 
19 (73) 
7 (27) 
21 (87.5) 
3 (12.5) 
19 (83) 
4 (17) 
Fisher‟s exact test 
EX vs SW, p=.294 
EX+SW vs. NTx, p=1.0 
 
#: number; EX: exercise group; SW: swallow group; NTx: no treatment group; No statistically significant 
differences between groups evident. 
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not statistically significantly differ from the treatment groups (EX+SW) in age (Mann-Whitney U 
test, p=.849) and gender (Fisher‟s exact test, p=1.0). 
Tumor Characteristics 
Table 3.5 summarizes the tumor characteristics, including tumor site (i.e. oral cavity, 
nasopharynx, oropharynx, hypopharynx, larynx or unknown primary tumors), tumor size (i.e. T1, 
T2, T3 or T4, T4 being the worst), nodal disease category (i.e. N0, N1, N2 or N3, N3 being the 
worst) and tumor stage (i.e. I, II, III or IV, IV being the worst) of patients in the EX and SW 
treatment groups and of patients in the NTx group. At the time of recruitment to the treatment 
groups, patients were alternately assigned to the EX and SW groups, matching for these 
characteristics at best possible. There were no statistically significant differences between the EX 
and SW treatment groups in the distribution of tumor site (χ2(5)= 2.048, p=.842) and tumor 
stage (Mann-Whitney U test, p=.762). The NTx group also did not statistically significantly 
differ from the treatment groups (EX+SW) in terms of either tumor site (χ2(5)= 7.631, p=.178) 
or tumor stage (Mann-Whitney U test, p=.260). 
Pre-treatment Swallowing Physiology, Function and Quality-of-Life (QOL) Assessments 
Pre-treatment swallowing assessment of all patients in the EX and SW treatment groups 
revealed physiological and functional swallowing abilities to be within functional limits (i.e. 
absence of any physiological impairments affecting patients‟ abilities to tolerate a full oral diet 
safely) on a baseline MBS study, as outlined by the inclusion criteria. Although the intention was 
the perform all pre-treatment MBS studies prior to the initiation of any RT, miscellaneous factors 
resulted in unexpected delays, and 23 of 50 MBS studies had to be performed within the first 
week of RT. These 23 patients did not self-report experiencing any dysphagia or RT related 
toxicities and demonstrated functional swallowing abilities on the MBS study. Table 3.6 presents 
pre-treatment aspiration (%), PAS scores (mean), FOIS scores (mean) and MDADI scores  
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Table 3.5: Tumor characteristics including tumor site, tumor size, nodal disease category and tumor stage, of patients in the exercise 
(EX) and swallow (SW) treatment groups and no treatment (NTx) group. 
 
 
 
EX (N=26) 
 
 
SW (N=24) 
 
NTx (N=23) 
 
p value 
 
Tumor site 
No. of patients (%) 
 
 
Oral cavity 
Nasal cavity 
Oropharynx 
Hypopharynx  
Larynx  
unknown 
 
 
2 (8%) 
1 (4%) 
9 (34%) 
2 (8%) 
7 (27%) 
5 (19%) 
 
Oral cavity  
Nasal cavity 
Oropharynx 
Hypopharynx 
Larynx  
unknown 
 
2 (9%) 
1 (4%) 
12 (50%) 
1 (4%) 
6 (25%) 
2 (8%) 
 
Oral cavity  
Nasal cavity 
Oropharynx 
Hypopharynx 
Larynx  
unknown 
 
2 (9%) 
1 (4%) 
6 (26%) 
2 (9%) 
12 (52%) 
0 
 
Pearson chi square 
EX vs. SW,χ2(5)= 2.048, p=.842 
EX+SW vs. NTx, χ2(5)= 7.631,p=.178 
Tumor size  
No. of patients (%) 
 
T0 
T1 
T2 
T3 
T4 
unknown 
 
3 (12%) 
6 (23%) 
5 (19%) 
6 (23%) 
1 (4%) 
5 (19%) 
T0 
T1 
T2 
T3 
T4 
unknown 
1 (4%) 
4 (17%) 
9 (37%) 
4 (17%) 
4 (17%) 
2 (8%) 
 
T0 
T1 
T2 
T3 
T4 
unknown 
0 
6 (26%) 
8 (35%) 
8 (35%) 
0 
1 (4%) 
 
 
N/A 
 
 
 
 
 
N/A 
Nodal disease  
No. of patients (%) 
 
N0 
N1 
N2 
N3 
unknown 
 
4 (15%) 
8 (31%) 
9 (35%) 
3 (11%) 
2 (8%) 
N0 
N1 
N2 
unknown 
 
8 (33%) 
3 (13%) 
11 (46%) 
2 (8%) 
 
N0 
N1 
N2 
N3 
unknown 
 
12 (52%) 
2 (9%) 
8 (35%) 
1 (4%) 
0 
Tumor stage 
No. of patients (%) 
 
I 
II 
III 
IV 
unknown 
 
2 (8%) 
1 (4%) 
10 (38%) 
12 (46%) 
1 (4%) 
I 
II 
III 
IV 
unknown 
3 (12%) 
5 (21%) 
4 (17%) 
11 (46%) 
1 (4%)
 
I 
II 
III 
IV 
unknown 
6 (26%) 
2 (9%) 
6 (26%) 
9 (39%) 
0 
Mann-Whitney U test 
EX vs. SW, p=.762 
EX+SW vs. NTx, p=.260 
 EX: exercise group; SW: swallow group; NTx: no treatment group; N/A: not applicable No statistically significant differences between groups evident
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Table 3.6: Pretreatment aspiration (%), Penetration Aspiration Scale (PAS) scores and 
Functional Oral Intake Scale (FOIS) scores estimated from Modified Barium Swallow (MBS) 
studies, and pretreatment MD Anderson Dysphagia Inventory (MDADI) scores- overall, global, 
emotional, functional and physical domains, of patients in the exercise (EX) and swallow (SW) 
treatment groups 
  
 
 
 
EX (N=26) 
 
SW (N=24) 
 
p value 
 
Aspiration 
 
 
 (%) 
 
2/26 (8%) 
(trace instance, 
eliminated 
spontaneously) 
 
 
1/24 (4%) 
(trace instance, 
eliminated 
spontaneously) 
 
Fisher‟s exact test 
p=1.0 
PAS scores 
 
Mean (range) 
Median 
Mode 
2 (1 to 8) 
1 
1 
1.8 (1 to 8) 
1.5 
1 
 
Mann-Whitney U test 
p=.915 
FOIS scores* 
 
Mean (range) 
Median 
Mode 
 
6.5 (5 to 7) 
7 
7 
6.6 (5 to 7) 
7 
7 
Mann-Whitney U test 
p=.551 
MDADI scores 
Overall  
Mean (range) 
Median 
Mode 
 
94.85 (64 to 100) 
100 
100 
91.25 (57 to 100) 
97.5 
100 
Mann-Whitney U test 
p=.234 
Global Mean (range) 
Median 
Mode 
 
4.85 (2 to 5) 
5 
5 
4.67 (1 to 5) 
5 
5 
p=.197 
Emotional Mean (range) 
Median 
Mode 
 
28.5 (21 to 30) 
30 
30 
28.67 (20 to 30) 
30 
30 
p=.695 
Functional Mean (range) 
Median 
Mode 
 
23.73 (15 to 25) 
25 
25 
23.17 (15 to 25) 
25 
25 
p=.505 
Physical Mean (range) 
Median 
Mode 
 
37.69 (21 to 40) 
40 
40 
34.83 (19 to 40) 
38 
40 
p=.095 
EX: exercise group; SW: swallow group; No statistically significant differences between the groups evident 
*A recommended FOIS score of 5 and 6 were always related to patients‟ inability to take certain tough solid 
consistencies due to dental treatments or extractions in preparation for RT 
 
(mean) obtained from the swallowing assessment of patients in both EX and SW treatment 
groups. Appendix D presents the PAS, FOIS and MDADI tools. 
 Physiological assessment: The EX and SW groups did not differ in % aspiration (Fisher‟s exact  
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test, p=1.0) and PAS scores (Mann-Whitney U test, p=.915) at pre-treatment. Two patients in the 
EX group and one patient in the SW group aspirated at pre-treatment, however these were only 
single instances of aspiration, were not repeated, eliminated spontaneously and did not warrant 
any dietary or behavioral intervention. Most importantly there was no indication of a need for a 
PEG tube for patients to meet their nutritional and hydration statuses safely.  
 Functional assessment: The EX and SW groups did not differ in FOIS scores (Mann-Whitney U 
test, p=.551). Scores of 5 and 6 (i.e. modified, full oral diets) were always related to patients‟ 
inability to take certain tough solid consistencies due to dental treatments or extractions in 
preparation for RT. 
 QOL assessment: The Mann-Whitney U test did not reveal any statistically significant
differences between the treatment groups on the pre-treatment MDADI-overall scores (p=.234), 
global domain scores (p=.197), emotional domain scores (p=.695), functional domain scores 
(p=.505) and physical domain scores (p=.095).  
Patients in the NTx group were recruited in a retrospective manner and did not undergo 
pre-treatment, baseline swallowing evaluations. However, as per the consultation notes in 
patients‟ charts, none of these patients exhibited any dysphagia, impairing eating ability at pre-
treatment. 
Cancer Treatment-Related Characteristics 
 Pre-treatment Surgeries: 13/26 (50%) patients in the EX group, 6/24 (25%) patients in the SW 
group and 4/23 (17.39%) patients in the NTx group underwent pre-treatment surgeries beyond a 
diagnostic biopsy to treat their tumors. These were not statistically significantly different 
between the EX and SW groups (χ2(1)= 3.311, p=.069) and between the EX+SW and the NTx 
groups (χ2(1)= 3.1, p=.078). Incisional biopsies were not considered as surgeries since all 
patients undergo these for staging and treatment planning. Surgeries performed included, wide 
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local excisions of tumors, laser excisions of tumors, excisions of glands and/or lymph nodes, 
parotidectomy, partial cordectomy, partial glossectomy, partial mandibulectomy, modified neck 
dissections and flap reconstructions. All MBS studies in patients, who underwent pre-RT/C 
surgeries, were performed post-surgery and these revealed functional oropharyngeal and 
pharyngoesophageal swallowing abilities.  
3.4. Rationale for Selecting Therapeutic Tasks 
The therapeutic tasks for the EX group were: the Masako exercise performed at a 
frequency and intensity of 10 repetitions in each of 7 sets daily; the Pharyngeal Squeeze exercise 
performed at a frequency and intensity of 10 repetitions in each of 7 sets daily and the Shaker 
exercise performed at a frequency and intensity of 3 sets daily. The therapeutic task for the SW 
group was: 34 swallows of saliva and/or water in each of 7 sets daily. These exercise protocols 
are described in detail in Table 3.7. 
Significant impairments in tongue-base retraction, hyolaryngeal elevation and UES 
opening have been shown to occur most commonly in the oral, pharyngeal and esophageal 
phases of swallowing, post-RT/C. 
82, 174
 The Masako technique has been shown to improve 
tongue-base retraction, without functional changes in overall swallowing, in a highly limited 
group of HNC patients. 
149
 The Shaker exercise is one of the few evidence-based exercises 
shown to improve UES opening in the tissues of healthy older adults as well as previously 
treated, limited number of HNC patients. 
83, 145-147
 The pharyngeal squeeze maneuver has been 
considered as a valid measure of pharyngeal strength and “motor integrity”. 142 All three 
exercises have been employed in isolation or in combination of twos in previous investigations 
of prophylactic swallowing exercises; however, a combination of the three exercises known to 
physiologically benefit all three phases of swallowing has not been investigated in an outcome-
study previously. The review of current clinical practice and the recommendations of exercise  
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Table 3.7: Exercise protocols performed by patients in the exercise (EX) and swallow (SW) 
treatment groups 
Group Therapeutic task Repetitions/Set Sets/Day Total/Day 
EX Masako maneuver: 
Stick out your tongue, hold it between your 
lips or front teeth and swallow. You may 
take water as needed, but do not do the 
exercise while holding a sip in your mouth. 
 
10 
 
7 
 
70 
 
 
Pharyngeal Squeeze exercise: 
Glide up the pitch scale on the “ee” sound 
and hold the highest pitch for several 
seconds 
10 7 70 
Shaker exercise (Part A): 
 Lie down on your back on the bed or 
floor 
 Do not use a pillow  
 Keep your shoulders flat against the 
bed or floor 
 Lift up your head, bringing your chin 
forward until you can see your toes 
 Keep your head lifted for 60 seconds, 
and then lower your head and rest for 
60 seconds. 
 
3 
 
 
 
3 9 
Shaker exercise (Part B): 
 Lie down on your back on the bed or 
floor 
 Do not use a pillow 
 Keep your shoulders flat against the 
bed or floor 
 Lift up your head, bringing your chin 
forward until you can see your toes. 
Then immediately lower your head. 
 
30 3 90 
SW Swallow your saliva. Count each swallow as 
one repetition of the exercise. You may take 
tiny sips of water as and when needed, 
however, please try to do as many swallows 
with saliva only as you can. 
 
34 
 
7 
 
238 
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physiology, justify the scientific adequacy of such a program in hypothesizing improved 
outcomes. The frequency and intensity of the Masako and pharyngeal squeeze exercises were 
determined by estimating an average number of ROM exercises reported in other studies and 
clinical protocols as described earlier. The frequency and intensity of the Shaker exercise has 
been recommended in the literature as described earlier. 
Clinically, when patients are unable to perform exercises due to toxicities, they are 
instructed to continue to swallow and use the swallowing muscles. Therefore to objectively 
assess this task with ensured intensity, it was selected as the therapeutic task for the SW 
treatment group. The number of repetitive swallows performed by patients in the SW group was 
determined by adding the total number of Masako maneuvers (i.e. 70) + pharyngeal squeeze 
exercises (i.e. 70) + neck lifts in the Shaker exercise (i.e. 99) performed by patients in the 
exercise group. Since repetitive swallowing has not been employed as a therapeutic task in 
dysphagia previously, its intensity could be estimated most appropriately by this method. As 
described earlier, the principle of specificity of exercise physiology suggests that the training task 
should resemble the target activity as much as possible to make maximum gains. 
93
 In addition, 
the authors of this study confirmed that by performing 234 additional swallows (i.e. 34 x 7), 
patients would achieve a 40% increase in the average use of the swallowing musculature, beyond 
regular swallowing accomplished when eating, drinking and saliva swallows. Therefore this 
number was thought to clinically significantly increase patients‟ use of the muscles of 
swallowing.  
Lear, Flanagan, and Moorrees (1965) have investigated the average frequency of 
swallowing over 24 hours in 20 healthy adults. 
175
 They reported that on an average, humans 
swallow 585 times per day; the range being 203 to 1008. Lear et al., (1965) expressed that this 
number actually appeared to be notably less than expected. 
175
 Swallowing occurred most 
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frequently during meals and least during sleep. Sato and Nakashima (2006) have reported a mean 
of 2.9 ± 1.3 swallows per hour in eight normal human adults during sleep.
176
 Performing normal 
activity at a highly increased capacity is a necessary aspect of exercise as per Pollock et al., 
(1998). 
169
 A 40% increase in normal activity was hypothesized to be therapeutic in this study, 
since this intensity corresponded with the intensity of behavioral exercises, which appear intense, 
from literature reports and clinical practice.  
Each patient in both the EX and SW treatment groups was instructed to attend 
swallowing therapy sessions once every week for 45 minutes, throughout the duration they were 
undergoing RT/C. During the session, patients partially completed their therapeutic tasks (50%) 
for the day under the study coordinator‟s supervision, reported current diet and severity of 
treatment toxicities and clarified any questions regarding their swallowing. In addition, patients 
filled out the M D Anderson Dysphagia Inventory (MDADI) questionnaire on each weekly visit 
with the speech pathologist. Appendix C displays the weekly progress note employed in this 
study and the IRB-approved MDADI questionnaire appears in Appendix D. The first swallowing 
therapy session was conducted during the first week of RT and the last session was conducted 
during the last week of RT. Following the completion of RT/C, MBS studies were completed for 
each patient. Patients whose studies indicated the need for structured swallowing therapy were 
referred for these services promptly.  
3.5. Data Collection 
Experimental Groups i.e. EX (exercise) and SW (swallow) groups 
 Pre RT 
The following data was obtained from patients‟ electronic medical records (EMR) prior 
to the initiation of RT: age (years), gender, tumor site, TNM classification, tumor stage, any 
previous surgical interventions beyond a diagnostic biopsy, ChT or RT for HNC and baseline 
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weight (lbs.) Information obtained from patients‟ baseline MBS studies included: PAS scores, 
FOIS scores and diet consistencies tolerated. In addition, patients filled the MDADI 
questionnaire, scores of which were obtained.  
 During RT 
On a weekly basis during RT, the following information was obtained from patients: diet   
consistencies tolerated, PEG placement, weight, MDADI scores, RT toxicity (i.e., xerostomia, 
mucositis, soreness or pain in the mouth, odynophagia, nausea and/or vomiting, dysgeusia, 
trismus and reduced appetite), and changes in swallowing (i.e. choking with solids and/or 
liquids, nasal regurgitation, oral regurgitation, reflux, difficulty initiating a swallow, globus 
sensation, feeling of foods sticking in the throat, gagging, oral intake, hoarseness and wet or 
gurgly voice quality). Additionally, patients were requested to return a daily log indicating the 
frequency and intensity of exercises completed. At the completion of treatment, the total 
numbers of days from the beginning to the end of RT was calculated and reported as the total 
duration of RT. 
 Post RT 
Following the completion of RT, the following information was obtained from patients‟ post 
treatment MBS studies: PAS scores, FOIS scores and diet consistencies tolerated. In addition, 
patients filled the MDADI questionnaire.  
No Treatment i.e NTx Group 
The following data was obtained from patients‟ EMR: age (years), gender, tumor site, 
TNM classification, tumor stage, previous surgical interventions beyond a diagnostic biopsy, 
ChT or RT for HNC, duration of RT, baseline weight (lbs), post-treatment weight and PEG tube 
placement if at all during RT.  
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3.6. Standardized Dependent Measures 
In the HNC-dysphagia literature, one of the most frequent methodological limitations is 
that researchers do not consistently use standardized tools to evaluate patient outcomes. 
14
 This 
results in the inability to compare study findings and to interpret findings of combined studies to 
generalize to clinical patient care. Fortunately, the World Health Organization‟s International 
Classification of Functioning, Disability and Health (ICF) has encouraged communication 
professionals around the world to adopt standardized outcome measures, 
177
 and to shift focus 
from the impaired structure alone, to its direct impact on function, activity and participation. 
178, 
179
 In addition, the importance of recognizing environmental and personal facilitators and 
barriers, which affect patients‟ participation and activities, is encouraged. Specific to HNC, there 
is limited research related to cancer interventions‟ impact on patients‟ functioning. 180 The ICF 
has established an initial core set of structures and functions specific to HNC, however 
standardizing outcome measures to use with the ICF framework is only now underway.
180, 181
 
The current prospective investigation therefore attempts to adopt the ICF approach to outcomes 
evaluation by utilizing the PAS to assess physiology, 
182
 FOIS to assess function 
183
 and MDADI 
to assess QOL, 
184
 which are valid and reliable outcome measures. Assessment of prophylactic 
behavioral swallowing therapy as a facilitator and lack of compliance as a barrier are undertaken 
in this study, consistent with the recommendations of the ICF model. 
The Penetration Aspiration Scale (PAS) 
 The development of the PAS (Appendix D1), originally a 9-point scale, reduced to an 8-
item scale, has been described by Rosenbek, Robbins, Roecker, Coyle and Wood (1996), and has 
been assessed for validity, inter-judge and intra-judge reliability. 
182
 The scale was designed to be 
useful to both clinical researchers and clinicians. Score 1 represents no penetration or aspiration, 
scores 2 through 5 represent laryngeal penetration with increasing depth and scores 6 through 8 
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represent aspiration and sensation response to aspiration. In the current investigation, the PAS 
was utilized to objectify the baseline and post-treatment MBS findings of penetration and 
aspiration of food and/or liquid boluses.  
The Functional Oral Intake Scale (FOIS) 
 Crary, Carnaby Mann and Groher (2005) described the development and psychometric 
assessment of the FOIS (Appendix D2) in 302 acute stroke patients.
183
 Originally, a 10-point 
rating scale, reduced to a final 7-point rating scale, the scale has been shown to indicate changes 
in oral intake of acute stroke patients over time. Levels 1 through 3 indicate non-oral feeding i.e. 
PEG tube dependence, levels 4 to 6 indicate limited, yet full oral feedings and level 7 indicates a 
regular oral diet intake. Inter-rater reliability, consensual validity, criterion validity and cross 
validation of the scale have been adequately established. Scores can be reported by the clinicians 
or patients themselves to reflect diets tolerated, demonstrating its ease of employment. In the 
current study, the FOIS was employed to indicate the feeding status of each individual patient at 
baseline and post-RT/C. At the completion of RT/C, patients reported a FOIS score, based on 
their oral intake at that time. At the post-treatment follow-up MBS study, the clinician assigned 
FOIS scores to patients based on the physiology of swallowing exhibited. Both scores were 
included in data analyses. 
M D Anderson Dysphagia Inventory (MDADI) 
 Chen, Frankowski, Bishop-Leone, Hebert, Leyk, Lewin and Goepfert (2001) described 
the development of the MDADI instrument (Appendix D3).
184
 The MDADI has been reported as 
a valid and reliable tool, which allows HNC patients‟ reports of their swallowing-related QOL. It 
constitutes four domains: global, emotional, functional and physical. The global domain (1 to 5) 
is scored separately; however the emotional (1 to 30), functional (1 to 25) and physical (1 to 40) 
domains together estimate the overall score. 
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3.7. Data Analyses 
The test statistics employed to analyze group differences in hypothesis 1 (EX vs. SW)  
and hypothesis 2 (EX+SW vs. NTx) are presented in Table 3.8. Group differences between  
Table 3.8: List of hypotheses 1 and 2 variables compared between or within the exercise (EX), 
swallow (SW) and/or no treatment (NTx) groups, their level of measurement and test statistic 
employed for analyses. 
 
Hypotheses 
Post-treatment Variables 
(level of measurement) 
 
Test statistic 
Hypotheses 1a Aspiration (nominal) Pearson Chi square 
 PAS scores (ordinal) Mann-Whitney U 
 Pre vs. post-treatment aspiration (nominal) McNemar‟s 
 Pre vs. post-treatment PAS scores (ordinal) Wilcoxon‟s signed rank 
Hypotheses 1b PEG (nominal) Pearson Chi square 
 FOIS scores (ordinal) Mann-Whitney U 
 Pre vs. post-treatment PEG (nominal) McNemar‟s 
 Pre vs. post-treatment FOIS scores (ordinal) Wilcoxon‟s signed rank 
Hypotheses 1c MDADI (continuous) Mann-Whitney U 
 Pre vs. post-treatment MDADI (continuous) Wilcoxon‟s signed rank 
Hypotheses 1d Weight (continuous) Mann-Whitney U 
Hypotheses 2 PEG (nominal) Pearson chi square 
PAS: Penetration Aspiration Scale; PEG: feeding tube; FOIS: Functional Oral Intake Scale; MDADI: MD 
Anderson Dysphagia Inventory 
nominal level outcome variables were assessed using the Pearson chi square test. If a cell count 
had less than the expected count of 5, the Fisher‟s exact test was used. Group differences 
between ordinal level outcome variables were assessed using the Mann-Whitney U test. Due to 
evident non-normal distributions of continuous variables, the non-parametric Mann-Whitney U 
test was also utilized to assess group differences between continuous variables.
185
 To assess 
within-group differences between pre-treatment and post-treatment outcomes within groups, the 
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McNemar test was applied for nominal level variables and the Wilcoxon‟s ranked test for ordinal 
level variables. Again, due to non-normal distributions of continuous variables, the Wilcoxon‟s 
ranked test was also use to assess within-group differences between pre-treatment and post-
treatment continuous level outcomes. The type I error rate was set at α = .05.  
To assess the correlations between physiological and functional, QOL and weight 
outcomes as outlined in hypothesis 3 of this study, the following test statistics
185
 were used 
(Table 3.9): nominal variables (Phi correlation), one nominal and another ordinal or continuous 
variable (Point biserial correlation) and two ordinal or continuous level variables (Kendall‟s 
tau). No statistical analyses were conducted for the secondary research questions proposed in this 
study; graphical representation of the data was presented. 
 
Table 3.9: List of hypothesis 3 variables employed in correlation analyses, along with the level 
of measurement and test statistic employed to conduct analyses. 
Hypotheses 
Correlated Variables 
(level of measurement) 
 
Test statistic 
Hypothesis 3 Aspiration (nominal) vs. PEG (nominal) Phi correlation 
 Aspiration (nominal) vs. FOIS scores (ordinal) Point biserial 
 Aspiration (nominal)  vs. MDADI (continuous) Point biserial 
 Aspiration (nominal) vs. Weight (continuous) Point biserial 
 PAS scores (ordinal) vs. PEG (nominal) Point biserial 
 PAS scores (ordinal) vs. FOIS scores (ordinal) Kendall‟s tau 
 PAS scores (ordinal) vs. MDADI (continuous) Kendall‟s tau 
 
PAS scores (ordinal) vs. Weight (continuous) 
 
Kendall‟s tau 
 PAS: Penetration Aspiration Scale; PEG: feeding tube; FOIS: Functional Oral Intake Scale; MDADI: MD 
Anderson Dysphagia Inventory 
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CHAPTER 4: RESULTS 
The IBM SPSS Statistics v19.0.1 (SPSS, Inc., Chicago, IL) software was employed to 
conduct the statistical analyses of all data in this study. Descriptive statistics, nonparametric 
statistics and correlation analyses were utilized to test the proposed hypotheses as explained in 
the Data Analyses section of Chapter 3: Design and Methods.  
4.1. Cancer Treatment-Related Characteristics 
At post-treatment, the EX, SW and NTx groups were assessed and compared in terms of 
cancer-treatment related characteristics including, radiation dosage employed (continuous, non-
normal), duration of RT (continuous, non-normal) and % employment of ChT (nominal, 2 levels). 
The Mann-Whitney U test was employed to assess group-differences on the continuous, non-
normal variables and the Pearson chi square test was utilized to assess group-differences in % 
ChT employed (Table 4.1) 
Table 4.1: Cancer treatment-related characteristics including, neo-adjuvant or concomitant ChT 
(% patients), radiation dosage (mean, range, median and mode) and radiation therapy duration 
(mean, range, median and mode) employed in the cancer treatment of patients in the exercise 
(EX) and swallow (SW) treatment groups and no treatment (NTx) group  
 
GROUPS 

 
 
EX (n=26) 
 
SW (n=24) 
 
NTx (n=23) 
 
 
p value 
 
% Chemotherapy 
(Neo-adjuvant 
and/or concomitant) 
 
 
20/26 (77%) 
 
16/24 (67%) 
 
11/23 (47.83%)* 
 
Pearson chi square 
EX vs. SW, χ2(1)= 0.651, p=.420 
EX+SW vs. NTx, χ2(1)=4.015, p=.045* 
Radiation Dosage 
(Gy) 
 
Mean= 66.61  
Range= 31 to 74 
Median= 70 
Mode= 70 
Mean= 64.92 
Range= 30 to 70 
Median= 70 
Mode= 70 
 
Mean= 67.17 
Range= 60 to 75 
Median= 70 
Mode= 70 
Mann-Whitney U test 
EX vs. SW, p=.496 
EX+SW vs. NTx, p=.547 
Duration of RT 
(days) 
Mean= 46 
Range  23 to 58 
Median= 48 
Mode= 47 
 
Mean= 48 
Range= 15 to 64 
Median= 51 
Mode= 53, 52 
 
Mean= 48 
Range= 39 to 71 
Median= 48 
Mode= 49 
 
Mann-Whitney U test 
EX vs. SW, p=..311 
EX+SW vs. NTx, p=.326 
EX: exercise group; SW: swallow group; NTx: no treatment group; RT: radiation therapy; *Chemotherapy 
utilization in NTx group vs. EX+SW groups (p=.045*) 
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Chemotherapy (ChT): The EX and SW treatment groups did not differ statistically significantly 
in the number of patients who received neo-adjuvant and/or concomitant ChT (χ2(1)=0.651, 
p=.420). However, the NTx group received ChT, statistically significantly less frequently than 
patients in the treatment groups (EX+SW) (χ² (1) = 4.015, p=.045*). 
RT Dosage & Duration: Radiation dosage employed in the treatment of HNC did not differ 
statistically significantly between the EX and SW treatment groups (Mann-Whitney U test, 
p=.496) and between the NTx group and treatment groups (EX+SW) (Mann-Whitney U test, 
p=.574). The mean number of days from the initiation to the completion of RT was also not 
significantly different between the EX and SW groups and between the EX+SW and NTx 
groups.(Mann-Whitney U test, p=.311 and .326  respectively) 
4.2. Hypotheses Testing 
Hypothesis 1a: Physiological outcomes in exercise (EX) vs. swallow (SW) treatment groups 
 Aspiration  
Post-treatment MBS studies could be completed in only 42 of the total 50 patients. One 
patient died prior to the MBS study, 2 patients‟ insurances refused to cover the cost of the test. 
Five other patients failed to follow-up for the test. Although the intention was to complete MBS 
studies within 3 weeks following the completion of RT/C; miscellaneous conflicts resulted in 
unexpected delays. The mean duration of post-treatment MBS studies from RT completion, was 
rounded down to 4 weeks (median= 3 weeks; mode= 2, 3 weeks). However, 39/42 MBS studies 
were performed within 6 weeks post-treatment, and the remaining 3 were performed beyond this 
timeline. 4/22 (18%) patients in the EX group and 6/20 (30%) patients in the SW group exhibited 
post-treatment aspiration. These differences were not statistically significant (Fisher‟s exact test, 
p=.477) (Table 4.2). Further, differences between pre-treatment vs. post-treatment aspiration 
were not statistically significant within the EX group (McNemar test, p=.625); however they 
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Table 4.2: Pre-treatment and post-treatment physiological (aspiration % and Penetration 
Aspiration Scale scores), functional (PEG tube dependence % and Functional Oral Intake Scale 
scores), quality-of-life (MD Anderson Dysphagia Inventory scores) and weight loss in the 
exercise (EX) vs. swallow (SW) treatment groups 
 
 EX Group 
 
SW Group  
Outcomes 
 
Pre Post Pre Post p value 
 
Physiology: 
Aspiration (%) 
 
2/26 
(8%) 
 
4/22  
(18%) 
 
1/24  
(4%) 
 
6/20  
(30%) 
 
Fisher‟s exact test, EX vs. SW, p=.477 
McNemar‟s test 
Pre vs. post EX, p=.625 
Pre vs. post SW, p=.031* 
 
PAS (Mean) 2 3.14 1.8 3.7 Mann-Whitney U testEX vs. SW, p=.594 
,  
Wilcoxon‟s signed rank test 
Pre vs. post EX, p=.022* 
Pre vs. post SW, p=.002* 
 
Function:  
PEG (%) 
0 8/26  
(31%) 
0 13/24  
(54%) 
Pearson chi square 
EX vs.SW, χ2(1)=2.805, p=.094 
 
FOIS (Mean) 6.5 3.8 6.6 3.7 Mann-Whitney U test, EX vs. SW, p=.571 
 
Wilcoxon‟s signed rank test 
Pre vs. post EX, p <.001* 
Pre vs. post SW, p <.001* 
 
QOL: MDADI (Mean) 
 
Overall (1-100) 
 
 
 
94.85 
 
 
63.1 
 
 
91.25 
 
 
62.3 
Mann-Whitney U test  
(between/within groups) 
Between EX vs. SW, p=.627 
Within EX & SW p<.001* 
 
Global (1-5) 4.85 2.1 4.67 2.2 Between EX vs. SW, p=.410 
Within EX & SW p<.001* 
 
Emotional (1-30) 
 
28.5 21.7 28.67 21.9 Between EX vs. SW, p=.977 
Within EX & SW p<.001* 
 
Functional (1-25) 
 
23.73 16 23.17 16.2 Between EX vs. SW, p=.854 
Within EX & SW p<.001* 
 
Physical (1-40) 
 
37.69 22.1 34.83 22.3 Between EX vs. SW, p=.454 
Within EX & SW p<.001* 
 
Weight Loss (Mean) Post-pre 
 
-13.5 lbs 
Post-pre 
 
-13.9 lbs 
 
Mann-Whitney U test (post-pre) 
EX vs. SW, p=.719 
EX: exercise group; SW: swallow group; PAS: Penetration Aspiration Scale; PEG: feeding tube; FOIS: Functional 
Oral Intake Scale; MDADI: MD Anderson Dysphagia Inventory; post: post-treatment; pre: pre-treatment 
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were significant in the SW group (McNemar test, p=.031*). 
 Penetration-Aspiration Scale (PAS) Scores 
The mean post-treatment PAS scores for patients in the EX and SW groups were 3.14 and 
3.7 respectively (Table 4.2). These differences were not statistically significant (Mann-Whitney 
U test, p=.594). However, differences in pre-treatment vs. post-treatment PAS scores were 
statistically significant within each group: EX (Wilcoxon signed rank test, p=.022*) and SW 
(Wilcoxon signed rank test, p=.002*). Silent aspiration i.e. a PAS score of 8, was evident in 3 
(14%) and 4 (20%) patients in the EX and SW groups, respectively (Table 4.3). Ten patients who 
aspirated in this study can be categorized based on the severity of aspiration as follows: 4 trace, 
highly inconsistent (2 EX and 2SW); 2 mild, inconsistent, eliminated completely by using 
compensatory strategies (2 EX); 3 mild, consistent, reduced but not eliminated by using 
compensatory strategies (1 EX and 2 SW) and 1 severe, frank aspiration, unable to eliminate by 
using compensatory strategies (1 SW). Thus, only 4 patients (8%) as a group and 1 patient (4%) 
in the EX group exhibited significant aspiration post-RT/C.  
Table 4.3: Distribution of Penetration Aspiration Scale (PAS) scores among patients in the 
exercise (EX) and swallow (SW) groups at pre-treatment and post-treatment 
 EX Group SW Group 
PAS scores Pre-treatment 
(N=26) 
Post-treatment 
(n=22) 
Pre-treatment  
(N=24) 
Post-treatment  
(n=20) 
 
Normal  
 
1 
 
 
14 (54%) 
 
8 (36%) 
 
12 (50%) 
 
7 (35%) 
 
 
 
Penetration  
2 
 
7 (27%) 6 (27%) 10 (42%) 3 (15%) 
3 
 
3 (11%) 1 (4.5%) 1 (4%) 2 (10%) 
4 
 
0 0 0 1 (5%) 
5 
 
0 3 (14%) 0 1 (5%) 
 
 
Aspiration 
6 
 
0 0 0 0 
7 
 
1 (4%) 1 (4.5%) 0 2 (10%) 
8 1 (4%) 3 (14%) 1 (4%) 4 (20%) 
EX: exercise group; SW: swallow group; PAS: Penetration Aspiration Scale; MBS: Modified Barium Swallow 
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 Characteristics of Aspirating vs. Non-Aspirating Patients in the Treatment Groups (EX+SW)  
  
Table 4.4 characterizes patients who exhibited post-treatment aspiration (n=10) vs. those 
who did not aspirate post-treatment (n=32), in terms of demographics (age and gender), tumor 
characteristics (tumor site and tumor stage) and cancer treatment-related characteristics (surgery, 
ChT, radiation dosage and treatment duration). Patients who aspirated post-treatment exhibited 
statistically significantly longer RT duration as compared to the non-aspirating group (Mann-
Whitney U test, p=.027*) 
Table 4.4: Comparison of patient demographics (age and gender), tumor characteristics (tumor 
site and stage) and cancer treatment-related characteristics (pre-RT surgery, use of chemotherapy 
and radiation dosage), in aspirating vs. non-aspirating patients in the treatment groups, at post-
treatment. 
n=42 
 
 Aspiration (n=10) 
 
No Aspiration (n=32) p value 
Age (years) 
 
Mean ± SD 63 (SD=12) 61 (SD=14.5) Mann-Whitney U, p=.506 
 
Gender Females 
Males 
 
3  
7 
30% 
22% 
7 
25  
70% 
78% 
Fisher‟s exact p=.678 
Tumor site OC  
NPhx 
OPhx  
HPhx  
Lx 
U 
 
0 
0 
9  
0 
1  
0 
0 
0 
45% 
0 
10% 
0 
 
3 
2 
11 
1 
9 
6 
100% 
100% 
55% 
100% 
90% 
100% 
 
 
χ2(5)=9.752, p=.083 
Tumor stage I 
II 
III 
IV 
 
1 
0 
2 
7 
25% 
0 
17% 
35% 
3 
5 
10 
13 
75% 
100% 
83% 
65% 
Mann-Whitney U, p=.149 
Surgery Yes 
No 
 
1 
9 
6% 
35% 
15 
17 
94% 
65% 
Fisher‟s exact p=.061 
Chemotherapy Yes 
No 
 
8 
2 
26% 
18% 
23 
9 
74% 
82% 
Fisher‟s exact p=1.0 
RT Dosage Mean 69.6 Gy 63.91 Gy Mann-Whitney U, p=.121 
 < 70 
≥ 70 
 
1 
9 
8% 
31% 
12 
20 
 
92% 
69% 
 
Duration of RT  
(days) 
Mean(Range) 
Median 
Mode  
51.6 (47 to 54) 
53 
53 
45.59 (15 to 64) 
49 
52 
Mann-Whitney U, p=.027* 
SD= standard deviation; χ2= Pearson‟s chi square; df= degrees of freedom; OC= oral cavity; NPhx= nasopharynx; 
OPhx= oropharynx; HPhx= hypopharynx; Lx= larynx; U= unknown primary; RT= radiation therapy; PAS= 
Penetration-Aspiration Scale; FOIS= Functional Oral Intake Scale 
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Hypothesis 1b: Functional outcomes in exercise (EX) vs. swallow (SW) treatment groups 
 PEG tube dependence 
8/26 patients in the EX group vs. 13/24 patients in the SW group relied on a PEG tube to 
meet their nutrition and hydration requirements at the completion of treatment (Table 4.2). These 
differences were not detected as statistically significant (χ2(1)=2.805, p=.094); however, within 
the EX and SW groups, post-treatment PEG tube dependence was statistically significant 
(McNemar test, p=.008* and .000* respectively). Table 4.5 provides information regarding the 
timing of reactive  (during or after cancer treatment) PEG tube placements in patients of the EX 
and SW treatment groups based on radiation dosage completed. Within the first four weeks of 
RT/C, 5/8 patients in the EX group vs. 10/13 patients in the SW group received PEG tubes. The 
remaining three PEG tube dependent patients in each group received PEG tubes towards the 
latter half of treatment or immediately at the completion of treatment.  
Table 4.5: PEG tube placements in patients of the exercise (EX) and swallow (SW) groups, 
categorized based on of radiation treatment (RT) dosage completed 
RT dosage completed EX group SW group 
≤ 10 Gy 2 1 
11 to 20 Gy - 3 
21 to 30 Gy - 5 
31 to 40 Gy 3 
 
1 
41 to 50 Gy 1 - 
51 to 60 Gy - - 
61 to 70 Gy 2 3 
 
RT: radiation dosage; EX: exercise group; SW: swallow group; Gy: unit or RT 
 Functional Oral Intake Scale (FOIS) scores  
The mean post-treatment FOIS scores of patients in the EX and SW groups were 3.8 and 
3.7 respectively. These differences were not statistically significant (Mann-Whitney U test, 
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p=.571). However, both EX and SW treatment groups reported significantly worse FOIS scores 
at post-treatment, compared to pre-treatment (Wilcoxon signed rank test, p=.000* and p=.000* 
respectively). 77% and 62% patients in the EX and SW groups respectively, continued to tolerate 
a full oral diet (FOIS scores 4 to 7) post-treatment, as compared to 100% at pre-treatment (Table 
4.6). 38.5% and 33% patients in the EX and SW groups respectively, tolerated only liquids 
(FOIS score 4) at post-treatment. 
Table 4.6: Distribution of Functional Oral Intake Scale (FOIS) scores among patients in the 
exercise (EX) and swallow (SW) groups at pre-treatment and post-treatment 
 EX Group (N=26) SW Group (N=24) 
 
FOIS scores Pre-treatment Post-treatment Pre-treatment Post-treatment 
 
PEG tube 
 
1 
 
 
0 
 
4 (15%) 
0  
3 (12%) 
2 
 
0 2 (8%) 0 3 (13%) 
3 
 
0 0 0 3 (13%) 
Full oral diet 
(modified) 
4 
 
0 10 (38.5%) 0 8 (33%) 
5 
 
5 (19%) 10 (38.5%) 5 (21%) 5 (21%) 
6 
 
3 (12%) 0 0 0 
Full oral diet 
(Normal) 
7 
 
18 (69%) 0 19 (79%) 2 (8%) 
EX: exercise group; SW: swallow group; FOIS: Functional Oral Intake Scale 
 Characteristics of PEG Tube vs. Non-PEG Tube Dependent Patients in the Treatment Groups 
of This Study (EX+SW) 
 
Table 4.7 characterizes patients who exhibited post-treatment PEG tube dependence 
(n=21) vs. non-PEG tube dependent patients (n=29), in terms of demographics (age and gender), 
tumor characteristics (tumor site and tumor stage) and cancer treatment-related characteristics 
(surgery, ChT, radiation dosage and treatment duration). Patients who required PEG tubes in this 
study, appeared to have underwent significantly less frequent pre-RT surgeries (χ2(1)=5.52, 
p=.019*), higher radiation dosage (Mann-Whitney U test, p=036*) and longer duration to RT 
completion (Mann-Whitney U test, p=.028*). 
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Table 4.7: Comparison of patient demographics (age and gender), tumor characteristics (tumor 
site and stage) and cancer treatment-related characteristics (pre-RT surgery, use of 
chemotherapy, radiation dosage and treatment duration) in PEG tube dependent vs. non-PEG 
tube dependent patients at post-treatment. 
N=50 
 
 PEG tube (n=21) 
 
No PEG tube (n=29) p value  
Age (years) Mean (SD) 64 (13) 61 (15) Mann-Whitney U, p=.672 
 
Gender Females 
Males 
 
7 
14 
70% 
35% 
 3 
26 
30% 
65% 
Fisher‟s exact p=.073 
Tumor site OC  
NPhx 
OPhx  
HPhx  
Lx 
U 
 
0 
1 
11 
2 
4 
3 
0% 
50% 
52% 
67% 
31% 
43% 
 
4 
1 
10 
1 
9 
4 
100% 
50% 
48% 
33% 
69% 
57% 
 
 
χ2 (5)=5.30, p=.380 
Tumor stage 
*not staged (n=1) 
I 
II 
III 
IV 
 
1 
2 
6 
11 
20% 
29% 
46% 
46% 
4 
5 
7 
13 
80% 
71% 
54% 
54% 
Mann-Whitney U, p=.298 
Surgery Yes 
No 
 
4 
17 
21% 
55% 
15 
14 
79% 
45% 
χ2 (1)=5.52, p=.019* 
Chemotherapy Yes 
No 
 
18 
3 
50% 
21% 
18 
11 
50% 
78% 
χ2(1)=3.39, p=.066 
RT Dosage Mean 67.67 Gy 64.45 Gy Mann-Whitney U, p=.036* 
 < 70 
≥ 70 
 
3 
18 
20% 
51% 
12 
17 
80% 
49% 
 
Duration of RT  
(days) 
Mean 
Range 
Median 
Mode  
 
49.86 
23 to 64 
52 
53 
45.45 
15 to 58 
47 
47 
Mann-Whitney U, p=.028* 
SD= standard deviation; χ2= Pearson‟s chi square; df= degrees of freedom; OC= oral cavity; NPhx= nasopharynx; 
OPhx= oropharynx; HPhx= hypopharynx; Lx= larynx; U= unknown primary; RT= radiation therapy; PAS= 
Penetration-Aspiration Scale; FOIS= Functional Oral Intake Scale 
Hypothesis 1c: Quality-of-life (QOL) in exercise (EX) vs. swallow (SW) treatment groups 
Mean post-treatment MDADI scores of patients in the EX vs. SW groups were: overall 
63.1 vs. 62.3, global 2.1 vs. 2.2, emotional 21.7 vs. 21.9, functional 16 vs. 16.2 and physical 22.1 
vs. 22.3, respectively. Between groups, no statistically significant differences were obtained in 
changes in post-treatment MDADI scores (from pre-treatment) including, overall scores (Mann-
Whitney U test, p=.627), global scores (Mann-Whitney U test, p=.410), emotional scores (Mann-
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Whitney U test, p=.977), functional scores (Mann-Whitney U test, p=.854) or physical scores 
(Mann-Whitney U test, p=.454). However, within the EX and SW groups, pre-treatment vs. post-
treatment MDADI scores statistically significantly differed for the overall scores and scores of 
each domain: global, emotional, functional and physical (Wilcoxon signed rank test, p<.001*, 
each difference).  
Hypothesis 1d: Pre-treatment to post-treatment weight loss in exercise (EX) vs. swallow 
(SW) treatment groups 
The mean weight loss post-treatment exhibited by the EX and SW treatment groups was  
-13.5 lbs. and -13.9 lbs. respectively (Table 4.2). These differences were not statistically 
significantly (Mann-Whitney U test, p=.719). 
 Physiological, Functional, Quality-of-Life (QOL) and Weight Outcomes in Patients Who 
Exhibited Post-Treatment Aspiration and/or PEG Tube Dependence  
 Of the 10 patients who aspirated in the current study, seven (70%) required reactive PEG 
tube placements (i.e. during or at the completion of RT/C) (Table 4.8). Three of these 10 patients 
(1 EX group; 2 SW group) eliminated aspiration with postural and/or dietary changes without 
warranting PEG tube placement. Of the 21 patients who received PEG tubes, only 7 aspirated on 
the post-treatment MBS study. 
Table 4.8: Number of patients who exhibited aspiration and/or PEG tube dependence in the 
exercise (EX) and swallow (SW) treatment groups 
 
Groups 
 
Aspiration 
+ PEG 
No aspiration  
+ PEG 
Total PEG 
 
EX group 
(# aspiration =4 & # PEG = 8) 
 
 
3 (75%) 
 
5 (62.5%) 
 
8 
SW group 
(# aspiration =6 & # PEG = 13) 
 
4 (67%) 9 (69%) 13 
Total 
(# aspiration = 10; # PEG = 21) 
7 (70%) 14 (67%) 21 
EX: exercise group; SW: swallow group; PEG: feeding tube; #: number 
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 Tables 4.9 and 4.10 characterize patients who aspirated (vs. non aspirating patients) or 
required a PEG tube at post-treatment (vs. non-PEG tube dependent patients), respectively. 
Patients who exhibited aspiration on the post-treatment MBS study were assigned significantly 
worse FOIS scores by the clinician, at the post-treatment MBS study (Table 4.9), which is 
expected, since aspiration can result in dietary and behavioral alterations in eating (Mann-
Whitney U test, p=.009*). PEG tube dependent patients exhibited significantly worse PAS scores 
at the post-treatment MBS study (Mann-Whitney U test, p=.042*), were assigned worse FOIS 
scores by the clinician (Mann-Whitney U test,p=.000*) and had significantly lower MDADI-
overall and emotional scores (Mann-Whitney U test, p=.040* and .017* respectively) as 
compared to the non-PEG tube dependent patient-group (Table 4.10). 
Table 4.9: Comparison of physiological outcomes (PAS scores), functional outcomes (PEG tube 
dependence and FOIS scores), quality-of-life (QOL) outcomes (MDADI scores) and weight loss 
in aspirating vs. non-aspirating patients at post-treatment (EX+SW) 
 
n=42 
 
Aspiration (n=10) 
 
 
No Aspiration (n=32) 
 
p value 
PAS scores 
Mean (range) 
 
 
 
7.7 (6-8) 
 
 
2.1 (1-5) 
 
 
Not applicable 
PEG tube 
Yes 
No 
 
 
7 (70%) 
3 (30%) 
 
 
11 (34%) 
21 (66%) 
Fisher‟s exact p=.070 
FOIS scores 
Mean (range) 
Post-RT/C 
MBS (n=42) 
 
 
3.8 (1-7) 
4 (1-5) 
 
3.7 (1-7) 
5.6 (3-7) 
 
Mann-Whitney U, p=.927 
Mann-Whitney U, p=.009* 
MDADI Mean 
- Overall 
- Global 
- Emotional 
- Physical 
- Functional 
 
-29.7 
-2.7 
-7.9 
-5.9 
-14.3 
 
 
-29.34 
-2.59 
-6.13 
-7.59 
-14 
Mann-Whitney U, p value 
.779 
.717 
.181 
.240 
.848 
Weight loss 
Mean (range) 
-13.2(-21.5 to -0.5) -13.5 (-46 to +6) 
Mann-Whitney U, p=.848 
 
EX: exercise group; SW: swallow group; PAS: Penetration Aspiration Scale; FOIS: Functional Oral Intake Scale; 
MDADI: MD Anderson Dysphagia Inventory; RT/C: radiation therapy with/without chemotherapy; MBS: Modified 
Barium Swallow; χ2: Chi square; df: degrees of freedom; SD: Standard deviation 
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Table 4.10: Comparison of physiological outcomes (aspiration and PAS scores), functional 
outcomes (FOIS scores), quality-of-life (QOL) outcomes (MDADI scores) and weight loss in 
PEG tube dependent vs. non-PEG tube dependent patients at post-treatment (EX+SW) 
 
N=50 
 
 
PEG tube (n=21) 
 
 
No PEG tube (n=29) 
 
p value 
Aspiration (n=42) 
Yes 
No 
 
7 (70%) 
11 (34%) 
 
3 (30%) 
21 (66%) 
 
 
Fisher‟s exact p=.070 
PAS scores (n=42) 
Mean (range) 
4.4 (1 to 8) 
 
2.7 (1 to 8) 
 
Mann-Whitney U, p=.042* 
FOIS scores Mean (range) 
Post-RT/C 
MBS (n=42) 
 
 
2.5 (1 to 5) 
4.3 (1 to 7) 
 
4.6 (4 to 7) 
6 (5 to 7) 
 
Mann-Whitney U, p=.000* 
Mann-Whitney U, p=.000* 
MDADI Mean  
- Overall 
- Global 
- Emotional 
- Functional 
- Physical 
 
 
-34.81 
-2.90 
-8.57 
-8.43 
-15.95 
 
-27.21 
-2.38 
-5.48 
-6.62 
-13.59 
 
Mann-Whitney U, p value 
 .040* 
.398 
 .017* 
.076 
.211 
 
Weight loss  
Mean (range) 
 
-15.6 (-41 to -0.5) 
 
-12.3 (-46 to +6) 
 
Mann-Whitney U, p=.201 
 
EX: exercise group; SW: swallow group; PAS: Penetration Aspiration Scale; FOIS: Functional Oral Intake Scale; 
MDADI: MD Anderson Dysphagia Inventory; RT/C: radiation therapy with/without chemotherapy; MBS: Modified 
Barium Swallow; χ2: Chi square; df: degrees of freedom; SD: Standard deviation 
Hypothesis 2: PEG tube outcomes between the treatment and no treatment groups  
At post-treatment, 8/26 (31%) patients in the EX group, 13/24 (54%) patients in the SW 
group and 10/23 (43.5%) patients in the NTx group exhibited PEG tube dependence (Table 
4.11). The NTx group‟s post-treatment PEG tube dependence rate did not statistically 
significantly differ from that of the EX group (χ2 (1)= .001, p=.97) or the SW group (χ2 (1)= 
0.185, p=.667). At 3 months post-treatment also, the NTx group‟s post-treatment PEG tube 
dependence rate did not statistically significantly differ from that of the EX group (Fisher‟s exact 
test, p=.455) or the SW group (χ2 (1)= 2.108, p=.146). However, the EX group exhibited 
significantly higher PEG tube elimination rates as compared to the SW group at 3 months post-
treatment (Fisher‟s exact test, p=.016*) (Figure 4.1).  
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Table 4.11: PEG tube dependence outcomes between the exercise (EX) vs. swallow (SW) vs. no 
treatment (NTx) groups at post-RT/C and 3 months post-treatment 
 
 
PEG 
 
 
EX 
GROUPS 
 
SW  
 
 
NTx  
 
 
p value 
 
 
Post-treatment 
 
8/26  
(31%) 
 
13/24  
(54%) 
 
10/23  
(43.5%) 
 
Pearson chi square  
NTx vs. EX, χ2 (1)= .001, p=.97 
NTx vs. SW, χ2 (1)= 0.185, p=.667 
 
3 month f/u 4/25  
(16%) 
1 Died 
 
12/24 
(50%) 
5/18 
(28%) 
5 missing data 
Fisher‟s exact test,  
EX vs. SW, p=.016* 
NTx vs. EX, p=.455 
Pearson chi square  
NTx vs. SW, χ2 (1)= 2.108, p=.146 
 
EX: exercise group; SW: swallow group; NTx: no treatment group; PEG: feeding tube; f/u: 
follow up 
 
 
Figure 4.1: PEG tube dependence (%) in patients in the exercise (EX), swallow (SW), and NTx 
groups at post-treatment and 3 months post-treatment 
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Since, patients in the NTx group received ChT significantly less frequently, PEG 
dependence rates were additionally compared at post-treatment and 3 months post-treatment only 
in patients who received RT + ChT in the EX, SW and NTx groups (Table 4.12). At post-
treatment, the EX group (RT+ChT) exhibited significantly lower PEG tube dependence rates as 
compared to the SW group (RT+ChT) (χ2 (1)= 4.05, p=.044*) and the NTx group (χ2 (1)= 4.045, 
p=.044*) . The SW group did not exhibit significantly different rates of PEG tube dependence as 
compared to the NTx group (Fisher‟s exact test, p=1.0). At 3 months post-treatment, the EX 
group continued to exhibit significantly lower PEG tube dependence rates as compared to the 
SW group (Fisher‟s exact test, p=.011*) and the NTx group (Fisher‟s exact test, p=.009*). 
There were no statistically significant differences between the SW and NTx group‟s PEG tube 
dependence rates at 3 months post-treatment (Fisher‟s exact test, p=.679) (Figure 4.2)  
Table 4.12: PEG tube dependence outcomes at post-treatment and 3 months post-treatment, 
between patients in the exercise (EX) vs. swallow (SW) vs. no treatment (NTx) groups, who 
received chemotherapy (ChT) in addition to radiation therapy (RT) 
 

PEG
 
 
EX 
(RT+ChT) 
n=20 
 
GROUPS 
 
SW  
(RT+ChT) 
n=16 
 
 
NTx  
(RT+ChT) 
n=11 
 
 
p value 
 
Post-treatment 
 
7/20 
(35%) 
 
11/16 
(69%) 
 
8/11 
(73%) 
 
Pearson chi square  
EX vs. SW, χ2 (1)= 4.05, p=.044* 
EX vs. NTx, χ2 (1)= 4.045, p=.044* 
 
Fisher‟s exact test 
SW vs. NTx, p=1.0 
 
 
3 month f/u 2/20 
(10%) 
8/16 
(50%) 
5/8 
(62.5) 
Fisher‟s exact test,  
EX vs. SW, p=.011* 
EX vs. NTx, p=.009* 
SW vs. NTx, p=.679 
 
EX: exercise group; SW: swallow group; NTx: no treatment group; PEG: feeding tube 
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Figure 4.2: PEG tube dependence (%) at post-treatment and 3 months post-treatment between 
patients in the exercise (EX), swallow (SW), and no treatment (NTx) groups, who received 
radiation therapy + chemotherapy. 
Additionally, during the data collection process, a higher rate of prophylactic PEG tube 
placement was observed at the non-Baton Rouge MBPCC sites (23%) vs. MBPCC-Baton Rouge 
(6%) (Table 4.13). 
Hypothesis 3: Correlations between physiological swallowing outcomes, functional 
swallowing outcomes, swallowing-related QOL outcomes and weight loss. 
Only 42 of the total 50 patients enrolled in the study completed the post-treatment MBS 
study, as described earlier. As is evident in Table 4.14, the phi correlation indicated a significant 
relationship between aspiration at post-treatment and PEG tube dependence (p=.047*); however 
the value 0.307 indicates only a weak positive relation. Patient-reported FOIS scores at post-
treatment did not correlate with physiological outcomes (aspiration and PAS scores) in this 
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GROUPS at post-RT+ChT vs. at 3 months 
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nEX Group 
nSW Group 
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 At 3 months post-treatment: EX vs. SW, p=.011*; EX vs. NTx, p=.009* SW vs. NTx, p=.679  
  
EX: exercise group; SW: swallow group; RT+C: radiation therapy with  chemotherapy; mos: months 
69% 
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Table 4.13: PEG tube placement patterns at MBPCC at three different timelines A) prospective 
patient recruitment timeline, 12/1/10 to 1/31/12 at the Baton Rouge site and B) retrospective NTx 
group recruitment timeline, 12/1/10 to 9/30/11 at the non-Baton Rouge sites 
 DATA COLLECTION SITES 
 
 
PEG placements 
MBPCC-Baton Rouge 
(timeline of recruitment of EX & SW)  
12/1/10 to 1/31/12 
MBPCC- Non Baton Rouge 
(timeline of recruitment of NTx) 
 12/1/10 to 9/30/11 
Prophylactic 
 
3/53 (6%) 7/30 (23%) 
Reactive 
 
21/50 (42%) 
EX: 31%; SW: 54%  
 
10/23 (43%) 
None 29/50 (58%) 
 
13/23 (57%) 
Total PEG 24/53 (45%) 17/23 (74%) 
 
    MBPCC: Mary Bird Perkins Cancer Center; EX: exercise group; SW: swallow group; NTx: no treatment group 
Table 4.14: Correlations between physiological swallowing outcomes i.e. aspiration and 
Penetration Aspiration Scale (PAS) scores and functional outcomes i.e. PEG dependence, 
Functional Oral Intake Scale (FOIS) scores reported by patients at post-treatment and FOIS 
scores recommended by the clinician at the time of post-treatment Modified Barium Swallow 
(MBS) study of patients in the treatment groups i.e. EX + SW. 
n= 42  Functional outcomes 
 
  PEG dependence FOIS scores (patient) FOIS(clinician) 
P
h
y
si
o
lo
g
ic
a
l 
o
u
tc
o
m
es
 
 
Aspiration 
 
 
Phi correlation 
Value= .307 (p=.047*) 
 
Point biserial correlation 
r=.014 (p=.929) 
 
Point biserial correlation 
r=-.432 (p=.004*) 
PAS scores 
 
Point biserial correlation 
r=.015 (p=.925) 
Kendall‟s correlation 
tau_b=-.075 (p=.552) 
Kendall‟s correlation 
tab_b=-.468 (p=.000*) 
EX: exercise group; SW: swallow group; PAS: Penetration Aspiration Scale; FOIS: Functional Oral Intake Scale 
study. However, clinician reported FOIS scores (functional outcome) estimated from the MBS 
study correlated with aspiration and PAS scores (physiological outcomes), as expected with a p 
value of .004* and <.001* respectively. Similarly, changes in MDADI scores (QOL outcome) 
and weight loss post-treatment did not correlate with aspiration or PAS scores (Table 4.15). 
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Table 4.15: Correlation between physiological swallowing outcomes i.e. aspiration and 
Penetration Aspiration Scale (PAS) scores and quality-of-life (QOL) outcomes i.e. MDADI 
scores (overall and global) and weight outcomes i.e. weight loss post-treatment 
 
n= 42 
  
QOL and Weight outcomes 
   
MDADI 
Overall 
 
MDADI 
Global 
 
MDADI  
Emotional 
 
 
MDADI 
Functional 
 
MDADI 
Physical 
 
Weight 
loss 
P
h
y
si
o
lo
g
ic
a
l 
o
u
tc
o
m
es
 
 
Aspiration 
 
 
Point biserial 
correlation 
r=-.011 
(p=.945) 
 
 
Point biserial 
correlation 
r=.028 
(p=.858) 
 
Point biserial 
correlation 
r=-.179 
 (p=.256) 
 
 
Point biserial 
correlation 
r=.170 
 (p=.283) 
 
 
Point biserial 
correlation 
r=-.018 
 (p=.910) 
 
 
Point biserial 
correlation 
r=.015 
(p=.925) 
PAS 
scores 
 
Kendall‟s 
correlation 
tau_b=-.056 
(p=.637) 
 
Kendall‟s 
correlation 
tau_b=-.119 
(p=.356) 
Kendall‟s 
correlation 
tau_b=-.184  
(p=.124) 
Kendall‟s 
correlation 
tau_b=.079  
(p=.512) 
Kendall‟s 
correlation 
tau_b=-.034  
(p=.770) 
Kendall‟s 
correlation 
 tau_b=-.084 
(p=.473) 
QOL: quality-of-life; PAS: Penetration Aspiration Scale; FOIS: Functional Oral Intake Scale; MDADI: MD 
Anderson Dysphagia Inventory Scale 
4.3 Secondary Research Findings 
Radiation Toxicities 
Each week, when patients were seen in swallowing therapy, they were requested to rate 
the severity of toxicities experienced on a scale of 1 to 5, 5 being the worst. Toxicities assessed 
included, xerostomia, mucositis, pain, odynophagia, nausea/vomiting, dysgeusia, trismus and 
reduced appetite. Figure 4.3 is a graphical presentation of the changes in individual toxicities 
experienced by patients as a group, with RT advancement. Weekly changes in toxicities 
appeared consistently similar in both EX and SW treatment groups; dysgeusia, reduced appetite 
and xerostomia (in decreasing order) being the three most severe toxicities experienced 
throughout the treatment weeks, in both groups. 
Dysphagia Symptoms 
 Every week patients rated the symptoms, choking with solids and liquids, nasal and oral 
regurgitation, reflux, difficulty initiating a swallow, globus sensation, foods sticking in the
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Figure 4.3: Proportions of severity of RT toxicities, including xerostomia, mucositis, pain, odynophagia, nausea/vomiting, dysgeusia, 
trismus and reduced appetite reported by patients in the exercise (EX) vs. swallow (SW) groups, throughout radiation therapy (RT) 
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 (Figure 4.3 continued)   
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(Figure 4.3 continued) 
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throat, gagging, NPO status, hoarseness and wet/gurgly voice quality (1 to 5, 5 being the worst). 
Figure 4.4 is a graphical presentation of the progressive changes in individual symptoms reported 
by patients. The EX group reported hoarseness, globus sensation and difficulty initiating a swallow 
(in decreasing order) as the three most severe dysphagia symptoms throughout RT; whereas for the 
SW group these were hoarseness, difficulty initiating swallow, reflux, foods sticking in the throat 
and globus sensation (in decreasing order).  
Patient-Reported Compliance with Therapeutic Tasks 
 All patients in the study were requested to maintain a log of the number of sets of exercises 
completed on a daily basis. At each therapy session, patients returned completed log sheets to the 
attending speech pathologist. Figure 4.5 presents the group percentage of the number of sets of 
exercises completed by patients in the EX and SW treatment groups. A progressively downward 
trend in compliance with exercises was evident, indicating that compliance reduced as RT 
advanced. 
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Figure 4.4: Proportions of severity of dysphagia symptoms, including choking with solids and liquids, nasal and oral regurgitation, 
reflux, difficulty initiating a swallow, globus sensation, foods sticking in the throat, gagging, NPO status, hoarseness and wet/gurgly 
voice quality reported by patients in the exercise (EX) vs. swallow (SW) groups, throughout radiation therapy (RT) 
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 (Figure 4.4 continued) 
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(Figure 4.4 continued) 
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Figure 4.5: Group percentages of exercises completed by patients in the exercise (EX) group: 
Masako, pharyngeal squeeze and Shaker exercises and swallow (SW) group: repetitive swallows 
over the course of radiation therapy with/without chemotherapy (RT/C) 
 
 
 
20 
30 
40 
50 
60 
70 
80 
Week 1 
(EX 4.7, 
SW 3.9) 
Week 2 
(EX 9.7, 
SW 8.1) 
Week 3 
(EX 
14.5, 
SW 
12.9) 
Week 4 
(EX 
19.3, 
SW 18) 
Week 5 
(EX 
23.7, 
SW 
22.4) 
Week 6 
(EX 
27.8, 
SW 
27.1) 
Week 7 
(EX 
32.3, 
SW 
31.4) 
≥Week8    
(EX 
35.1, 
SW 
34.6) 
P
e
r
c
e
n
ta
g
e
 o
f 
e
x
e
r
c
is
e
s
 c
o
m
p
le
te
d
 (
%
)
 
Weeks of RT 
 
 
 
EX: exercise group; SW: swallow group; RT: radiation therapy 
		EX	Group	
														Masako	
														Pharyngeal	squeeze	
														Shaker	
SW	Group	
													Repe ve	swallows	
  EX Group 
              Masako 
              Pharyngeal squeez  
              Shaker 
SW Group 
             Repetitive swallows 
 81 
 
 
 
 
 
 
 
Figure 4.6: Percentage of exercises completed by patients in the exercise (EX) group (Masako, 
pharyngeal squeeze and Shaker exercises) with PEG tube placements and without PEG tubes. 
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Figure 4.7: Percentage of repetitive swallows completed by patients in the swallow (SW) group 
with PEG tube placements and without PEG tubes. 
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CHAPTER 5: DISCUSSIONS 
The purpose of the current study was to investigate the effects of two different behavioral 
prophylactic swallowing exercise (PSE) protocols performed during radiation therapy (RT), on 
swallowing physiology, function, quality-of-life (QOL) and weight outcomes following radiation 
therapy with/without chemotherapy (RT/C) for head and neck cancers (HNC). The investigation 
was conducted via a prospective study design including 26 patients in the „behavioral 
swallowing exercise‟ or EX group and 24 patients in the „repetitive swallowing‟ or SW group. 
Patients were alternately assigned to the treatment groups and every effort was made to match 
the two groups for age, tumor site and tumor stage. Additionally, 23 patients were retrospectively 
recruited to a „no treatment‟ (NTx) group within identical timelines of the prospective study. 
There were no statistically significant differences between the EX and SW treatment groups at 
pre-treatment in demographics, tumor characteristics, swallowing physiology, functional and 
QOL, or cancer treatment-related characteristics. A significantly less number of patients in the 
NTx group received combined modality treatments (i.e. both ChT and RT as opposed to RT 
alone), as compared to the treatment groups. Therefore, PEG tube dependence outcomes were 
also compared between the treatment and no treatment groups in patients who underwent both 
RT and ChT. 
In summary, data analyses revealed that there were no significant differences between the 
EX and SW groups in terms of swallowing physiology (i.e. aspiration % and mean PAS scores), 
function (i.e. PEG tube dependence % and mean FOIS scores), QOL (i.e. mean MDADI scores) 
and weight loss at post-treatment. However, within each group, significantly worse scores were 
evident in each of these domains: swallowing physiology, function and QOL, from pre-treatment 
to post-treatment. 
Additionally, the NTx group‟s PEG tube dependence rates were statistically similar to   
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those of the EX and SW groups, both at post-treatment and 3 months post-treatment. However, 
the EX group demonstrated significantly better rates of PEG tube elimination (16%) as compared 
to the SW group (50%) at 3 months post-treatment. Among patients who specifically received 
both RT and ChT, the EX group demonstrated significantly lower feeding tube dependence as 
compared to the SW and NTx groups, at both timelines (i.e., post-treatment and 3 months post-
treatment). The SW group and the NTx group did not differ from each other in PEG tube 
dependence rates; yet, the SW group exhibited better outcomes than the NTx group. Majority of 
PEG tube placements in patients occurred due to treatment-related toxicities, rather than the 
presence of aspiration. In addition, significantly worse post-treatment MDADI overall scores and 
emotional domain scores were reported by patients who received PEG tubes vs. those who did 
not. A statistically significant, yet weak positive correlation was evident between swallowing 
physiology (aspiration and PAS scores) and functional outcomes (clinician-assigned FOIS 
scores) at the post-treatment MBS study.  However, patient-reported FOIS scores did not 
correlate with PAS scores or the presence of aspiration. 
The findings of this study indicated that performing PSE (i.e. Masako, pharyngeal 
squeeze and Shaker exercises) resulted in improved swallowing function (determined by PEG 
tube dependence) as compared to performing repetitive swallows as the therapeutic task or no 
therapy. The following sections discuss the findings of this study in relation to the proposed 
hypotheses and to the literature. 
5.1. Physiological Outcomes 
 This study hypothesized that the EX group will exhibit significantly lower rates of 
aspiration and lower Penetration Aspiration Scale (PAS) scores at post-treatment, as compared to 
the SW group. This hypothesis was rejected based on data analyses. However, there were within-
group differences from pretreatment to post-RT/C. Both, the EX and SW treatment groups 
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demonstrated significantly worse post-treatment PAS scores; yet only the SW group exhibited 
significantly worse post-treatment aspiration rates. This particular finding encourages the current 
clinical assumption that PSE may help patients to better retain swallowing physiology 
determined by aspiration rates. 18% aspiration in the EX group appeared to be comparable to 
that reported in other studies employing PSE (i.e. 14% to 18%), 
89, 91
 but lower than that reported 
in studies not employing PSE (i.e. 23% to 65%).
11, 85, 186-190
 The SW group‟s aspiration rates on 
the other hand, appeared to be at the lower end of the range reported in the literature not 
employing PSE, but higher than that in other studies employing PSE regimens. Additionally, the 
EX group‟s mean post-treatment PAS score also appeared to be lower than that reported in the 
literature employing a PSE regimen. 
86
 The worse PAS score in the current study was obtained 
with thin liquids. PAS scores could not be compared with the van der Molen et al., (2011) study 
89
 as they reported mean PAS scores across consistencies; whereas the current study reported 
only the worse PAS score obtained with any consistency. Patient demographics, tumor 
characteristics and cancer treatment-related factors of the patients in this study appear quite 
similar to those reported in the comparable studies; however methodological differences and 
institutional factors affecting outcomes cannot be accounted for at this time.  
 This current finding along with findings from two other studies, 
89, 91
 confirm the positive 
impacts of performing PSE in reducing physiological swallowing impairments post-RT/C, 
determined by aspiration. The intense, salient task of repetitive swallowing appeared to have 
produced insignificantly worse aspiration rates than performing an intense, biomechanical event-
specific exercise regimen focusing on tongue base retraction, hyolaryngeal excursion and upper 
esophageal sphincter (UES) opening. Two of the three exercises (i.e. pharyngeal squeeze and 
Shaker exercises) did not involve the act of swallowing i.e. they were not salient to swallowing, 
but were salient to specific events within the act of swallowing. The results of this study 
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encourage the use of exercises geared towards the specific events of swallowing physiology to 
minimize the effects of RT/C, since they produced better outcomes in swallowing function. The 
SW group‟s post-treatment aspiration rate (30%) appeared at the lower end of the range reported 
in the literature not employing a PSE regimen. Additionally, since this rate was not statistically 
different when compared to the rate of the EX group, the relative benefits of performing 
repetitive swallows over behavioral exercises and no exercises cannot be ruled out. Repetitive 
swallows in this study were performed either dry or with sips of water as needed. Altering the 
regimen of repetitive swallows such as altering the consistency used during practice (nutritious 
thickened liquid or pureed consistencies) or increasing the frequency/ intensity schedule, appears 
to be worth investigating, to determine if outcomes may improve. The McNeill Dysphagia 
Therapy Program (MDTP)- 
155, 156
 which is a 3 week intensive program employing hard 
swallows with an increasing hierarchy of bolus consistency and volume modifications at a high 
intensity,
155, 156
 has been shown to improve swallowing outcomes. Increasing the richness of 
repetitive swallows employed in this study, either by adding effort to it or by further increasing 
its saliency with the introduction of an appropriate bolus, appears important. The current study‟s 
author‟s motivation of investigating these aspects emerges from the knowledge that patients 
undergoing RT/C experience among several toxicities, pain, fatigue and even depression,
191
 
which evidently result in a reduction in adherence to a complex, exercise program. Identifying 
the value of a simple, more feasible, scientifically sound exercise program may significantly 
reduce the burden of performing complex behavioral exercises in this fragile and overwhelmed 
patient population undergoing RT/C in addition to decreasing swallowing impairments. The 
current study‟s findings indicate that the employment of salient swallowing tasks with 
alterations, may have the potential to meet this need.  
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 Characteristics of Aspirating vs. Non-Aspirating Patients in the Treatment Groups  
 Since no significant differences in aspiration rates or PAS scores were revealed between 
the EX and SW groups, they were combined to assess for patient and cancer-related factors 
potentially contributing to the occurrence of aspiration. Of the 10 patients who aspirated in this 
current study, only four patients exhibited significant aspiration, all four patients relied on PEG 
tubes at post-treatment to meet their nutritional needs; two of them (in the EX group) eliminated 
PEG tubes prior to the 3-month follow up consultation. Patients who underwent pre-RT/C 
surgeries in this study exhibited significantly lower aspiration rates. However, this finding is 
confounded by the large difference in the number of aspirating vs. non aspirating patients. Pre-
RT/C surgeries have been previously reported to increase the risk of aspiration post-treatment; 
192
 this was not evident in the current study, possibly related to the small aspirating group of 
patients. Patients who aspirated post-treatment, also had a prolonged duration/ course of RT (by 
approximately 5 days) as compared to non-aspirating patients. Duration of RT, which was 
defined as the number of days from the initiation to the completion of RT, is representative of a 
patient‟s treatment schedule. Therefore slightly longer RT durations, may not necessarily 
indicate that the patients received significantly higher dosages of RT, rather they imply the 
length of planned therapy in addition to any missed days due to miscellaneous reasons. Longer 
RT durations in some patients in this study (especially the ones who aspirated post-treatment) 
were mainly caused by treatment breaks due to miscellaneous reasons including, technical 
malfunctions of the radiation delivery machines; holidays; hospitalizations due to dehydration or 
PEG tube placements and breaks from treatment due to altered laboratory values.  
 Post-treatment patient-reported FOIS scores did not significantly differ between the 
aspirating and non-aspirating groups of patients. This finding indicates that patient-reported 
FOIS scores may not truly represent the actual change in swallowing physiology. Both groups of 
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patients reported lower scores than pre-treatment. However, at the post-treatment MBS study, 
patients in the aspirating group were assigned significantly lower FOIS scores as compared to the 
non-aspirating group of patients. This is expected considering that dietary restrictions or use of 
compensatory strategies become necessary to prevent patients from developing aspiration 
pneumonia. The fact that patients, who did not aspirate on the post-treatment MBS studies, 
underestimated their ability to tolerate a variety of foods and liquids towards the end of RT/C, 
explains the impact of RT/C toxicities on oral intake. Previous studies have reported the role of 
reduced pharyngeal peristalsis in impairing transit of food and liquid boluses through the 
pharynx into the UES, negatively impacting oral intake and eating ability during RT/C. 
24
 
Despite absence of aspiration, RT toxicities (dysgeusia, reduced appetite and xerostomia) 
impacting pharyngeal bolus transit appeared significant enough to hinder functional eating 
ability among patients in the current study. The most severe dysphagia-related symptoms 
reported by patients in this study included: hoarseness, globus sensation, difficulty initiating a 
swallow, foods sticking in the throat and reflux. These are consistent with literature reports 
24
 and 
were thought to relate to the low FOIS scores reported in both groups of patients, irrespective of 
the presence/absence of aspiration.  
 The post-treatment MBS did not only identify patients who exhibited aspiration so that 
appropriate dietary and compensatory strategy recommendations could be made; but it also 
identified patients whose physiological swallowing abilities were near-intact and were 
underestimating this function. The MBS study helped these patients realize their physiological 
abilities to tolerate a variety of food and liquid consistencies. Inability to recognize this could 
potentially have led to these patients continuing to restrict eating and drinking, which could have 
resulted in true dysphagia from reduced use of swallowing muscles. Therefore irrespective of 
patients‟ eating abilities at the completion of RT/C, MBS studies should be performed so that 
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immediate appropriate dietary, exercise and compensatory recommendations can be made, prior 
to the development of permanent radiation fibrosis. 
 Literature reveals factors associated with aspiration in patients with HNC, including 
advanced age, 
94, 192
 long-term post-completion of treatment, 
192
 tumors of the larynx and/or 
hypopharynx, 
193
 advanced tumors (i.e., T3 or T4), 
192, 194
 surgical procedures 
192
 and ChT. 
28, 94, 
195
 A phase 3 clinical trial reported that risk factors for developing dysphagia in the acute phase 
of RT/C include large tumors, lymph node disease involvements, pre-treatment swallowing 
difficulties, six treatments per week and tumors located anywhere but the vocal cords. 
196
 
Additionally, long-term dysphagia was associated with large tumor sizes, pre-treatment 
swallowing problems and tumors located anywhere but the vocal cords. 
196
 Factors including 
previous or concurrent comorbidities, age, social support, continued smoking and alcohol 
consumption and additional surgical interventions to treat the cancer are all considered to affect 
the manner in which patients recover after RT. 
24
 However, these factors are associated, but not 
100% predictive of the occurrence of aspiration after RT/C. 
24
 No specific demographics, tumor-
related or cancer treatment related factors associated with occurrence of aspiration in this study, 
again potentially related to the relatively small number of aspirating patients. 
5.2. Functional Outcomes 
Patients in the EX group of this study exhibited a statistically similar rate of PEG tube 
dependence (31%) as compared to the SW (54%) and NTx (43.5%) groups at post-treatment. 
Also, the EX group did not exhibit better post-treatment FOIS scores than the SW group, 
resulting in the rejection of hypotheses 1b and 2. Further analyses of the data demonstrated that 
the non-treatment group exhibited significantly less ChT utilization as compared to the treatment 
groups of this study. Although the NTx group of this study did not initially exhibit statistically 
significantly higher reactive PEG tube dependence as compared to the EX or SW treatment 
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groups either at post-treatment or at 3 months post-treatment, the recognition of the impact of 
including ChT in addition to RT in patients‟ cancer treatment protocol, altered this finding. 
Therefore among patients who were treated with combined modalities (RT+ChT), the NTx group 
exhibited worse PEG tube dependence rates as compared to the EX group, both at post-treatment 
and 3 months post-treatment. At 3 months post-treatment, a significantly higher rate of PEG tube 
elimination was noted in the EX group (10%) as compared to the SW group (50%) and the NTx 
group (62%), among patients who received both RT and ChT. As a group, the EX group (16%) 
still did significantly better, as compared to the SW group (50%) in terms of PEG tube 
dependency. However, this difference was not apparent between the EX and NTx (28%) groups.  
The SW and EX groups, exhibited post-treatment PEG tube dependence rates within the range 
reported in other studies employing intense, evidence based PSE. Nguyen et al., (2009) reported 
10% PEG dependence in their patient cohort at post-treatment, which is the lowest, reported in 
the literature. More than half of the patients in that study had early stage tumors, influencing 
these findings, as acknowledged by the authors. 
187
 16% is the lowest reported PEG tube 
dependence (EX group) rate in the literature employing PSE regimens (i.e. 17% 
91
) and that not 
employing PSE regimens (36 to 73% 
30, 48, 50
). Carnaby-Mann et al., (2012) who employed a 
different PSE regimen and recently reported the lowest PEG tube dependence rate at post-
treatment (i.e. 25%), did not provide rates at 3 months post-treatment, but reported 17% PEG 
dependence at 6 months post-treatment. 
91
  
Literature reports that 18% to 79% patients consume ≤ 50% of their nutrition orally after 
the completion of RT/C,
10, 38, 44, 48, 89, 109, 188, 190, 197
 As a group 30% and individually 23% patients 
in the EX group of this study exhibited ≤ 50% oral intake in this study, both percentages along 
the lower end of reported ranges. The finding that 77% patients in the EX group continued to 
intake all of their required nutrition orally, is among the highest reported in the literature. PSE 
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regimens are conducted to minimize the swallowing impairments known to occur, post-RT/C; 
however, patients continue to exhibit the expected RT/C toxicities- reduced oral intake being one 
of them, throughout RT, despite performing exercises. Therefore it is not surprising that this 
study‟s findings in terms of oral intake abilities are not particularly better than literature reports; 
yet scores are amongst the highest reported, despite the large percentage of patients with 
advanced stage tumors, consistent with other studies.  
The functional outcomes evident in this study are significant in promoting the exercise 
regimen of the EX group. The combination of swallowing-specific Masako exercises and 
biomechanical event-specific pharyngeal squeeze and Shaker exercises as hypothesized by the 
study, appeared effective in reducing functional swallowing impairments, determined by PEG 
tube dependence (at 3 months post-treatment) and FOIS scores (post-treatment). In comparing 
16% PEG tube dependence of the EX group (3 months post-RT/C) in this study with 35% 
reported by van der Molen et al., (2012) 
89
 at 3 months and 17% reported by Carnaby-Mann et 
al., (2012) 
91
 at 6 months post-treatment, leads to several important inferences of the PSE 
regimen of the EX group. Patients in the EX group of the current study performed 70 Masako, 70 
pharyngeal squeeze and 3 sets of Shaker exercises daily as an ongoing home program and 
attended therapy x1 per week. Such a unique combination of exercises addressing the 
oropharyngeal and particularly the pharyngoesophageal biomechanical events of swallowing has 
not been investigated previously. The intensity regimen of the recommended protocol appears 
higher than that employed in other studies such as that by the van der Molen et al., (2011) 
89
 and 
Carnaby-Mann et al., (2012) 
91
 studies. However, Carnaby-Mann et al., (2012) provided therapy 
on a daily basis. Despite therapy once per week, patients in the EX group of the current study 
achieved similar, if not better functional outcomes. Consulting patients once a week is clinically 
more practical and feasible in terms of easier insurance approvals and lower costs to patients, 
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easier availability of personnel with the expertise to provide these services and reduced burden 
to the patient, who is already scheduled for several appointments on a daily basis. Additionally, 
this schedule is better generalizable to a clinical setting. Findings of this study strongly suggest 
the clinical utility and generalization of the EX group‟s PSE regimen.  
Between-institution factors also appeared to have played a potential role in these 
outcomes. The current clinical practice at the non-Baton Rouge sites of MBPCC favor 
prophylactic PEG tube placements; one reason for which may be related to lack of swallowing 
therapy services available for these patients, unless they agree to travel to outpatient centers for 
the same. Percentages of reactive + prophylactic PEG tube placement in the NTx group were 
much higher (74%) than in individual study groups or as a total group inclusive of three 
additional prophylactic PEG tube dependent patients in the treatment group. It appears that 
prophylactic PEG tube placements, potentially caused reduced use of the swallowing muscles 
with subsequently worse functional outcomes in the NTx group‟s patients. The results of the 
current study suggest that for some patients in the NTx group, worse swallowing outcomes could 
possibly have been avoided, with either exercise regimen of this study. Addition of studies like 
the current one to the literature will strengthen the need for PSE for HNC patients undergoing 
RT/C, in improving post-treatment swallowing function outcomes.  
Insignificant, yet better functional outcomes than the NTx group, further confirm the 
argument for the need to continue to strengthen the SW group‟s exercise regimen to potentially 
improve outcomes and achieve better compliance with exercise regimens necessary from 
patients. 
 Characteristics of PEG Tube Dependent vs. Non-PEG Tube Dependent Patients in the 
Treatment Groups 
 
In this study, 21 of 50 patients received reactive PEG tubes. As a group only 7 of these 
patients exhibited any aspiration (33%). The role of treatment toxicities (67%) in resulting in a 
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need for alternative nutrition modalities, appeared quite substantial. 4-6 weeks post-treatment is 
considered to be an acute healing period 
24
 when most patients experience gradual resolution of 
treatment toxicities and therefore it is justifiable that patients who continue to require PEG tubes 
beyond this point may have a true expression of dysphagia-related need for alternative feeding. 
The EX group‟s PEG tube dependence rate at post-treatment along with the high rate of 
elimination of PEG tubes at 3 months post-treatment indicate patients‟ ability to resume 
swallowing and oral intake and eliminate tube feedings. This finding encourages the use of this 
post-RT/C timeline for valid assessments of the true expression of dysphagia. This timeline may 
also be suitable to perform MBS studies (4-6 weeks), after adequate healing time has been 
allowed and true residual dysphagia and its impact on eating ability can be assessed. 
Relatively lower percentages of pre-treatment surgeries, higher RT dosages and longer 
durations of RT, differentiated PEG tube dependent patients from non-PEG tube dependent 
patients in this study. These factors may have a potential role in the establishment of guidelines 
for candidacy for prophylactic PEG tube placements; however it is noteworthy, that these factors 
were not exclusive among the PEG tube dependent patients. Patients who underwent pre-
treatment surgeries or received lower dosages of RT over a short duration of time also received 
PEG tubes. Alternatively, several patients with higher dosages of radiation and longer RT 
durations completed treatment without the need for PEG tubes. The cause-effect relationship 
between longer durations of RT and PEG tube placements were not clear in the current study. 
Several PEG tube dependent patients appeared to have experienced an increase in RT duration 
only because they missed treatments due to hospital admissions for PEG tube placements itself. 
Longer RT durations did not cause patients to get PEG tubes, rather tube placements resulted in 
lengthening of RT time. Patients who required PEG tubes in this study exhibited higher rates of 
aspiration, higher PAS scores, worse FOIS scores reported at post-treatment and worse FOIS 
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scores assigned by the clinician based on the post-treatment MBS results. This finding is 
encouraging in that physiological swallowing impairments correlated with the need for 
dysphagia-related PEG tube dependence. 
Paleri and Patterson (2010) 
52
 recently reviewed the literature of feeding tube-use in the 
HNC patient population. They identified factors, most associated with feeding tube placements 
including: oropharyngeal/ hypopharyngeal tumors, 
198, 199
 stage III or IV tumors, 
198
 flap 
reconstructions, 
198
 tracheotomy, 
198
 ChT utilization, 
198
 increased age, 
198
 malnutrition and 
dysphagia, 
200
 pain on swallowing, aspiration or other dysphagia symptoms 
200
 and higher RT 
dosage to the pharyngeal constrictor muscles. 
201, 202
 Factors least associated with feeding tube 
placements included: nasopharyngeal tumors,
203
 laryngeal tumors 
199
 and tumors of the sinuses. 
199
 Less than 100% aspiration rates or PEG tube placement rates reported in the non-PSE 
employing literature indicates that some patients certainly get through RT/C without severe 
dysphagia and need for alternative feeding modalities. Several patient-demographic, tumor and 
cancer treatment-related factors have been reported to be associated with reduced or increased 
likelihood of significant physiological and functional swallowing impairments, as described 
previously; however, a predictive model which would foresee a given patients‟ outcomes is not 
available. This has led to vast advancements in the investigation of genetic biomarkers of 
patients‟ response to cancer treatment and the severity of toxicities. 204 Cytokines have been 
shown to contribute, as well as indicate tissue damage in irradiated patients. 
205
 Investigations to 
assess the use of cytokine-studies at pre-treatment in identifying patients who may be expected to 
have more than normal toxicity, are currently underway in the field. Such studies will hopefully 
help significantly in characterizing patients who are at higher risks of developing dysphagia from 
RT/C toxicities and availing them of intensive prophylactic regimens for swallowing, 
lymphedema and nutrition rehabilitation, to maximize outcomes. 
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Given that no conclusive guidelines regarding upfront gastrotomy tube placements exist 
despite the vast literature attempting to classify patients that may likely benefit from such an 
approach, the decision continues to be made based on individual physicians‟ or facilities‟ 
experiences with their cohort of patients. 
52
 Based on the known quality-of-life impairments of 
PEG tubes, the cost of feeding through a PEG tube (as reviewed by the author‟s of this study in 
Appendix E) and the risk of permanent dysphagia from muscle disuse, future studies 
standardizing guidelines and criteria for PEG tube placements are warranted. 
5.3. Quality-of-Life (QOL) Outcomes    
 Although no significant differences appeared in post-treatment MDADI scores (i.e. 
overall scores, global, emotional, functional and physical domains) between the EX and SW 
groups; within each group, significantly worse scores were evident in each of these domains, 
from pre-treatment to post-treatment. This finding indicates the significant negative impacts of 
RT/C on patients‟ QOL, via treatment induced-toxicities.  
Wilson, Carding and Patterson, (2011) recently reported MDADI scores of 65.0 (SD= 
17.6) at 3 months post-treatment, indicating significant deterioration in QOL. 
206
 This is 
comparable to the post-treatment overall scores obtained in this study, i.e. 62.72. The Kulbersh 
et al., (2006) study is the only study reporting post-treatment MDADI scores (percentages) in 
patients who received PSE, starting 2 weeks prior to cancer-treatment (Global assessment 71.7, 
Emotional 71.5, Functional 68.3, and Physical 65.1). 
88
  Scores were obtained at a median of 9 
months following treatment, hence are not comparable to the findings of this current study. They 
also reported scores on a NTx group whose median follow-up time was 14 months post-
treatment (Global 45, Emotional 57.5, Functional 61.3, and Physical 49), once again not 
comparable, given the largely different timelines. 
QOL impairments related to PEG tube placements have been described in the literature  
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previously. 
52-63
 Statistically significant negative impacts of having a PEG tube, on patients‟ 
QOL were revealed in this study, via the MDADI-overall and emotional scores. Patients who 
received PEG tubes reported worse scores on these measures at post-treatment. Few studies have 
even reported improved QOL with the prophylactic PEG tube placement practice. 
207-209
 
Methodological differences, particularly varying assessment tools 
207-209
 and differing timelines 
of PEG tube placements, resulted in inability to make direct comparisons. Other studies have 
compared QOL in patients with prophylactic PEG tubes vs. nasogastric (NG) tubes using various 
QOL questionnaires; the findings however, are not relevant for comparison with the current 
study. 
208
  
Whether PEG tube placements, particularly prophylactically, result in worse QOL cannot  
be concluded at this time; 
45
 however, the current study‟s and literature‟s findings definitely 
indicate worse QOL with PEG tubes placed in general. Future studies with larger patient cohorts 
are recommended to evaluate the impact of alternative modalities of feeding, placed 
prophylactically or reactively, on patients‟ QOL. The high cost associated with feeding via PEG 
tubes and the significant negative QOL associated with PEG tubes are further encouraging in the 
employment of PSE in HNC patients. This is supported by the results of the current and previous 
studies employing PSE and demonstrate its benefits in reducing aspiration, PEG tube 
dependence, and cost-effectiveness (vs. feeding via PEG tubes- Appendix E). 
5.4. Weight Loss and PEG Tube Placements 
 Post-RT/C weight loss was not found to be statistically significantly different in the EX 
vs. SW groups or between PEG tube dependent vs. non-PEG tube dependent patients. Weekly 
weight loss between the EX and SW patient groups did not vary significantly at any point 
through RT. In the current study, a mean weight loss of 7.5% was evident (combined EX+SW 
groups), as compared to 7.8% weight loss reported in the most recent, van der Molen, et al., 
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(2011) study. 
89
 The Carnaby-Mann et al., (2012) study reported 6.69 kg (14.7 lbs) weight loss 
comparable to 13.5 lbs weight loss in the EX group of this study. 
91
  Patients without PEG tubes 
(EX+SW) experienced a mean weight loss of 6.5%, whereas patients with reactive PEG tubes 
had lost on an average 9% weight. This is understandable to an extent, as patients who received 
PEG tubes may have already experienced weight loss prior to tube placements. Yet, receiving 
PEG tubes did not necessarily mean that patients continued to maintain or gain weight, due to the 
known complications associated with tube feeding and complexities of learning the method of 
feeding through this modality. 
54
 
Ten percent weight loss is generally considered severe weight loss during RT/C in HNC 
patients. 
52, 210, 211
 More than 10% weight loss is considered a risk for malnutrition and any 
weight loss exceeding 20% has been associated with an increase in morbidity and mortality. 
110
 
At least 10% weight loss post-RT/C is typically reported in the literature. 
44
 Although not 
significant, the van der Molen et al., (2011) study, 
89
 Carnaby-Mann et al., (2012) study 
91
 and 
this current study (particularly the EX group) do report lower weight loss percentages. This may 
be related to methodological differences from other studies, however it could also reflect 
improved nutrition intake by patients, related to the speech clinician‟s consistent delivery of the 
importance of swallowing, eating and maintaining weight. This finding indicates yet another 
advantage of providing prophylactic swallowing therapy to this patient population. Additionally, 
like most radiation oncology centers, a full-time nutritionist at the MBPCC followed each of the 
patients on the study on a weekly basis, to assist in nutritional needs.  
 Thus despite rejecting hypotheses 1a, 1b (entire cohort), 1c and 1d of this study, the 
EX group showed a better trend over the SW group, NTx group, other PSE-employing literature 
and non-PSE employing literature in physiological, functional, quality-of-life and weight 
outcomes, beyond the acute post-treatment healing period. Particularly when accounted for 
 98 
patients who underwent both RT and ChT, the EX group exhibited significantly better PEG tube 
outcomes than the SW and the NTx groups, both at post-treatment and 3 months post-treatment. 
The SW group also showed improved outcomes as compared to the NTx group. Long-term 
benefits of performing intense, swallowing exercises prophylactically were evident in this study, 
potentially due to muscle preservation, as reported by Carnaby-Mann et al., (2012).
155
 PEG tube 
dependence in the EX group of this study at post-treatment and 3 months post-treatment stood 
out as a statistically and clinically significant finding.  
5.5. Correlations Between Physiological, Functional, Quality-of-Life (QOL) and Weight 
Outcomes Post-Radiation Therapy with/without Chemotherapy (RT/C) for Head and Neck 
Cancers (HNC) 
 The current study abided by the recommendations of the World Health Organization‟s 
(WHO) International Classification of Functioning, Disability and Health (ICF)- 
recommendations, in assessing not just physiological outcomes, but functional and QOL 
outcomes as well. 
178, 179
 Although an initial core set of structures and functions specific to HNC 
has been provided, establishment of standardized outcomes measures to use with the ICF 
framework is underway. 
180, 181
 The current study therefore employed valid and reliable tools to 
measure physiology (PAS), function (FOIS) and QOL (MDADI) in patients. 
There was a statistically significant; however weak correlation between aspiration and 
PEG tube dependence at post-treatment in this study, leading to an inference that patients who 
aspirated at post-treatment MBS studies were more likely to have PEG tubes placed reactively, 
during or immediately post-treatment. However, this relationship was weak, probably 
attributable to the fact that only 10 patients exhibited any aspiration in this study. Also, both 
aspiration and PAS scores assigned to patients by SLPs based on their post-treatment MBS 
studies, correlated significantly with the assigned FOIS scores. This is expected, as aspiration of 
boluses plays a vital role in dietary and compensatory strategy recommendations made. 
82
 
 99 
Langmore (2010) has reported that aspiration is commonly known to result post-RT/C 
particularly when the site of cancer is the larynx. 
24
 A major post-treatment impact of RT/C in 
the form of tissue fibrosis, often results in reduced bolus transit and clearance through the 
pharyngoesophageal pathway, 
24
 causing dysphagia characterized by feeling of foods sticking in 
the throat and choking. The weaker relationships between aspiration and PEG tube dependence 
are thus further justified, in that patients may not have aspirated, rather experienced significantly 
reduced pharyngeal peristalsis and reduced pharyngeal clearance, increasing risk of aspiration 
from pharyngeal residue, after the swallow. These were consistent with patient-reports of RT 
toxicity-related dysphagia symptoms. No other significant correlations were revealed between 
physiological swallowing outcomes (aspiration and PAS scores), QOL outcomes (MDADI- 
overall, global, emotional, functional and physical domain scores) and weight loss. Patients with 
PEG tube dependence in this study, exhibited worse MDADI-overall and emotional scores post- 
treatment- a finding indicative of a relationship between functional and QOL life impairments. 
5.6. Secondary Research Findings 
Radiation Toxicities 
Radiation toxicities occurring through treatment included but were not limited to 
xerostomia, mucositis, soreness and pain associated with the mucositis, odynophagia, nausea/ 
vomiting, dysgeusia, trismus and reduced appetite. Of the 21 patients who received PEG tubes in 
this study (EX+SW), only 7 of them (33%) exhibited any aspiration at the post-treatment MBS 
study. All other PEG tubes were placed during treatment, due to induced toxicities (67%). The 
three most important toxicities that prevailed and/or worsened throughout treatment were 
dysgeusia, reduced appetite and xerostomia. These can therefore be most closely related to PEG 
tube placements in patients. There is vast literature to support medical management of RT 
toxicities (chapter 2). All patients in the current study were assessed by their radiation 
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oncologists, at least once a week and were prescribed necessary treatments for RT toxicities; 
despite which, toxicities caused a significant reason for PEG tube placements (67%).  
Dysphagia Symptoms 
Some of the common dysphagia symptoms occurring during RT/C included but were not 
limited to, choking with solids and liquids, nasal and oral regurgitation, reflux, difficulty 
initiating a swallow, globus sensation, foods sticking in the throat, gagging, NPO status, 
hoarseness and wet/gurgly voice quality. Among the topmost severe dysphagia symptoms 
reported by patients in the EX group were hoarseness, globus sensation and difficulty initiating 
a swallow; whereas for the SW group these were hoarseness, difficulty initiating a swallow, 
reflux, foods sticking in the throat and globus sensation. Patients in both the EX and SW 
treatment groups performed one swallowing-salient exercise i.e. Masako and repetitive swallows 
respectively. However, only the SW group of patients consistently reported the dysphagia 
symptom, foods sticking in the throat. Clinically, this symptom is associated with reduced 
pharyngeal peristalsis post-RT/C. It is speculated that the addition of the pharyngeal squeeze and 
Shaker exercises to address pharyngoesophageal swallowing abilities, to the EX group‟s exercise 
regimen, potentially benefited improved pharyngoesophageal bolus transit, and support its 
generalization to the clinic. 
Compliance with the Therapeutic Regimen 
 As elaborated earlier, every patient in the study met with the SLP/ study coordinator on a  
weekly basis. During this visit, each patient was encouraged to perform at least 50% of the 
therapeutic tasks assigned for that day, under the clinician‟s supervision. Additionally, each 
patient filled out a log sheet provided to him/ her each day to indicate the number of sets of each 
exercise that he/she had completed that day. Most patients were compliant with logging the 
exercises, whereas for some patients, caregiver input to estimate the number of sets, sometimes  
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on a daily basis was required. 
As a group, patients in both, the EX and SW groups exhibited a gradual decrease in 
compliance with exercises from over 60% during the first week of treatment, to below 35% in 
the last week. Patients in the EX group appeared to be more compliant with the Masako and 
pharyngeal squeeze exercises than the Shaker exercises. Through several weeks of RT, the SW 
group appeared to be slightly more compliant with their therapeutic task than the EX group with 
any of the exercises. Although a highly intensive exercise regimen was assigned to both groups, 
at no point were patients more than 75% (mean) compliant with their exercises. Despite this, 
patients, particularly in the EX group exhibited low aspiration rates and better abilities to 
eliminate PEG tube dependence at 3 months post-treatment.  
This finding could extend the future scope of research in several directions: could 
reducing the intensity of exercises maintain the obtained outcomes, and potentially improve 
patient compliance? Or could strengthening the repetitive swallowing exercise protocol either in 
terms of intensity/frequency or saliency, result in improved outcomes?  van der Molen et al., 
(2011) employed a different set of exercises at a relatively lower intensity, but also reported 
higher PEG tube dependence rates at 3 months post-treatment. 
89
 On the other hand, Carnaby-
Mann et al (2012) employed the Masako and pharyngeal squeeze exercises with a few other 
exercises, at a relatively lower intensity with daily therapy and reported outcomes comparable to 
those obtained in the current study. 
91
 Future studies are therefore warranted to assess the optimal 
intensity of exercises and frequency schedule of therapy, potentially based on the dosage of 
radiation employed in cancer treatment. Therapy once a week was certainly as beneficial in this 
study as was daily therapy in the Carnaby-Mann et al., (2012) study. 
91
 
 An interesting finding of this study, which may correlate with the clinical impressions of 
many clinicians working with the HNC population was that patients in the EX group who ended 
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up with PEG tube placements, evidently exhibited much reduced mean percent compliance with 
exercises as compared to patients who did not end up with feeding tubes. This was true of the 
SW group as well; however, in this group of patients, it appeared as if the mean compliance 
percent dropped following the third week of RT, after most patients actually underwent PEG 
tube placements and reduced the frequency of swallowing exercises. Patient non-compliance in 
therapy has been previously reported by self-perceptions of exercises being too „strange‟ and 
„annoying‟, they „forget‟ to do them and that it is difficult to „practice daily‟. 89 Patients stop 
doing the exercises during RT because of pain in the mouth, nausea and fatigue. 
89
 van der 
Molen et al., (2011) reported that only 7 of their 49 patients (14%) practiced exercises on a daily 
basis, whereas on an average other patients did exercises 4 days per week (range 0 to 7 days). 
89
  
Additionally, other studies have reported that patients typically do not comply with swallowing 
recommendations as they are not satisfied with dietary alterations recommended, lack of family 
support and lack of resources. 
212
 Depression and fatigue at the beginning of RT/C have recently 
been reported to have a negative effect on patient-compliance with a PSE regimen. 
191
 Other 
studies have also described issues of patient compliance in therapy in various outpatient and 
nursing home facilities as well; 
213, 214
 however these are not comparable to the current group of 
patients who are physically quite fragile as they undergo toxic RT/C for HNC. Further studies 
are warranted to investigate factors that could increase the compliance of PSE and its effects on 
swallowing function. 
5.7. Should the Prophylactic Swallowing Exercise (PSE) Regimen Employed by Patients in 
the Exercise (EX) Group of This Study Be Generalized to Routine Clinical Practice? 
 Within the PSE regimens of the EX and SW groups of patients in this study, only the 
Masako exercise which requires completion of the act of swallowing appeared salient to 
swallowing. The pharyngeal squeeze and Shaker exercises although not salient to the act of 
swallowing, were salient to specific biomechanical events of the act of swallowing. Repetitive 
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swallows matched in intensity with the number of range-of-motions achieved by the EX group 
from doing exercises, were thought to be as salient as could be with the act of swallowing since 
they represent the function of swallowing itself. 
This study hypothesized that performing less complex, simple repetitive swallows would 
result in worse outcomes as compared to performing intense and complex, more difficult, 
evidence-based exercises. Among patients treated with RT + ChT, better functional outcomes of 
the EX group were evident. However, the premise and motivation of selecting repetitive 
swallows as the therapeutic task in the first place, was the fact that treatment toxicities often 
reduce patients‟ oral intake, resulting in PEG tube placements, which further reduce the use of 
swallowing muscles, causing them to atrophy. 
97
 Long-term superiority of complex, 
biomechanical event-specific exercises over the act of swallowing as the therapeutic task, and no 
therapy was evident in this study. Peck et al., (2010) have reported higher neural activation 
levels with the effortful swallow and the Mendelsohn‟s maneuver, than with dry swallows. 215 
This report further justifies the superiority of complex, intense exercises over simple, repetitive 
swallows in obtaining desired swallowing outcomes. Given that there were no statistically 
significant differences in demographics, tumor characteristics, cancer treatment-related 
characteristics and pre-treatment swallowing function, between the two groups of patients, the 
therapeutic task itself was thought to be have played a significant role in the achieved outcomes. 
It is difficult however, to determine if patients with specific tumor sites or smaller stages may 
benefit from rather simple „repetitive swallows‟ vs. „complex exercises‟ as the therapeutic task in 
maintaining swallowing physiology and function. 
The unique combination of exercises employed in this study can be appreciated in terms 
of its comprehensive focus on the oropharyngeal and pharyngoesophageal phases of 
swallowing, encouraging the clinical utility of this regimen as a prophylactic program for 
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patients undergoing organ preservation treatments for HNC. Therapy provided once a week, 
resulted in essentially similar if not better swallowing outcomes as compared to the Carnaby-
Mann, et al., (2012) study which utilized daily therapy at a slightly lower intensity than this 
study. 
91
 Results of this study appear worth future investigations with a larger cohort of subjects, 
with more homogeneous, advanced tumor and cancer treatment characteristics. In particular, the 
effects of this combination of exercise on muscle preservation is indicated, such as the 
investigation conducted by Carnaby-Mann et al., (2012). 
91
 Given its significant benefits, this 
study proposes the employment of this protocol in patients undergoing RT/C for HNC. As 
elaborated in detail earlier, the authors of this study continue to recommend future investigations 
with alterations in the exercise regimen of the SW group since this group did not exhibit 
statistically significantly worse post-treatment outcomes as compared to the EX group, and 
exhibited slightly better outcomes than the NTx group. Intensity/ frequency and saliency 
alterations to this protocol in future investigations are strongly recommended. 
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CHAPTER 6: CONCLUSIONS 
6.1. Conclusions and Clinical Implications 
In conclusion, the prophylactic swallowing exercise (PSE) protocols performed by 
patients in the EX group of this study undergoing RT/C for HNC resulted in better post-
treatment swallowing outcomes. Benefits were characterized by improved swallowing 
physiology (i.e. lower rates of aspiration and higher PAS scores), function (i.e. significantly 
lower rates of PEG tube dependence, at post-treatment and particularly at 3 months post-
treatment, and ability to maintain oral intake) and QOL (i.e. better overall and emotional domain 
scores on the MDADI in the non-PEG tube dependent patients). Significantly lower PEG tube 
dependence rates at post-treatment and 3 months post-treatment, as compared to the SW and 
NTx groups were revealed in patients who underwent both ChT and RT. In particular, a 
combination of the Masako, pharyngeal squeeze and Shaker exercises to address the 
oropharyngeal and pharyngoesophageal phases of swallowing, provided a beneficial combination 
to improve post-treatment swallowing outcomes, especially at 3 months post-treatment, by which 
time most RT/C toxicities have significantly resolved. Clinical application of this protocol is 
recommended in centers that already employ a prophylactic approach to swallowing as well as in 
centers where such therapy is not employed at this time.  
Although the long-term significance of behavioral exercises over repetitive swallows 
were evident in this study, at post-treatment no significant differences emerged between groups 
in physiological, functional, QOL or weight outcomes. The ease of performing simple, repetitive 
swallows in these settings call for future investigations with alterations to this protocol. Impacts 
of altering the consistency used when practicing these swallows, intensifying the task with effort 
(i.e. hard repetitive swallows) or altering the frequency/ intensity of swallows itself, are 
warranted to assess the relative benefits of this protocol, even if these may be limited to a  
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subgroup of patients.  
Compliance with the PSE regimen differentiated patients of the EX group who ended up 
with PEG tubes vs. not. However, several patients with reduced compliance were also able to 
quickly resume full oral diets and eliminate alternative feeding within 3 months post-treatment. 
Compliance with the therapeutic task did not distinguish the SW group‟s patients with/ without 
PEG tubes. Compliance in therapy is a key clinical issue and obtaining more objective insights 
into patients‟ conformity with exercises will benefit the understanding of the optimal frequency 
and intensity of exercises..  
The current study was the first to investigate the differential impacts of performing 
prophylactic swallowing exercises vs. encouraging patients to continue to swallowing through 
RT/C, with a significantly high intensity. Findings proved the superiority of exercises in 
preserving swallowing physiology and function. The practice of prophylactic swallowing 
training is not common clinical practice in Cancer Centers at this time. Presumably, patients 
undergoing treatments at these centers are probably only encouraged by the doctors and the 
nutritionists to continue to swallow through treatment to maintain function. According to the 
findings of the current study, this practice is certainly not as beneficial to patients and there is a 
significant need for the establishment of prophylactic swallowing therapy as common practice 
for HNC patients. Conducting this study has substantially impacted multidisciplinary patient care 
at the MBPCC which currently lacks the services of a part-time/ full-time SLP.  
Dysgeusia, reduced oral intake and xerostomia appeared to be the most prominent RT/C- 
toxicities in patients enrolled in this study. Additionally, hoarseness, globus sensation, difficulty 
initiating a swallow, reflux and foods sticking in the throat were among the more severe 
dysphagia symptoms reported by patients during the course of RT. A high percentage of PEG 
tubes in this study were placed due to treatment toxicities rather than aspiration. Placement and 
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use of PEG tubes caused patients to reduce the use of swallowing muscles and in turn a need to 
continue to rely on PEG tubes for a prolonged duration. 
All patients, who reported no dysphagia or eating restrictions at pre-treatment, exhibited 
functional swallowing abilities on pre-treatment MBS studies. Pre-treatment MBS studies proved 
minimally beneficial in this study. Therefore it may be proposed that in the absence of 
complaints of dysphagia by patients, pre-treatment MBS studies could be differed, reducing one 
additional cost to patients going through the expensive course of RT/C. However, literature has 
indicated the presence of dysphagia and aspiration at pre-treatment in patients with more 
advanced stage cancers. MBS studies may be more beneficial in this sub-population.  
Overall, it is hoped that continued future advances in the understanding of prophylactic 
preservation of swallowing in HNC patients, will result in positive impacts on patients‟ QOL and 
reduce the burden of dysphagia and related complications post-treatment. This study can be 
considered a significant contribution to current literature striving to establish an optimal muscle 
preservation regimen for patients undergoing RT/C for HNC.  
6.2 Limitations of the Study 
The no treatment group employed in this study included patients who were treated at co-
facilities of the MBPCC-Baton Rouge, during identical timelines of prospective patient 
recruitment. Retrospective recruitment of this group was the best possible option, given that 
emerging evidence supports the employment of PSE. Prospective recruitment of a no treatment 
group in this scenario would pose ethical concerns regarding denying therapy to patients who 
might otherwise benefit significantly from a PSE regimen to maintain healthy swallowing 
function following RT/C. This is a common challenge encountered in studies of this nature. 
216
 
It is noteworthy that only five studies have previously investigated the impact of PSE on 
swallowing outcomes, of which only three studies have included some type of a „control‟ group 
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(i.e. 1 retrospective, 1 prospective non-randomized from a co-facility and 1 prospective 
randomized). Therefore the employment of a no treatment group in determining if either exercise 
protocols in this study would result in improved swallowing outcomes was considered necessary. 
The drawbacks of the no treatment group in this study, considered prior to recruitment were: 
between-institution differences (radiation delivery machines and physicians), physicians‟ 
opinions on prophylactic and reactive PEG tube placements potentially influenced by lack of 
speech pathology services, and most importantly the inability to obtain pre-treatment and post-
treatment MBS studies and vital information regarding patients‟ swallowing physiology, 
function and QOL. The author of this investigation considered the possibility of alternatively 
recruiting a within-institution comparison group retrospectively (of a previous timeline) to 
represent the no treatment group in this study. This would potentially help to better interpret the 
impact of PSE on swallowing outcomes in PEG tube dependence patterns within the institution. 
However, the prime shortcoming of this approach again would be physicians‟ bias against PEG 
tube placements in prospectively recrtuited patients due to the presence of the speech pathologist 
on site, versus more readily placed PEG tubes in previously treated patients. Although, simply 
comparing reactive PEG tube placements between the treatment groups and the within-institution 
group, would compensate for this issue; yet the limitation of unmatched groups and inability to 
control any subtle or extensive changes in HNC patient-care protocols evolving from differential 
timelines, could still influence PEG tube outcomes. Additionally, since the no treatment group 
was found to not match with the treatment groups in terms of utilization of ChT in this study, 
analyses of PEG tube outcomes were difficult to interpret. Application of the criteria “treatment 
with both RT and ChT” revealed the expected outcomes, yet doing so, further reduced the 
number of subjects in each group.  
Patient assessments in this study were not blinded to the study coordinator who was also  
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the evaluating and treating speech pathologist. Although all measures reported are rather 
objective, future measures to improve this aspect of the study are recommended.  
The patient group employed in the current study was heterogeneous in terms of tumor 
sites, tumor stage and cancer-treatment related characteristics. Such variances result in 
limitations in performing valid statistical analyses. Future studies should focus on specific tumor 
sites, stages and RT/C protocols to obtain more accurate and specific information regarding the 
benefits of prophylactic swallowing therapy in multiple HNC centers to ensure an adequate 
number of patients with the same tumor site and stage.  
Although the intention was to obtain pre-treatment MBS studies prior to the initiation of 
any RT and post-treatment MBS studies within 3 weeks after the completion of RT, 
miscellaneous conflicts resulted in some variations between the timelines at which these were 
obtained. Yet, all recruited patients exhibited pre-treatment MBS studies within functional limits 
and all but 3 post-treatment studies were performed within 6 weeks of completion of RT. 
Unfortunately, this is a common limitation of studies in related fields. Future studies should aim 
to assess the impacts of PSE on post-treatment physiological outcomes at fixed timelines across 
patients. 
Compliance measurements in this study were patient-reported. Any inaccuracies in these 
reports could not be controlled. Future studies are warranted to improve methods of assessment 
of compliance with swallowing exercises. Potential development of mechanical devices to track 
specific muscles movements in performing exercises, may provide better insights into patient 
compliance issues and the optimal frequency/ intensity schedules of exercise recommendations.   
6.3. Scope for Future Research 
The current study continues to recruit additional patients to improve the sample size and 
subsequent power of the results obtained. Additionally, appropriate IRB approvals have been 
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obtained to investigate the long-term PEG tube and oral intake statuses of patients enrolled in the 
current study (at 6 months and 12 months post-treatment). 
Future investigations with unique combinations of exercises such as the one proposed in 
this study on muscle physiology are recommended to further optimize prophylactic swallowing 
rehabilitation in HNC patients. 
Since post-treatment physiological, functional, QOL and weight outcomes did not differ 
between patients in the EX and SW groups, receiving RT/C future investigations modifying the 
repetitive swallowing exercise regimen, potentially with varied consistencies or frequency/ 
intensity are recommended, due to the relative ease of performing these over complex exercises. 
Investigations of swallowing exercises with larger, more specific patient characteristics 
are recommended. These will provide better insights into identifying specific groups of patients 
for whom prophylactic nutrition and swallowing therapy may be warranted to improve 
outcomes. 
Investigations of the strength of genetic biomarkers to identify high-risk patients and 
improved medical management of RT/C toxicities are also recommended in the field. These will 
contribute to improving the care of high-risk patients with HNC. 
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APPENDIX A  
Modified Barium Swallow (MBS) Study Protocol Employed at the OLOL-VC to Evaluate 
Patients’ Baseline and Post-treatment Swallowing Function 
 
Site: Radiology unit of the OLOL Regional Medical Center 
Performed by: Speech Pathologist, assisted by radiologist or a physician‟s assistant and a 
radiation technician 
Planes assessed: Lateral- to view the oral cavity anteriorly, the soft palate and the nasal cavity 
superiorly, the posterior pharyngeal wall and cervical vertebrae posteriorly and 
the UES inferiorly. 
Anterior-posterior (AP)- to assess symmetry of swallowed bolus/ impairments 
Products administered: E-Z-EM‟s Varibar® and E-Z- Paque® 
Trials: Thin liquid: 3 ml (x1), 5 ml (x2), 10 ml (x2) and spontaneous 3 ounces 
Paste: ½ tspn 
Graham cracker: ¼ piece  
Nectar- thick, honey-thin and honey-thick liquids: as needed 
Procedures & Instructions: Measured liquids and paste: “Take this and swallow it at once” 
Spontaneous size thin liquid: “Sip and swallow continuously in one breath” 
Graham cracker: “Chew well and swallow” 
Postural maneuvers, compensatory strategies and behavioral maneuvers were employed 
promptly as deemed necessary.  
Vocalize /i/ three times by taking breaths in between to allow recording of vocal fold 
motion under fluoroscopy.  
Documentation: Report generated. Results and recommendations reviewed with the patient 
and/or caregiver  
Standardized scales scored: Penetration Aspiration Scale (PAS) and Functional Oral Intake 
Scale (FOIS) 
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APPENDIX B 
Informed Consent Form 
STUDY TITLE:   Effects of Behavioral Swallowing Therapy during 
Radiation Therapy on Swallowing Physiology, Function, 
Quality-of-life and Weight Outcomes Following Organ-
Preservation Treatments for Oral, Pharyngeal and/or 
Laryngeal Cancers 
PERFORMANCE SITE (S): Mary Bird Perkins Cancer Center & 
     Our Lady of the Lake Regional Medical Center  
PRINCIPAL INVESTIGATOR: Andrew J. McWhorter, MD  
     7777 Hennessy Blvd., Suite 408 
     Baton Rouge, Louisiana 70808 
     United States  
     Phone: 225-765-5335 
     24-hour number: 225-202-0155 
 
CO-INVESTIGATORS:  Melda Kunduk, PhD 
      & 
     Aneesha Virani, ABD CCC-SLP 
     7777 Hennessy Blvd., Suite 408 
     Baton Rouge, Louisiana 70808 
     United States  
     Phone: 225-765-5335 
 
You may take home an unsigned copy of this consent form to think about or discuss with family 
or friends before making your decision. This consent form may contain words that are not clear 
to you. Please ask the co-investigator to explain any words or information that you do not 
understand clearly. Once you sign this consent form, you will be enrolled in this study.  
 
PURPOSE OF THE STUDY 
The purpose of this research study is to determine if performing swallowing exercises during 
radiation therapy with or without chemotherapy will result in reduced aspiration (i.e., choking), 
reduced feeding-tube dependence and better swallowing-related quality-of-life at the completion 
of cancer treatment. Cancer treatments may result in swallowing problems as side effects and 
subsequent feeding-tube dependence. A proactive approach to swallowing therapy is currently 
starting to emerge nationwide to offset these undesirable side effects of cancer treatment 
modalities. However, there is limited research data to understand specifics of its benefits. Since 
you will be undergoing radiation therapy with or without chemotherapy for your cancer 
diagnosis, you are eligible to participate in this study.  
 
Subject‟s Initials:         ID#:      
Page 1 of 5 
Dated: 8.17.2010 
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DESCRIPTION OF THE STUDY 
 
Length of Study and Number of Participants 
 
This study will be conducted during the entire course of your cancer treatment at the Mary Bird 
Perkins Cancer Center. Radiation treatments typically last for five to seven weeks. Sixty 
participants will be enrolled in this study. 
 
Procedures 
 
You are eligible to participate in this study based on your nature of cancer and results of the 
baseline Modified Barium Swallow Study. 
 
Your speech pathologist will give you a swallowing exercise protocol that you will perform 
everyday. Throughout your radiation treatments, your speech pathologist will visit with you at 
the Mary Bird Perkins Cancer Center twice per week to provide swallowing therapy either just 
before or after your radiation treatment. You will not be required to make an extra visit to the 
Mary Bird Perkins Cancer Center. During each visit with the speech pathologist, you will 
perform half of your exercises so that she can monitor your progress and identify any problems 
with the performance of exercises. She will also be able to answer any swallowing-related 
questions you may have. Any swallowing problems that may arise during this period will also be 
identified so that they can be managed appropriately and in a timely manner. You will be 
provided with log sheets to record exercises that you complete everyday to be returned to the 
check-in personnel, the following day when you return for radiation treatment. Each week, your 
weight and diet will be recorded. In addition, you will fill out a quality-of-life questionnaire, 
which asks twenty questions related to your swallowing. 
 
At the completion of radiation treatment with or without chemotherapy, your radiation 
oncologist will refer you for another routine Modified Barium Swallow Study, which will be 
performed by your speech pathologist, to identify any problems with the structure and function 
of swallowing. Your study-related swallowing therapy will end at this time. However, if you do 
suffer any swallowing problems, the speech pathologist will refer you to the Our Lady of the 
Lake Regional Medical Center- Voice Center for continuation of swallowing therapy. 
 
To assess the long term effects of swallowing therapy on swallowing function, you will be 
requested to fill a quality-of-life questionnaire and a swallowing status questionnaire when you 
return to Mary Bird Perkins for your 3 month, 6 month and 12 month follow up appointments. 
These questionnaires along with the doctor‟s notes from your consultation visit, will be reviewed 
to obtain additional long-term information regarding your swallowing function. 
 
BENEFITS TO SUBJECTS 
 
Performing swallowing exercises during radiation treatments may result in the following 
benefits: 
 
 
Subject‟s Initials:         ID#:      
Page 2 of 5 
Dated: 8.17.2010 
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a) Prevention or reduction in swallowing impairments and subsequent lung complications of 
aspiration during and following cancer treatments 
b) Reduction in feeding-tube dependence during and following cancer treatments 
c) Improvement in swallowing-related quality-of-life during and following cancer 
treatments 
 
RISKS TO SUBJECTS 
 
There are no known risks of swallowing therapy. 
 
However, when you perform exercises you may run the risk of biting your tongue, straining the 
neck or feeling tired. 
 
In addition, filling out the M D Anderson Dysphagia Inventory questionnaire may upset you 
because it may make you realize your swallowing-related limitations. You may be referred for 
counseling services if you or your doctor indicates a need for the same. 
 
ALTERNATIVES TO PARTICIPATION IN THE STUDY 
 
The alternative is to not participate in this study. In addition, if you develop dysphagia during 
cancer treatment, you may be referred for speech pathology services, which are available at the 
Our Lady of the Lake Regional Medical Center- Voice Center. 
 
SUBJECT REMOVAL 
 
The co-investigator may stop you from taking part in this study if at any time if it is believed to 
be in your best interest; if you do not follow the study procedures; or if the study is stopped. You 
could be taken off the study if your health worsens; if another treatment option appears to be 
appropriate; or for any other cause which prevents your continuing in the study as per your 
radiation oncologist. 
 
SUBJECT’S RIGHT TO REFUSE TO PARTICIPATE OR WITHDRAW 
 
Participation is voluntary. Refusal to participate will involve no penalty or loss of benefits to 
which you are otherwise entitled, and you may discontinue participation at any time without 
penalty or loss of benefits to which you are otherwise entitled. You may refuse to participate or 
withdraw from the study at any time without jeopardizing, in any way, your medical treatment at 
this institution in the present or future. Tell the researcher if you are thinking about withdrawing 
from the study so that you may do so safely. If you decide not to continue participation in the 
study you should seek medical advice for alternatives. Should significant new findings take place 
during the course of the research that may relate to your willingness to continue participation, 
that information will be provided to you.  
 
 
 
 
 
Subject‟s Initials:         ID#:      
Page 3 of 5 
Dated: 8.17.2010 
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SUBJECT’S RIGHT TO PRIVACY 
 
If the results of the study are published, the privacy of subjects will be protected and they will 
not be identified in any way. Your personal information may be disclosed if required by law.  
 
RELEASE OF INFORMATION 
 
Organizations that may inspect and/or copy your study-related medical records for quality 
assurance and data analysis include: 
 
 Primary investigator and co-investigators listed on page 1 of this consent form and their 
staff 
 Staff at Mary Bird Perkins Cancer Center, Baton Rouge 
 Institutional Review Board at Our Lady of the Lake Regional Medical Center- Voice 
Center, Baton Rouge  
 Institutional Review Board at Louisiana State University Health Sciences Center, New 
Orleans 
 Institutional Review Board at Louisiana State University, Baton Rouge 
 The Western Institutional Review Board® (WIRB®) 
 
While every effort will be made to maintain your privacy, absolute confidentiality cannot be 
guaranteed. Records will be kept private to the extent allowed by law. 
 
FINANCIAL INFORMATION 
 
The swallowing therapy is part of the study and there is no charge for this. You will not be paid 
for your participation in this research study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject‟s Initials:         ID#:      
Page 4 of 5 
Dated: 8.17.2010 
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SIGNATURES  
 
The study has been discussed with me and all my questions have been answered. Additional 
questions regarding the study should be directed to Aneesha Virani at the number listed on page 
1 of this consent form. If I have questions about subject‟s rights, or other concerns, I can contact 
the Chancellor of the LSU Health Sciences Center New Orleans at (504) 568-4801. I agree with 
the terms above, acknowledge I have been given a copy of the consent form, and agree to 
participate in this study. I have not waived any of my legal rights by signing this consent form. 
 
 
 
 
_____________________________________   ________________________ 
Signature of Subject  Date 
 
 
_____________________________________   ________________________ 
Signature of Principal Investigator  Date 
 
 
 
_____________________________________  ________________________ 
Consent Administered by  Date 
 
 
 
 
 
 
The study subject has indicated to me that the subject is unable to read. I certify that I have read 
this consent form to the subject and explained that by completing the signature line above the 
subject has agreed to take part. 
 
 
        
Signature of Reader   Date 
 
 
 
              
Signature of Witness       Date 
 
 
 
 
 
Subject‟s Initials:         ID#:      
Page 5 of 5 
Dated: 8.17.2010 
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APPENDIX C  
Progress Note Employed During Weekly Consultations with Patients in the EX and SW 
Treatment Groups 
 
Speech Pathology- Swallowing Therapy Weekly Progress Note 
 
 
Subjective: 
 
Session # ____________ 
Diet Recommended from the baseline MBS Study  ____________________________ 
Diet Tolerated as of today ________________________________________________ 
Number of RAD Completed ____________ 
Dose of RAD received as of last Radiation Treatment ____________ 
MDADI Obtained and Reviewed today            Yes/No 
Feeding tube placed                                           Yes [Date] ________/No 
 
 
Objective: 
 
 Weight today ____________ 
       Therapeutic tasks performed in the session today: 
              1. Swallows ____________ repetitions ____________ sets 
              2. Masako exercises ____________ repetitions ____________ sets 
              3. Pharyngeal squeeze exercises ____________ repetitions ____________ sets 
              4. Shaker exercises Part I: ____________ repetitions ____________ sets 
                                              Part II: ____________ repetitions ____________ sets 
              5. Postural Maneuvers ________________________________________________ 
              6. Behavioral Strategies _______________________________________________ 
              7. Swallow Maneuvers ________________________________________________ 
              8. Home Program Compliance since last session ____________________________ 
 
 
Assessment:           None =1        Minimal=2        Mild=3        Moderate=4        Severe=5 
 
Radiation Toxicities 
 
 
Dysphagia Symptoms 
Xerostomia 
Mucositis 
Soreness/ Pain 
Odynophagia 
Nausea/Vomiting 
Dysgeusia 
Trismus 
Reduced appetite 
                
1 
1 
1 
1 
1 
1 
1 
1 
2 
2 
2 
2 
2 
2 
2 
2 
3 
3 
3 
3 
3 
3 
3 
3 
4 
4 
4 
4 
4 
4 
4 
4 
5 
5 
5 
5 
5 
5 
5 
5 
Choking with solids  
Choking with liquids 
Nasal regurgitation  
Oral regurgitation  
Reflux  
Difficulty initiating swallowing 
Globus sensation 
Foods sticking 
Gagging 
NPO status 
Hoarseness 
Wet, gurgly voice 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
1 
 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
2 
 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
3 
 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
4 
 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
5 
 
 
Plan: Next Appointment ____________ 
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Appendix D 
Standardized Assessment Tools 
D1: Penetration Aspiration Scale 
182
 
Category Score Description 
 
 
 
1 Contrast does not enter the airway 
P
E
N
E
T
R
A
T
IO
N
 2 Contrast enters the airway; remains above vocal folds; no residue 
 
3 Contrast remains above vocal folds; visible residue remains 
 
4 Contrast contacts vocal folds; no residue 
 
5 Contrast contacts vocal folds; visible residue remains 
 
A
S
P
IR
A
T
IO
N
 6 Contrast passes glottis; no subglottic residue visible 
 
7 Contrast passes glottis; visible subglottic residue despite patient‟s response 
 
8 Contrast passes glottis; visible subglottic residue; absent patient response 
 
 
D2: Functional Oral Intake Scale (FOIS) 
183
  
Category Level Description 
 
N
O
N
-O
R
A
L
 1 Nothing by mouth (NPO) 
 
2 Tube dependent with minimal attempts of food or liquid 
 
3 Tube dependent with consistent intake of liquid or food 
 
F
U
L
L
-O
R
A
L
 
4 Total oral diet of a single consistency 
 
5 Total oral diet with multiple consistencies but requiring special preparation 
or compensations 
 
6 Total oral diet with multiple consistencies without special preparation, but 
with specific food limitations 
 
7 Total oral diet with no restriction 
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D3: M D Anderson Dysphagia Inventory (MDADI) 
184
  
                     THE M.D. ANDERSON DYSPHAGIA INVENTORY  
                                                                                    VOICE CENTER 
This questionnaire asks for your views about your swallowing ability. This information will help us understand how 
you feel about swallowing. The following statements have been made by people who have problems with their 
swallowing. Some of the statements may apply to you. Please read each statement and circle the response which 
best reflects your experience in the past week. 
 
My swallowing ability limits my day-to-day 
activities 
Strongly Agree        Agree No opinion      Disagree Strongly Disagree 
E2. I am embarrassed by my eating habits. Strongly Agree        Agree No opinion      Disagree Strongly Disagree 
F1. People have difficulty cooking for me. Strongly Agree        Agree No opinion      Disagree Strongly Disagree 
P2. Swallowing is more difficult at the end of the 
day. 
Strongly Agree        Agree No opinion      Disagree Strongly Disagree 
E7. I do not feel self-conscious when I eat. Strongly Agree        Agree No opinion      Disagree Strongly Disagree 
E4. I am upset by my swallowing problem.   Strongly Agree        Agree No opinion      Disagree Strongly Disagree 
P6. Swallowing takes great effort.   Strongly Agree        Agree No opinion      Disagree Strongly Disagree 
E5. I do not go out because of my swallowing 
problem. 
Strongly Agree        Agree No opinion      Disagree Strongly Disagree 
F5. My swallowing difficulty has caused me to 
lose income. 
Strongly Agree        Agree No opinion      Disagree Strongly Disagree 
P7. It takes me longer to eat because of my 
swallowing problem. 
Strongly Agree        Agree No opinion      Disagree Strongly Disagree 
P3. People ask me, “Why can‟t you eat that?” Strongly Agree        Agree No opinion      Disagree Strongly Disagree 
E3. Other people are irritated by my eating 
problem.   
Strongly Agree        Agree No opinion      Disagree Strongly Disagree 
P8. I cough when I try to drink thin liquids.   Strongly Agree        Agree No opinion      Disagree Strongly Disagree 
F3. My swallowing problems limit my social and 
personal life. 
Strongly Agree        Agree No opinion      Disagree Strongly Disagree 
F2. I feel free to go out to eat with my friends, 
neighbors, and relatives. 
Strongly Agree        Agree No opinion      Disagree Strongly Disagree 
P5. I limit my food intake because of my 
swallowing difficulty. 
Strongly Agree        Agree No opinion      Disagree Strongly Disagree 
P1. I cannot maintain my weight because of my 
swallowing problem. 
Strongly Agree        Agree No opinion      Disagree Strongly Disagree 
E6. I have low self-esteem because of my 
swallowing problem. 
Strongly Agree        Agree No opinion      Disagree Strongly Disagree 
P4. I feel that I am swallowing a huge amount of 
food. 
Strongly Agree        Agree No opinion      Disagree Strongly Disagree 
F4. I feel excluded because of my eating habits. Strongly Agree        Agree No opinion      Disagree Strongly Disagree 
Thank you for completing this questionnaire! 
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APPENDIX E 
Cost of Feeding Through a PEG Tube 
Callahan, Buchanan and Stump (2001) have reported highly conservative costs of PEG 
tubes in their cohort of 105 patients with various diagnoses. 
216
 Their investigation suggested that 
the total cost of feeding/ patient/ year was $ 31,832. For the purposes of this study, an estimation 
of the basic costs of a PEG tube for 3 months can be made from the cost-guidelines provided by 
Callahan et al., (2001): cost of the initial placement procedure $ 2200 (including hospital and 
physician‟s charges); cost of enteral formula per day $ 8.52; cost of one physician visit for any 
PEG tube related problems $ 56.95 and cost of one minor PEG tube related complication $ 288. 
Costs of fluoroscopic studies that may be required prior to or following PEG placement, PEG 
replacement costs, costs of major complications and cost of labor to feed patients are being 
ignored for the purposes of this study‟s argument. Additionally, a higher cost of enteral feeding 
due to higher nutritional needs of patients under active treatment is also being ignored for this 
explanation. With the included costs, 100 days of feeding via PEG, amounts to $ 3,396.95 per 
patient. So, the cost of feeding 8 additional PEG tube dependent patients in the SW group as 
compared to 4 patients in the EX group (at 3 months post-treatment), would sum up to $ 
27,175.6. If these patients are unable to eliminate their PEG tubes at 6 months, then the cost will 
rise to $ 53,983.6 which includes an additional cost of a major PEG tube related complication. 
The current study‟s inclusion criteria was that patients should not have received prophylactic 
PEG tubes, in order to determine the need for alternative feeding as a true result of RT toxicities. 
It is not uncommon for PEG tubes to be placed prophylactically in patients who are to undergo 
RT/C for HNC, and in fact this is the new standard of practice at some centers, sometimes 100% 
of the times. 
45, 217-219
 During the timeline of this current study, 3 patients underwent PEG tube 
placements prophylactically and hence were not recruited in this study. Cost of PEG tubes for 
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these additional 3 patients for 10 weeks (7 weeks of RT + approximately 3 weeks of post-RT 
healing) would sum up to $ 8,912.85, increasing the originally estimated PEG feeding cost to $ 
62,896.45 (8 patients from the SW group + 3 prophylactic tube feeders). If these patients are 
unable to eliminate dependence at 3 months, a further significant increase in this cost would 
occur. Not to mention, the cost of potentially losing swallowing ability from underuse would be 
irreparable.  Again, this study estimates a very conservative cost of feeding since the true costs of 
PEG feedings in this group of patients were not directly estimated, as this was not the aim of the 
study.  
This conservative cost is higher than the salary of a part-time/ full-time SLP at a 
Radiation Oncology Center, such as the MBPCC. Considering that the MBPCC does not have an 
on-site SLP, such a position is highly recommended. We hypothesize that this is justifiable, 
given the study‟s findings of improved physiological, functional, QOL and weight outcomes and 
also in terms of reducing healthcare costs to patients. During this study period, the study 
coordinators experienced the benefits of having an on-site SLP at this center allowing: weekly 
monitoring of patients‟ swallowing abilities and making appropriate dietary, exercise and 
compensatory strategy recommendations; eliminating the need for patients to travel to outpatient 
centers for therapy, while being occupied with daily RT appointments; clarifying patients‟ 
questions, concerns and myths regarding swallowing in the presence of toxicities, and 
encouraging patients to continue to swallow and eat orally despite expected RT toxicities. 
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